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Abstract 
 
Allergy to hen’s egg white is one of the most common forms of food allergies and, as 
a result, has been well investigated. However, allergy to hen’s egg yolk has been 
overlooked by many studies, despite evidence of causing important immunological 
hypersensitivity in humans. Furthermore, the use of recombinant allergens in 
diagnosis and treatment of allergy has been very popular due to their excellent 
pharmaceutical qualities and standardised content. Therefore, immunological studies 
of hen’s egg yolk and production of recombinant versions of egg yolk allergens is of 
great interest. My work involves investigating hen’s egg yolk proteome in relation to 
food allergy using molecular, proteomic and immunological methods. The major 
objectives of this study were three fold. First objective was to investigate 
sensitisation to egg yolk proteins in patients diagnosed with allergy to egg white. The 
second objective involved producing immunologically active recombinant versions 
of hen’s egg yolk allergens; chicken serum albumin and yolk glycoprotein 42 
(YGP42). The final objective was to develop a recombinant based mutant variant of 
chicken serum albumin with reduced immunoglobulin E (IgE) antibody reactivity. In 
order to investigate sensitisation to egg yolk proteins, I conducted Western 
immunoassays using sera from 25 patients with allergy to hen’s egg white (Chapter 
2). The results showed that 36% of the patients tested had concomitant sensitisation 
to egg yolk proteins indicating a possible link between allergy to egg white and 
allergy to egg yolk. The proteomic analysis identified vitellogenin-1, vitellogenin-2 
and apolipoprotein B as major IgE-reactive proteins. Then, the production of IgE-
reactive recombinant YGP42 and chicken serum albumin in Escherichia coli and 
Kluyveromyces lactis, respectively, are presented in Chapters 2 and 3. We were able 
to confirm that recombinant chicken serum albumin to have similar IgE-reactivity to 
xvii 
 
 
 
its natural counterpart. Finally, this thesis presents the successful production of a 
mutant variant of recombinant chicken serum albumin using site directed 
mutagenesis and showed that it completely lacks IgE-reactivity (Chapter 4).  The 
work presented in this study confirms hen’s egg yolk as an important source of food 
allergens. The recombinant allergens produced in this study may be useful in the 
preparation of standardised reagents for the diagnosis and immunotherapy of hen’s 
egg yolk allergy in the future.  
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Chapter 1: Literature review 
 
Publication: 
Dhanapala P, De Silva C, Doran T & Suphioglu C (2015): Cracking the egg: an 
insight into egg hypersensitivity, Molecular Immunology: 66: 375-383. 
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1.1 An insight into allergy: Classification and nomenclature 
 
Allergy is a term used to describe a collection of diseases manifesting in many 
different ways such as, food allergy (gastroenteritis), asthma, urticaria, anaphylaxis 
and rhinitis [1, 2]. Allergies mainly occur in young children. However, they can 
affect individuals from any age group, from infancy to adulthood to elderly [1]. In 
technical terms, allergy is a hypersensitivity disorder of the immune system caused 
by non-pathogenic environmental substances resulting in self-inflammatory damage. 
Antigens that trigger allergic reactions are termed as allergens. Hypersensitivity 
reactions of non-immunological nature are not categorized as allergies. For example, 
food intolerance due to enzymatic defects or pharmacological activity and side 
effects to drugs belong to non-allergic hypersensitivity disorders [2-4].  
Traditionally, allergic diseases were classified under Type I hypersensitivity 
according to Gell and Coomb’s classification of hyper-immune diseases (Table 1.1) 
[5]. Mutually exclusive and distinct pathophysiological mechanisms responsible for 
disease progression and symptoms were used as the basis for this classification [4-6]. 
Since the conception of Gell and Coomb’s classification about 40 years ago, 
numerous patho-physiologies and patho-mechanisms underlying allergic diseases 
have been discovered. Although, the framework provided by Gell and Coomb’s 
classification is not inaccurate, it is now considered outdated [3, 4, 6, 7]. Therefore, 
Gell and Coomb’s classification of hypersensitive diseases is no longer used in 
relation to allergic diseases. Nevertheless, it is still used by some authors 
occasionally when describing hypersensitivity diseases including allergies [4, 6]. 
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Table 1.1: Gell and Coomb’s classification of hypersensitivity disorders of the 
immune system [5, 8]. 
Category Disease name Mediator Antigen 
Type I Allergy IgE Allergens 
Type II Cytotoxic 
hypersensitivity 
IgG, IgM, 
complement 
Individual’s own 
cells, drugs, 
haptens 
Type III Immune complex 
hypersensitivity 
IgG, IgM Foreign sera, 
therapeutic 
antibodies 
Type IV Delayed-type 
(cellular) 
hypersensitivity 
T lymphocytes, 
macrophages 
Mycobacterium 
tuberculosis, heavy 
metals (Ni) 
 
A revised classification for allergic diseases is formulated by the European Academy 
of Allergy and Clinical Immunology (EAACI) nomenclature task force.  According 
to EAACI position paper, allergic diseases are separated into two categories, based 
on its immuno-pathological mechanisms known as antibody-mediated and non-
antibody mediated [3]. Majority of patients with allergies exhibit antibody-mediated 
allergic diseases. In antibody-mediated allergic diseases, the immune system 
produces antibodies of immunoglobulin E (IgE) isotype against allergens. 
Consequently, these patients are said to be suffering from IgE-mediated allergy. By 
contrast, patients suffering from non-antibody mediated allergy, do not exhibit raised 
levels of allergen specific IgE. Nevertheless, those patients also exhibit and suffer 
from typical allergic symptoms, as in IgE-mediated allergy. Little is known about the 
underlying mechanism responsible for non-IgE mediated allergies. However, it is 
believed that a cellular mechanism, independent from IgE antibodies, is responsible 
for non-antibody mediated allergic diseases [3, 7].  
The term atopy was introduced by Coca & Cooke in 1926 to describe the inherited 
hypersensitivity towards allergens in man [9]. Over the years, many physicians and 
researchers used the term atopy, simply to describe IgE-mediated allergic diseases. 
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However, at the same time, paediatricians used the term atopy to describe the genetic 
predisposition to develop IgE-mediated allergies due to the strong familial basis [4]. 
Because of this inconsistent use of the terminology, much confusion was created 
among readers. Therefore, EAACI position paper re-defined atopy as the genetic 
predisposition to produce IgE antibodies against allergens and develop typical 
symptoms of allergies. Therefore, the term atopy is no longer used to describe an 
IgE-mediated hypersensitivity [3, 7]. 
1.2 Molecular and cellular basis of allergy 
1.2.1 The role of T cell subsets in allergy and health 
 
Cluster differentiation 4 (CD4+) T helper (Th) lymphocytes are the main effector 
cells involved in pathogenesis of allergic diseases [10, 11]. Functional Th cell 
subsets include Th1, Th2, Th9, Th17, Th22, regulatory T (Tr) and follicular helper 
cells based on their overall cytokine secretion profile. It has been shown that all T 
helper cell subsets are derived from the same precursor Th cell known as 
undifferentiated or naive T helper (Th0) cell. Polarization into a committed Th cell 
subset from Th0 cells is driven under the influence of a combination of strong micro-
environmental signals and genetic factors acting at the level of antigen presentation. 
Initiation of a particular Th cell subset is directed through factors such as specific 
cytokines, cytokine receptors, and transcription factors at the time Th0 cells engage 
with the antigens [12]. Dose of antigen, route of antigen exposure, physical form of 
immunogen and the type of adjuvant are some of the environmental determinants 
proposed. However, the genetic basis of Th cell polarization still remains poorly 
understood [13-15]. In the context of allergies Th cell subsets, Th1, Th2 , Tr cell and 
recently identified Th17 subsets are of particular important in understanding the 
underlying mechanism governing pathogenesis of allergies [13-15].  
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Th1 lymphocytes produce interleukin-2 (IL-2), interferon-γ (IFN-γ) and tumour 
necrosis factor-β (TNF-β) and other cytokines responsible for macrophage activation 
and cell mediated immunity against intracellular pathogens such as bacteria and 
viruses. Th1 cell differentiation is stimulated by IL-12 and IFN-γ, and mediated by 
Signal Transducer and Activator of Transcription 4 (STAT4) and T-bet [12]. The 
signature Th1 cytokine, IFN-γ is known to activate macrophages and stimulate B 
lymphocytes to produce several subclasses of immunoglobulin G (IgG) antibodies, 
such as IgG1 and IgG3. IgG antibodies are capable of binding to high-affinity Fcγ 
receptors and complement proteins resulting in opsonisation and phagocytosis of 
particulate microbes [13].  Furthermore, Th1 cells are known to play a down-
regulatory function on Th2 activity by inhibiting IgE production by B cells [16].  
On the other hand, Th2 cells produce cytokines such as IL-4, IL-5, IL-6, IL-9, IL-10 
and IL-13 that promote antibody mediated defence against multicellular parasites 
such as gastro intestinal nematodes. Th2 cell differentiation is stimulated by IL-4 
mediated activation of Janus kinases 1 (JAK1) and JAK3 along with recruitment of 
transcription factors STAT3, STAT5, STAT6 and GATA3 [12]. IL-4 and IL-13 are 
known to stimulate IgE antibody production from B cells while IL-5 recruits and 
differentiates eosinophils. The main effector function of Th2 type cytokines are 
production of antigen specific IgE antibodies leading to mast cell and eosinophil 
mediated inflammation. Furthermore, an immunosuppressive role for Th2 
lymphocytes have been described since IL-4, IL-10 and IL-13 together are known to 
inhibit several macrophage functions. [16-19]. In the event of prolonged Th1 
response due to sustained intracellular microbial infection a switch to Th2 response 
may occur. This is considered as an important protective mechanism of Th2 immune 
response which results in downgrading the effects of prolonged cell mediated 
immunity of Th1 response which could damage the host [16, 20].  
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The IgE-mediated allergic hypersensitivity is considered to arise as a result of strong 
Th2 immune response against common environmental allergens in predisposed 
individuals. Cytokine profile of T cell clones derived from majority of allergic 
patients exhibit a Th2 phenotype with high production of IL-4, IL-5 and little or no 
production of IFN-γ [16, 20]. In healthy subjects, the concentration of serum IgE is 
the lowest compared to other 5 types of antibodies. The production of IgE is very 
low at birth and gradually increases until the age of 10 to 15 years. However, patients 
with allergies exhibit earlier and sharper IgE production indicating a predominant 
Th2 immune response [21].  
Furthermore, Th2 lymphocytes are known to preferentially induce production of 
IgG4 antibodies through the help of IL-10. The normal immune response of IgG4 is 
mainly limited to non-microbial antigens. The accompanying involvement of IgG4 in 
allergy has a protective role. In IgE-mediated allergies, increased production of IgG4 
antibodies is associated with a decrease in symptoms. In healthy individuals, the 
immune system reacts to allergens with increased allergen specific IgG4 antibodies 
without detectable IgE antibodies. This immune response is termed as the modified 
Th2 response, which represents the typical healthy immune response to allergens. 
However, it is quite common to find both allergen specific IgG4 and IgE antibodies 
together in affected individuals. Well known examples of this phenotype can be seen 
in allergy to bee venom, rodent proteins and mammalian serum albumins. 
Furthermore, IgG isotype (IgG1 and/or IgG4) is more common in subjects with IgE-
mediated allergy, than in IgE-negative subjects as in allergy to pollen and mites. 
Some allergens elicit the classical IgE-mediated immune response without any IgG 
antibody productions, whereas other allergens produce an IgG (IgG1 and/or IgG4) 
response without any detectable IgE. This difference in the type of immune response 
suggests that not all allergens are equal [22].  
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Two mechanisms have been suggested to explain the protective role of IgG4 
antibodies in relation to allergy. Firstly, it has been proposed that IgG4 antibodies act 
as blocking antibodies by preventing the interaction between IgE and allergens. On 
the other hand, IgG4 is considered as a marker for tolerance induction. A positive 
correlation has been observed between increments in IgG4 concentration, and 
reduction in allergic symptoms in follow up studies. However, the exact mechanism 
of IgG4 dependent tolerance induction is not clear. IgG4 is generally regarded as a 
non-pathogenic antibody. However, IgG4 has been implicated in both allergic and 
non-allergic diseases as well. For example BanLec1, a lecithin from banana is a 
known potent allergen that induces IgG4 resulting in allergies. However, the 
involvement of IgG4 antibodies as the sole food allergy mediator is not fully 
resolved. According to EAAIC taskforce report food specific IgG4 does not indicates 
food allergy. Furthermore, IgG4 antibodies are also involved in non-allergic diseases 
such as pemphigus and sclerosing autoimmune pancreatitis [22].    
In allergic individuals the underlying mechanism governing the preferential 
activation of allergen specific Th2 cells is not fully elucidated. The presence of IL-4 
in the immunological milieu of the patient during the initial allergen exposure is 
identified as a crucial factor driving the polarization of Th2 response. In vitro studies 
conducted using both human and murine T cells clones have demonstrated IL-4 as an 
important requirement for the development of Th2 immune response [23, 24].  
Furthermore, T cells from IL-4 deficient mouse models failed to stimulate a Th2 
response following in vitro stimulation [25].  However, despite these results it is still 
not clear what is the source of initial IL-4 production which is required for 
polarization of Th0 into active Th2 lymphocytes [16].     
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Tr cells are another subset of T lymphocytes described in humans responsible for 
suppression and regulation of overall immune responses against antigens. Majority of 
Tr cells exists as CD4+CD25+ T regulatory 1 (Tr1) type, secreting cytokines IL-10 
and transforming growth factor-β (TGF-β) (Figure 1.1) [26-28]. Tr1 cells play an 
important role in maintaining immunological tolerance to self and innocuous 
environmental substances by suppressing Th2 cells. Tr1 secreted IL-10 and TGF-β 
has shown to suppress IgE production and favour production of non-inflammatory 
antibodies such as IgG4 and immunoglobulin A (IgA).   Therefore, a weak Tr1 
immune function would lead to a stronger Th2 polarized immune response leading to 
allergy [26, 27]. Healthy and allergic individuals both represent Tr1, Th1 and Th2 
cells in different proportions. It has been proposed that the ratio all three T cell 
subsets to be a crucial factor determining health or allergy where patients suffering 
from allergy represent a dominant Th2 response against allergens while healthy 
individuals exhibit a dominant Tr1 response against allergens [27]. 
The newly discovered Th cell subset, Th17 has been reported to implicate in 
development of allergic asthma and atopic dermatitis. Development of Th17 cells is 
stimulated by TGF-β and IL-6 or IL-21, and is mediated by STAT3 and RAR-related 
orphan receptor gamma (RORγt). Th17 cells are characterised by the production of 
IL-17, IL-17F, IL-22 and other cytokines responsible for inducing autoimmunity. 
Studies conducted on mice have shown that IL-17 and IL-22 are capable of 
triggering inflammation. It has been shown that elevated levels of circulating Th17 
cells, plasma IL-17 and IL-22 are important characteristics of allergic asthma. 
However, the role of Th17 cells in development of allergic asthma hasn’t been 
completely elucidated. Further investigations at population level focusing on 
different classifications of asthma, and experiments on the cellular basis are required 
[12, 29].       
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1.2.2 Pathogenesis of IgE-mediated allergy 
 
The IgE-mediated immune response occurs in a cascade fashion from initial allergen 
exposure to the ultimate tissue inflammation. For simplification, the IgE-mediated 
allergic reaction is described in two phases known as sensitisation phase and 
activation phase (Figure 1.1) [2, 10, 15, 30].  
1.2.2.1 Sensitisation phase 
 
Immunological sensitisation starts during the initial encounter between an allergen 
and the immune system. Infiltrated allergens are captured by antigen presenting cells 
(APC) such as dendritic cells, macrophages and granulocytes, most likely from the 
site of entry. The epitopes of internalized allergens are then processed and presented 
to Th0 cells through class II major histocompatibility complex (MHC) molecules of 
APCs. Following engagement with the presented allergens, Th0 cells differentiate 
into an active cytokine secreting Th2 state. Polarization into Th2 lymphocytes is 
further aided by the presence of IL-4 in the patient’s immunological milieu.  Th2 
cells produce cytokines such as IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 that provide 
optimum help for IgE production, and activation of cellular components of the 
allergic cascade [2, 4, 13, 15, 31].  
Cytokines IL-4, IL-5 and IL-13 are recognized as the signature cytokines of Th2 
lymphocyte profile. IL-4 is the main cytokine responsible for inducing B cells to 
produce allergen specific IgE antibodies and further enhances the development of 
additional Th2 cells. Newly synthesized IgE antibodies then bind with high affinity 
IgE receptors (FcεRI) expressed on the surfaces of mast cells and basophils. IgE 
bound mast cells and basophils are now said to be sensitised, since they can be 
activated by subsequent allergen exposures. IL-5 has a role in development and 
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activation of eosinophils, which produce high levels of inflammatory mediators. IL-
13 further enhances IgE production and stimulates mucus secretion by epithelial cells 
[2, 4, 10, 13, 15, 31-33].  
1.2.2.2 Activation phase 
 
When a sensitised immune system is exposed to the same allergen, or a different 
cross-reactive allergen with the same IgE-binding epitopes, they bind and cross-link 
IgE immobilised on mast cells and basophils. Cross-linking cell bound IgE results in 
explosive degranulation of mast cells and basophils, releasing chemical mediators 
such as histamines, prostaglandins, cytokines and leukotrienes, which are responsible 
for the typical symptoms of allergy [10, 32].  
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Figure 1.1: The steps involved in the IgE-mediated allergic reaction. At the 
initial allergen exposure, APCs capture and present the allergens to Th0 cells. With 
the aid of IL-4 in the patient’s immunological milieu Th0 cells differentiate into an 
active Th2 type, secreting cytokines such as IL-4, IL-5 and IL-13. IL-4 produced by 
Th2 cells then activates B cell to produce allergen specific IgE antibodies and further 
enhances the differentiation of Th0 into Th2. At the end of the sensitisation phase 
IgE antibodies bind to FcεRI on mast cells and basophils. During the secondary and 
subsequent exposures to the same offending allergen they bind and cross-link IgE 
immobilised on mast cells and basophils. Cross-linking IgE antibodies result in 
explosive degranulation releasing variety of chemical mediators causing 
inflammation.  
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1.2.3 Pathogenesis of non-IgE mediated allergy 
 
Non-IgE mediated allergies are less commonly encountered than IgE-mediated 
allergic diseases. The underlying mechanism responsible for pathogenesis of non-IgE 
mediated allergies is believed to be cause by mechanisms independent from IgE 
antibodies. However, the pathophysiological mechanism responsible for non-IgE 
mediated allergic reaction is poorly understood. Non-IgE mediated allergies are 
mainly caused by food proteins, especially cow’s milk proteins (CMP) and soy 
proteins. Therefore, non-IgE mediated allergies are often referred to as non-IgE 
mediated food allergies (NFA). Some common manifestations of NFAs include food 
protein-induced enterocolitis syndrome (FPIES), food protein-induced allergic 
proctocolitis (FPIAP), and food protein-induced enteropathy (FPE) [34-36].  
Typically, patients suffering from NFAs do not exhibit allergen specific IgE 
antibodies in serology based diagnostic tests. However, some patients with NFAs 
were found to have low levels of IgE against offending food allergens. For example, 
some patients suffering from FPIES are reported to exhibit detectable levels of 
allergen specific IgE antibodies. Nevertheless, the clinical relevance between 
allergen specific IgE antibodies and FPIES is still not clear [37, 38].  
Only a limited number of studies have addressed the underlying immunological 
mechanism of NFAs. TNF-α is known to play an important role in pathogenesis of 
NFA. It has been shown that in patients with cow’s milk allergy, TNF-α production 
by mononuclear cells increases following CMP challenge leading to increased 
intestinal permeability [39]. A central role for TNF-α in pathogenesis of NFAs is 
further supported by studies presenting evidence of increased amounts of faecal 
TNF-α and the presence of TNF-α in the duodenal biopsy specimens in patients with 
FPIES. Furthermore, it has been shown that intact CMP holds a superior capability to 
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stimulate PBMCs from patients with FPIES to produce TNF-α than processed CMP. 
The authors also reported a substantial drop in TNF-α production following 
avoidance of CMP in FPIES patients [40-42]. The Th lymphocyte response in NFAs 
is also predominantly directed towards Th2 type as in IgE-mediated allergies 
however, without detectable allergen specific IgE antibodies. Morita et al., 
demonstrated that Th2 cytokines, namely IL-3, IL-5 and IL-13, were significantly 
produced by PBMCs from patients with NFAs when stimulated with CMP [43]. The 
increased production of TNF-α and the polarization of Th0 cells into Th2 state can be 
considered as important steps in pathogenesis of NFAs [38, 43-45].  
1.3 Allergens 
 
Antigens that stimulate IgE-mediated or non-IgE mediated allergic hypersensitivity 
disorders are defined as allergens [3]. Existing studies on molecular, biological and 
immunological basis of allergens are primarily investigated in the context of IgE-
mediated allergy. In this thesis, the role of allergens will be discussed in relation to 
IgE-mediated hypersensitivity only. Allergens are derived from numerous sources 
such as foods, animal dander, chemical additives, drugs, fungi, insect stings and 
pollen [19]. 
Most of the well-known allergens are glycoproteins with molecular masses ranging 
from 5 kDa to 70 kDa. The antigenic determinants of those allergenic glycoproteins 
are commonly found on their protein components [46]. Traditionally, it was thought 
that carbohydrates are not capable of serving as epitopes resulting in the formation of 
specific IgE antibodies.  However, this assumption has been proven false by studies 
presenting evidence on carbohydrates containing allergenic epitopes. For example, 
allergy to cetuximab, (chimeric mouse-human IgG1 monoclonal antibody against 
epidermal growth factor receptor) arises as a result of producing specific IgE 
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antibodies against oligosaccharide galactose-α-1,3-galactose on the Fab portion of 
the heavy chain [47, 48]. Furthermore, pure carbohydrates are also reported to cause 
IgE-mediated hypersensitivity as in allergy to galacto-oligosacharides (GOS) [48].  
Significant proportion of studies has been dedicated to investigate the role of food 
allergens in causing IgE-mediated hypersensitivity. Most common IgE-mediated 
food allergies in children are caused by peanuts, milk and hen’s egg proteins. 
Majority of the food allergies seen in adults are attributed to allergens derived from 
peanuts, tree nuts, fish and shellfish. All of these food sources contain thousands of 
proteins and yet only a handful of them cause allergy [49]. 
Availability of high amounts of allergenic proteins in the food source, resistance to 
processing, digestion and existence of multiple linear IgE binding epitopes are some 
characteristics of food allergens [46, 49]. The presence of proteins in high quantities, 
as a requirement to act as an allergen, is demonstrated by the increased prevalence of 
codfish allergy among Norwegians. The increased consumption of codfish coincides 
with the high frequency of codfish allergy in Norway. Consequently, allergy to fish 
is not prominent in Texas where beef consumption is high [46].  A single allergen is 
considered to carry at least two IgE-binding epitopes in order to cross-link mast cell 
bound IgE. Two types of IgE-binding epitopes are described, known as linear and 
conformational. Linear or sequential epitopes only require the primary amino acid 
sequence of the protein for IgE binding. On the other hand, conformational epitopes 
require secondary or tertiary structures in addition to the primary amino acid 
sequences for IgE binding. Conformational epitopes are mainly seen in aeroallergens 
where allergens are presented to the immune system in their native form. On the 
other hand, linear epitopes are of particular importance to food allergens. Food 
allergens are presented to the immune system after partial digestion or denaturation 
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in the gastrointestinal tract, which reveal their linear epitopes. Study by Vila et al., 
showed that patients with milk allergy have higher specific IgE antibodies to linear 
epitopes than to native α and β casein proteins [50].  
Resistance to digestion and denaturation is considered a distinctive character of food 
allergens. The ability of food allergens to withstand digestion in the gastrointestinal 
tract increases the probability of encountering the immune system in their intact 
form. Numerous studies have reported that food allergens hold a superior capability 
to resist in vitro pepsin digestion compared to non-food allergens and non-allergenic 
proteins. However, these in vitro digestion models do not fully represent the human 
digestion. Therefore, further studies are required to evaluate the relationship between 
allergenicity and resistance to gastric acid digestion [46, 49].  
Three-dimensional structures of some allergens have been studied using X-ray 
diffraction and nuclear magnetic resonance (NMR) in order to find a unifying link 
among allergens. Birch pollen allergens Bet v 1 and Bet v 2 and timothy grass pollen 
allergen Phl p 2 are some of the allergens subjected to structural studies. These 
studies found that the shape and the dimensions of the allergens to be a common 
trait. The average shortest and longest dimensions of the allergens were 3.4 nm and 
4.4 nm, respectively, giving them a spherical shape. However, structures of many 
more allergens need to be analysed to obtain a better understanding of the molecular 
basis of allergenicity [46].  
Obviously, not all proteins with above-mentioned characteristics are allergens.  
Therefore, it is still not clear why some proteins act as allergens while others do not. 
Development of an allergic disease is multifactorial. An allergen must be presented 
to a genetically or environmentally predisposed individual in order to induce an 
allergic reaction [19]. In order to find the answer to the question “What makes a 
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protein an allergen?”, genetic and environmental factors must be taken into account 
as well, along with their biochemistry. 
1.4 Risk factors of allergic diseases 
1.4.1 The genetic basis of allergic diseases 
 
Pathogenesis of allergic diseases is considered to have a strong hereditary factor. The 
risk of developing allergic diseases is higher in individuals with a family history. For 
example, a positive family history is found to be a strong risk factor for both asthma 
and rhinitis [51, 52]. An epidemiological study from Sweden showed that the risk of 
developing asthma and rhinitis increases up to four-fold and six-fold, respectively, in 
individuals with a family history [53]. Another population-based study from 
Germany investigated the risk of developing asthma and rhinitis in children with 
affected parents. This study estimated that if one parent had asthma, the odds ratio of 
a child inheriting asthma to be 2.6. The odds ratio reported for rhinitis was 3.6. 
However, the same study reported that 22% of children without a positive family 
history to be suffering from allergic diseases as well, indicating the influence of 
environmental factors [54].  
Although, there is compelling evidence of familial basis of allergic diseases, 
identification of culprit genes had been problematic. The presences of multiple 
markers, vaguely described phenotypes and possible involvement of multiple genes 
have all contributed to difficulties in conducting genetic studies. Multiple 
chromosome regions are implicated with numerous phenotypes of allergic diseases, 
indicating the genetic heterogeneity of allergies. Candidate gene approach and 
positional cloning are some of the techniques used to identify genes related to 
allergic diseases. Candidate gene approach is used to identify disease genes through 
polymorphisms in known genes. On the other hand, positional cloning involves 
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linking suspected chromosomal regions with a disease through genetic markers  [55, 
56].  
Several loci have been linked with IgE-mediated allergy by candidate gene approach. 
IgE-mediated allergy to short ragweed pollen allergen Ra5 has been reported to be 
involved with an allele of the HLA-DR (Human Leukocyte Antigen-antigen D 
Related) locus [57]. Furthermore, polymorphisms of the β-chain of the FcεRI 
receptor and IL-4 family of cytokine genes on chromosome 5 have been linked with 
IgE-mediated allergy [58, 59]. However, candidate gene studies had yielded some 
conflicting reports as well. For example, some alleles found to be linked with asthma 
were independent of raised IgE levels and other markers of IgE-mediated allergy 
[60]. 
Positional cloning studies have linked several chromosomes and chromosomal 
regions with allergic phenotypes, in particular with asthma and rhinitis. Diverse 
populations have been used for positional cloning studies. However, majority of the 
studies have included predominantly Caucasian populations. Some recently reported 
allergy related genes are ADAM33 on chromosome 20p, SPRINK5 on 5q31-35, 
IRAKM on 12q, DPP10 on 2q14-32, GPRA on 7p, HLA-G on 6p21 and PHF11 on 
13q14 [61-67]. A common finding in many studies was the existence of multiple 
susceptible loci in many linkage regions of chromosomes. Positions 31 to 35 on the 
long arm of chromosome 5 have shown to harbour multiple genes related to 
pathological mechanisms of allergy.  Genes regulating Th1/Th2 polarization and IgE 
production (i.e. IL-4, IL-13, TIM1 and TIM3), innate immunity (i.e. CD14) and 
genes improving T cell adhesion (i.e. CYFIP2) are some examples for susceptible 
genes on chromosome 5 with links to allergy [56, 59].  
Study conducted by Tripathi et al., using Boston Birth Cohort (BBC) investigated the 
link between allergic sensitisation to common environmental allergens, and 
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cockroach allergens with single-nucleotide polymorphisms (SNP) in known 
candidate genes in the pathogenesis of allergic diseases. It was shown that SNPs near 
or in JAK2, CNOT6, MAML1, CD40, IL-4R, and IL-5RA genes were associated 
with allergic sensitisation. SNPs near or in JAK1, JAK3, IL-5RA, FCER1A, and 
ADAM33 genes were associated with cockroach sensitisation. SNP rs6665683 in 
FCER1A was shown to have a strong association with cockroach sensitisation and 
high levels of specific IgE to cockroach allergens. Also SNP rs7851969 in JAK2 
showed consistent association with sensitisation to house dust mite, and cockroach 
allergens. Further validation to these findings can be brought by analysing the same 
genes on different populations [68].  
Large number of susceptibility genes for allergies have been uncovered by Genome-
wide association studies (GWAS). According to the Catalogue of Published 
Genome-Wide Association Studies, there are about 40 GWAS for asthma and 3 
GWAS for atopy been conducted along with a plethora of susceptible genes and loci.  
However, association of a gene to allergic disease does not certainly imply biological 
functionality. Therefore, follow-up studies are required to translate findings of 
GWAS into the biological functionality, which will then enhance diagnosis and 
therapeutics of allergies [69].  
1.4.2 The environmental basis of allergic diseases 
 
The rising incidence of allergic diseases cannot be justified by genetics alone. The 
history of environmental exposure and life style of affected individuals are also 
important risk factors of allergies.  This dimension of the allergic diseases was 
conceived from epidemiological studies, which illustrate the association between 
human health and adverse environmental conditions. The change in the environment 
could mean an addition of a risk factor such as infectious agents resulting in plagues. 
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However, the opposite is also true where an alteration in the environment results in 
removal of a protective factor leading to diseases [70]. Based on this model, 
epidemiologist David Strachan conceived the idea of hygiene hypothesis in his study 
that used the 1958 British birth cohort [71]. Hygiene hypothesis regards infections in 
early childhood as protective, which may prevent the development of allergies. 
Hygiene hypothesis also states that this benefit of infections is lacking or limited in 
highly developed regions of the world when compared to the rest of the world due to 
sanitary living standards and advanced health care. Excessive cleanliness, 
vaccinations and wide spread use of antibiotics commonly seen in the urban Western 
lifestyle, are considered strong risk factors for development of allergies [70-72].  
Even though, hygiene hypothesis is a well-accepted theory, there are evidence that 
do not agree with it. In Japan, where hygiene standards are high, asthma levels are 
much lower than in the United States or Australia. Also in the United States asthma 
is reported to be high among children who live in very poor housing [73].  
1.4.2.1 Cellular and molecular basis of hygiene hypothesis 
 
The framework required to support hygiene hypothesis is laid down by both the 
Th1/Th2 imbalance theory and early life events leading to allergic sensitisation. The 
capacity to mount an immune response against common environmental allergens is 
acquired even before birth. During the gestation period, the foetal immune cells 
normally assume a Th2 and Tr1 type response. Therefore, foetus is exposed to high 
concentrations of Th2 and Tr1 type cytokines. This is believed to be an adaptation by 
the foetus to down-regulate maternal Th1 immune response against foeto-paternal 
antigens, which may lead to foetal rejection. In addition, studies have demonstrated 
that foetus is often exposed to allergens that cross the placenta from the maternal 
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circulation. Therefore, in-utero priming of T lymphocytes by allergens and allergen 
sensitisation is possible [55, 74, 75].  
However, after birth it has been suggested that a normal individual’s immune system 
gradually changes to a Th1 type immune response against common environmental 
allergens.  By contrast, in potentially allergic individuals, further upregulation of Th2 
type immunity takes place. It has been proposed that in healthy subjects the shift 
from Th2 to Th1 immunity against allergens is achieved through the aid of 
infections. Macrophages when engulfing microbes such as Mycobacteria and 
Lactobacilli secrete IL-12, which is a known potent stimulator of Th1 lymphocytes. 
Therefore, it is said that IL-12 rich environment drives the development of Th1 
lymphocytes leading to down-regulation of Th2 lymphocytes [55, 74, 75].  
1.4.2.2 Population based studies on hygiene hypothesis 
 
Comparative studies conducted at the population level have provided some wide 
spread support to hygiene hypothesis [19, 55]. One of the most informative studies 
ever performed was the investigation of former East and West German populations 
following the fall of Berlin wall in 1989. Unification of Germany allowed researches 
to study genetically equal populations, which used to live under very different 
environmental conditions for about four decades. Allergies such as hay fever in 
particular were less common in East Germany than West Germany before 
unification. However, after unification an increase in hay fever among children from 
former East Germany was reported, with the advent of Western life style [76].  
Furthermore, an inverse relationship between allergies and infectious diseases was 
shown by serological studies conducted on hepatitis A, Helicobacter pylori, 
Toxoplasma gondii, childhood measles and Mycobacterium tuberculosis. During 
infections with such microbes, macrophages become active and secrete IL-12, which 
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promotes Th1 type immunity leading to down-regulation of Th2 immune response. 
These findings explain why populations, particularly in Western Europe, North 
America and Australia, exhibit a high degree of allergies due to the lack of infections 
caused by high sanitary living conditions [19, 55].  
1.5 Egg allergy 
 
Allergy to hen’s (Gallus domesticus) egg is one of the most common forms of 
childhood allergies seen in industrialised countries. The prevalence of egg allergy 
sufferers in industrialised countries ranges from 1.6% to 3.2% [77, 78]. The 
development of egg allergy generally occurs during infancy and resolves before the 
school age. Sensitisation to egg allergens can occur even before birth in utero and 
during breast-feeding. As a consequence, clinical reactions to eggs, even without 
direct exposure, can occur in infants sensitised in such ways [79]. Egg allergens are 
known to cause both IgE-mediated and non-IgE mediated allergic reactions. 
However, the most common form of egg hypersensitivity is due to IgE-mediated 
allergy. Clinical manifestations to egg allergy occur in various organ systems such as 
the skin, the respiratory system and the gastrointestinal system. Some of the common 
forms of clinical signs and symptoms of egg allergy are urticaria, angioedema, 
asthma and vomiting. In infants, the most common clinical manifestation is atopic 
dermatitis. Severe anaphylaxis due to egg allergy is possible, especially in patients 
with acute IgE-mediated sensitivity to hen’s egg. For example, 7% of severe 
anaphylactic reactions were reported due to egg ingestion in infants according to a 
survey from Germany. Generally, fatal reactions due to eggs are uncommon, but 
have been reported [78, 80].  
Six allergenic proteins from both the albumen and the yolk have been identified from 
the hen’s egg. The egg white contains four well known allergens, namely ovomucoid 
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(Gal d 1), ovalbumin (Gal d 2), ovotransferrin (Gal d 3) and lysozyme (Gal d 4) [78]. 
The egg yolk consists of two minor allergens known as α-livetin (Gal d 5) and yolk 
glycoprotein 42 or YGP42 (Gal d 6) [81, 82]. The immunogenic properties of egg 
white allergens have been extensively studied over the years [78]. Some of the 
earliest studies reported the degree of allergenicity of egg white allergens to be in the 
following order: lysozyme, ovomucin, ovalbumin and ovomucoid, based on skin 
prick test (SPT) diagnosis. However, further studies demonstrated that ovomucoid to 
be the dominant allergen followed by ovalbumin, ovotransferrin and finally 
lysozyme [83-87].  
Egg yolk proteome was not a popular subject for immunological studies like the egg 
white [78]. However, a limited number of studies have confirmed egg yolk as a 
source of allergenic proteins [78, 81, 82]. Currently, there could be many knowledge 
gaps in regards to the allergenicity of the hen’s egg yolk. For example, the frequency 
of recognition of egg yolk allergens in sensitised patients, T and B cell epitopes 
relevant to yolk allergens and the association of egg white and egg yolk allergies still 
remain to be investigated. 
1.5.1 Allergy to egg yolk 
 
Allergy to egg yolk is present in a considerable percentage of individuals however, 
with much less prevalence and potency than allergy to egg white. Unlike egg white 
allergy, which is commonly seen in young children with atopic dermatitis, egg yolk 
allergy mostly affects during the adulthood. The underlying immunological 
mechanism responsible for egg yolk allergy is IgE-mediated according currently 
available reports, and usually produce symptoms such as urticaria, vomiting, 
abdominal pain and diarrhoea [88-90].  
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The true existence of allergy to egg yolk was highly doubtful in the past despite well-
investigated reports on anaphylactogenic properties of egg white constituents. 
Although sensitisation to egg yolk had been reported before, its actual existence were 
not confirmed and the general notion was that allergy to egg yolk cannot occur 
without the existence of egg white allergy [91].   
However, Rubin SS., for the first time presented a case of a genuine sensitisation to 
egg yolk independent of egg white allergy [91]. The report describes the case of a 
19-year-old soldier, who was diagnosed with angioneurotic oedema following typhus 
fever and yellow fever vaccines. According to the patient’s medical history, he was 
not able to tolerate eggs but was able to consume hard-boiled egg white without any 
complications. SPTs on the patient were positive for egg yolk and negative for egg 
white, chicken feathers and chicken meat [91].  
Yellow fever and typhus fever vaccines are cultured in chick embryos and yolk sacs, 
respectively. It had been shown that those vaccines contain egg yolk constituents. 
Considering the patient’s medical history and SPT results, the author was able to 
conclude definitively that the allergic manifestations were due to egg yolk 
components in the administered vaccines. As a result, this case report confirmed the 
fact that genuine sensitisation to egg yolk exists and that it can occur without 
concomitant egg white sensitivity [91].  
1.5.2 Allergens in the hen’s egg Yolk 
 
1.5.2.1 Chicken serum albumin (Gal d 5) 
 
Chicken serum albumin (CSA) also known as α-livetin, is Gal d 5 the first allergen 
identified from the hen’s egg yolk. Gal d 5 is synthesised in the liver of laying hens 
and present in both the blood circulation and the egg yolk [82, 92]. It is a water-
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soluble globular glycoprotein with a molecular weight of 69 kDa.  Gal d 5 had been 
confirmed as an inhalant allergen as well as a food allergen through bronchial 
provocation and oral challenge tests, respectively. Gal d 5 is a partially heat resistant 
allergen, thus some patients are able to tolerate extensively heated egg yolk, but not 
raw egg yolk. The main route of sensitisation for Gal d 5 is through the respiratory 
tract as seen in bird-egg syndrome [82].  
Table 1.2: The six main allergens from the hen’s egg white and the yolk 
(allergen data obtained from www. allergen.org) 
Allergen name Source of 
the allergen 
Biochemical name(s) MW(SDS-PAGE) 
kDa 
Gal d 1 Egg white Ovomucoid 28 
Gal d 2 Egg white Ovalbumin 44 
Gal d 3 Egg white Ovotransferrin 78 
Gal d 4 Egg white Lysozyme 14 
Gal d 5 Egg yolk Chicken serum albumin/α-
livetin 
69 
Gal d 6 Egg yolk YGP42 35 
 
1.5.2.2 The bird-egg syndrome 
 
Bird-egg syndrome is an IgE-mediated hypersensitivity disorder. In bird-egg 
syndrome, allergy to egg yolk develops, following sensitisation to inhalant avian 
antigens derived from sources such as bird’s blood serum, feathers, droppings and 
dander [89]. This is different to cross reactivity, where a patient allergic to a certain 
allergen reacts to homologous or non-homologous allergens from the same or 
different species [93, 94]. In bird-egg syndrome, sensitisation and allergy to egg yolk 
occurs due to a common allergen present in both avian antigens and the egg yolk. 
The common allergen present in hen’s egg yolk and other avian antigens is Gal d 5 
[90, 92]. 
Most patients with bird-egg syndrome have regular exposure to pet birds or poultry 
where sensitisation to inhalant avian antigens occurs. Patients with bird-egg 
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syndrome suffer from both respiratory and gastrointestinal allergic symptoms such as 
asthma, rhinoconjunctivities, oedema, diarrhoea and vomiting. Unlike allergy to egg 
white, which is predominantly seen in children with atopic dermatitis, bird-egg 
syndrome mainly affects adults with an obvious gender predisposition where 
majority of patients tend to be females [89, 90]. The higher number of females 
reported in these studies may just relate to higher number of females in the poultry 
industry. However, in the study conducted by Quirce et al., majority of the patients 
with bird-egg syndrome was males [82]. Furthermore, allergens produced by birds at 
workplace may also increase IgG levels in excess and can lead to allergic alveolitis. 
Currently, these IgG levels can be quantified and qualitatively evaluated using the 
UniCAP system, a type of ImmunoCAP [95]. Furthermore, radioallergosorbent test 
(RAST) inhibition experiments had demonstrated inhibition of IgE binding to 
livetins of hen’s egg yolk by avian antigens from different bird species. This result 
indicates that serum proteins from different bird species have highly conserved 
epitopes which allow specific IgE antibodies to cross react [89]. 
1.5.2.3 YGP42 (Gal d 6) 
 
Gal d 6 is the second allergen identified from the hen’s egg yolk. It is a glycoprotein 
with a molecular weight of 35 kDa. Gal d 6 is the C-terminal fragment of 
vitellogenin-1 (VTG-1) precursor, which is a serum lipoprotein specific for laying 
hens. VTG-1 is produced in the liver of laying hens and transported into the growing 
oocyte by receptor-mediated endocytosis. Following delivery into the oocyte, VTG-1 
precursor is enzymatically cleaved into several fragments giving rise to mature 
proteins lipovitellin-1, phosvitin, lipovitellin-2 and YGP42 [81, 96].  
Gal d 6 contains three glycosylation signals at positions 1662, 1698 and 1703. The 
periodate oxidation treatment of Gal d 6 does not abolish the IgE binding capacity, 
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indicating that sugar residues are not related to allergenicity. Furthermore, heat 
treatment and reduction does not affect the allergenicity of Gal d 6. However, 
simulated gastric acid digestion completely eliminated its IgE reactivity. Gal d 6 was 
also investigated for any implication in bird-egg syndrome. The inhibition 
immunobloting experiments did not demonstrate any degree of inhibition of 
allergens from chicken meat and feather extracts. Therefore, Gal d 6 is not 
considered to be involved in bird-egg syndrome [81].  
1.5.2.4 Other IgE binding proteins in the egg yolk 
 
Apart from the recently discovered egg yolk allergens Gal d 5 and Gal d 6, few other 
proteins from the hen’s egg yolk proteome have exhibited a possible allergenic 
potential [97, 98]. Three abundant egg yolk proteins from the egg yolk known as 
apovitellenin I, apovitellenin VI and phosvitin have demonstrated substantial IgE 
binding capacity among egg allergic patients.  Furthermore, all of these proteins were 
found to effectively inhibit binding of egg yolk specific IgE. However, the clinical 
relevance of these proteins in relation to food allergy has not been established so far. 
Therefore, their status as allergens still remains uncertain [98].  
1.5.3 Diagnosis of egg allergy 
 
Several diagnostic tools must be used to confirm egg allergy in an individual. 
Diagnosis of egg allergy usually commences with an investigation of medical history 
and physical examination looking for evidence of clinical reactivity to eggs. Next 
steps may involve in vitro and in vivo diagnostic tests. Some of the commonly used 
diagnostic tests are the measurement of allergen-specific IgE antibodies, SPT, atopy 
patch tests, diagnostic elimination diets and oral food challenges (OFC) [80]. SPT 
involves introducing allergens into the skin using a lancet to detect egg specific IgE 
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antibodies [99]. The reliability of SPT depends on the quality of the allergen extract 
used. A wheal size greater than or equal to 3 mm is considered positive for egg 
allergy when a clear clinical history is taken into account. However, SPTs have a 
poor positive predictive value (PPV). Therefore, a positive SPT result without a 
clinical history may not indicate egg allergy. A negative SPT essentially rule out 
IgE-mediated egg allergy since it has a high negative predictive value (NPV) [80, 
100, 101]. 
Egg allergen specific IgE antibodies can be quantified using standardized in vitro IgE 
assays. As in SPT, the accuracy of the result heavily depends on the quality of the 
allergen extracts used. The predictive values for egg specific IgE for diagnosis 
reported by various study groups are not consistent. These variations are mainly due 
to the different parameters used in the studies. Therefore, it has been recommended 
to consider the relevant variables when determining cut-off levels in patient 
populations [102, 103].  
To date, the gold standard for diagnosis of all food allergies is double blind placebo 
controlled food challenge (DBPCFC). The major drawback of challenge tests is that 
it can trigger potentially life threatening allergic reactions. Therefore, challenge tests 
are only conducted by trained health care personal with adequate facilities. DBPCFC 
are widely used in diagnosis of egg and milk allergy however, requires substantial 
improvements for implication in everyday practice [102].  
1.5.4 Management of egg allergy 
 
Currently, there is no cure for allergies. Therefore, patients are required to undergo 
management according to the guidelines prepared by dieticians and clinicians. Egg 
avoidance is essential in managing egg allergy. Avoidance of eggs when they are 
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prepared in a recognizable form can be easily achieved. However, avoiding eggs in 
manufactured food products and contaminated food can be challenging. Furthermore, 
mothers nursing infants, who are known to be sensitised to eggs, must also take extra 
care since breast milk can contain egg allergens derived from the diet. Therefore, 
mothers may have to depend on an egg free diet if infants develop clinical reactions 
following breast feeding [104]. An egg free diet does not impose the risk of 
nutritional deficiency unless there are additional dietary limitations such as 
vegetarian diet or multiple food allergies. If such situation arises, a dietician should 
be consulted [101].  
Apart from dietary elimination of eggs, patients may have to avoid vaccines derived 
from chicken eggs. Measles, mumps and rubella (MMR), influenza and yellow fever 
vaccines are cultured in chicken eggs. Influenza and yellow fever vaccines both 
contain measurable quantities of egg proteins both from the albumen and the yolk 
and patients with egg allergy have reacted adversely following administration of 
these vaccines. Patients with mild egg allergy are capable of receiving the 
vaccination with minimal or no side effects. However, for patients with severe egg 
allergy, administration of vaccines is not generally recommended. However, MMR 
vaccine is deemed safe to administer to egg allergic patients. A large scale study that 
vaccinated egg allergic children showed no risk of severe allergic reactions [100, 
101, 105].  
In egg allergy, provision of emergency medication commonly involves the use of 
antihistamines and adrenaline. Antihistamines are administered orally and are 
recommended to treat mild reactions. Adrenaline is available as a self-injectable auto 
injector and is recommended in the event of severe allergic reactions. Both 
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medications provide symptomatic relief by reversing the effects of chemical 
mediators released during the allergic reaction [100, 101, 105].  
As for treatment strategies at experimental level, some progress has been made in 
increasing tolerance to eggs by means of oral immunotherapy, also known as oral 
tolerance induction (OTI). OIT has demonstrated successful results in peanut allergy. 
It has been shown that early consumption of peanuts in infancy to result in reduction 
of peanut allergy. These findings indicate that consumption of peanuts during 
infancy may result in prevention of developing peanut allergy [106]. Although some 
patients were able to tolerate certain doses of egg proteins, none of them were able to 
tolerate the complete dose. The efficiency of OTI is still questionable since it is not 
clear whether partial tolerance is resulted by OTI or due to spontaneous allergy 
resolution and therefore, it requires further investigations [104, 105, 107]. Based on 
the current results, OTI is still not recommended for use in routine clinical practice 
[105].  
1.6 A potential cure for allergies: Allergen-specific immunotherapy 
 
Allergen-specific immunotherapy (SIT) is the only treatment strategy that has 
demonstrated a curative potential in allergies [108]. SIT involves gradually 
administering allergen extracts to the patient in order to increase the capacity of the 
immune system to tolerate allergens [109, 110]. The allergen extracts used in 
immunotherapy are now known as allergen vaccines since they have the capacity to 
act as immune modifiers [111]. The traditional route of administration of 
immunotherapy is subcutaneously and known as injection immunotherapy. Injection 
immunotherapy is known as the most efficient form of immunotherapy. Nasal, oral, 
intra-lymphatic and sublingual are some other forms of immunotherapy. [109-111].  
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Injection immunotherapy is proven to work well with insect venom allergy, 
especially for Hymenoptera venom allergy. In fact, venom immunotherapy is now 
approved as the standard care for Hymenoptera venom allergy. Furthermore, some 
clinical trials have demonstrated promising results with allergen SIT for pollen 
allergy and house dust mite allergy [111, 112]. Injection immunotherapy also had 
limited success in reducing clinical reactivity in patients allergic to fruits, vegetables 
and tree nuts [107]. Despite these successes, immunotherapy for food allergies is still 
deemed unsafe. The last injection immunotherapy trial conducted to treat peanut 
allergy resulted in failure. Majority of patients in the test group produced severe 
adverse reactions following injection immunotherapy. Therefore, injection 
immunotherapy for food allergies is currently abandoned [111, 113, 114].  
The mechanism on how tolerance is achieved during immunotherapy is not well 
understood. Recent studies have shown that immunotherapy causes a change in the 
overall Th cell response by increasing Th1 differentiation and reversing Th2 into 
Th0. As a result of this immune deviation, the immune system increases the 
production of IgG1 and IgG4, while decreasing the production of allergen specific 
IgE [115]. Further observations during immunotherapy include an increase in CD8+ 
cells and reduction in inflammatory cell recruitment, activation and mediator 
secretion [111, 115].  
1.7 The application of recombinant DNA technology in allergy diagnosis and 
SIT 
 
Commercial allergen extracts, derived from natural sources, have many drawbacks 
that cannot be resolved by any practical methods currently available. Natural allergen 
products are often contaminated with various allergenic and non-allergenic 
substances. In some cases, the allergen of interest is very low or absent. Therefore, 
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patients undergoing treatment with natural allergen extracts face the risk of 
developing new sensitisations. Furthermore, precise diagnosis of allergic diseases is 
difficult with the use of natural allergen preparations due to the contamination issue 
[115-118].  
For successful diagnosis and SIT of allergic diseases, the purity and the definition of 
the allergen extracts are crucial. The above-mentioned difficulties associated with 
commercial allergen extracts can be successfully overcome with the use of 
recombinant DNA technology. With the use of recombinant DNA technology, 
recombinant allergens can be harvested in unlimited amounts with properly defined 
immunological, biological and molecular features. Recombinant allergens can be 
produced to mirror the IgE-reactivity of natural allergens for diagnosis and are 
already in use for clinical diagnosis [115-118].  
Furthermore, recombinant allergens can be genetically engineered to produce 
hypoallergens with reduced IgE-binding activity. Advantages of using recombinant 
based hypoallergens over natural allergens in SIT are two-fold. Firstly, hypoallergens 
offer improved safety due to low IgE-reactivity. Secondly, the dose that can be safely 
administered to patients can be increased. Therefore, the efficacy of hypoallergen 
based SIT can also rises with the dose increments [116]. The first injection 
immunotherapy trial conducted with recombinant based hypoallergenic variants of 
the major birch pollen allergen Bet v 1 was highly successful. Patients that 
underwent immunotherapy showed strong IgG antibody response against the Bet v 1 
allergen and exhibited reduced clinical reactivity during subsequent birch pollen 
seasons [116, 119]. 
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1.8 Aims of this study 
 
As described above, very little is known about allergy to egg yolk. The existence of 
allergy to hen’s egg yolk was highly doubted by many in the past. Recent discovery 
of allergens Gal d 5 and Gal d 6 has spurred much interest in hen’s egg yolk allergy. 
However, in depth investigations involving hen’s egg yolk in relation to food allergy 
has been rarely performed. Therefore, allergy to hen’s egg yolk is still a developing 
area. The use of recombinant allergens has been a very popular approach in the field 
of allergy for both diagnosis and therapy due to the many advantages they offer. 
However, to date, production of recombinant versions of hen’s egg yolk allergens 
Gal d 5 and Gal d 6 have not been reported in the literature. Thus, the main focus of 
this PhD project was to investigate allergy to hen’s egg yolk in humans, mainly at 
molecular level, and to produce recombinant versions of hen’s egg yolk allergens. 
The work of this thesis was conducted in order to provide a better understanding and 
fill research gaps in knowledge regarding allergy to hen’s egg yolk. Below is a brief 
description of the research hypotheses addressed and the manner in which they were 
investigated in this PhD project.  
 
In Chapter 2, I investigated the in vitro IgE-reactivity of hen’s egg yolk proteins 
using molecular and proteomic methods. Furthermore, in addition to hen’s egg yolk I 
included egg yolks from emu and quail in some of the work conducted. The first aim 
of this study was to investigate the existence of sensitisation to egg yolk proteins 
from hen, emu and quail in patients with allergy to hen’s egg white. It was 
hypothesised that majority of patients diagnosed with allergy to hen’s egg white 
would have concomitant sensitisation to egg yolk proteins. Here, Western 
immunoblot was used as a rapid method of identifying IgE reactive proteins using 
sera from a cohort of 25 egg white allergy patients. The second aim of this chapter 
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involved identifying the IgE-reactive egg yolk proteins from all of the bird species 
used in the Western immunoassays. The third and final aim of Chapter 2 was to 
produce a recombinant version of hen’s egg yolk allergen Gal d 6 as a soluble 
fraction in an E. coli expression system. It was hypothesised that cloning and 
expression of complementary DNA (cDNA) coding for Gal d 6 in E. coli would 
allow production of an IgE-reactive recombinant Gal d 6 as a soluble fraction. 
 
In Chapter 3, the main objective was to produce an IgE reactive recombinant version 
of hen’s egg yolk allergen Gal d 5 as a soluble fraction. Firstly, an E. coli expression 
system was used to clone and express recombinant Gal d 5. It was hypothesised that 
cloning and expression of cDNA coding for Gal d 5 in E. coli would allow 
production of an IgE-reactive recombinant Gal d 5 as a soluble fraction. However, 
the hypothesis was rejected as 100% of the recombinant Gal d 5 was expressed as an 
insoluble fraction by E. coli. Therefore, as an alternative method I used an eukaryotic 
protein expression system Kluyveromyces lactis (K. lactis) yeast strain. Here, I 
hypothesised that the cloning of cDNA coding for mature Gal d 5 in frame with the 
yeast secretion signal would allow production of recombinant Gal d 5 as a secreted 
protein. Finally, in this chapter, we comparatively analysed the IgE-binding 
reactivity of recombinant and natural Gal d 5 using sera from egg white allergy 
patients.  
 
In Chapter 4, the main objective was to produce a recombinant based mutant variant 
of Gal d 5 with reduced IgE binding capacity in order to develop a hypoallergen for 
potential use in immunotherapy in the future. In this Chapter, site directed 
mutagenesis (SDM) technique was used to disrupt disulfide bonds of Gal d 5 to 
synthesize a mutant Gal d 5 DNA. Then cDNA coding for mutant Gal d 5 was cloned 
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into K. lactis for recombinant protein expression. It was hypothesised that 
recombinant Gal d 5 with a modified conformation resulted by disulfide bond 
disruption would reduce or completely impair interaction with IgE antibodies. 
However, K. lactis yeast expression system failed to express the mutant Gal d 5 
despite successful cloning. Therefore, as an alternative approach I expressed mutant 
Gal d 5 as a soluble fraction in an E. coli expression system. The recombinant based 
mutant Gal d 5 was then comparatively analysed with wild-type recombinant Gal d 5 
to evaluate the IgE-binding capacity, which successfully demonstrated reduction in 
IgE binding.  
 
The Chapter 5, which is the final chapter of this PhD thesis, discuss the findings 
presented in Chapters 2-4.  All the findings are summarised and presented in Chapter 
5 and explains how the work of this PhD project has contributed to improve 
knowledge regarding allergy to hen’s egg yolk.   Furthermore, this chapter also 
provides future directions of the current project.  
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Chapter 2: Immunological analysis of egg yolk 
proteins from hen, quail and emu and production 
of recombinant Gal d 6 in E. coli 
 
 
Publication: 
De Silva C, Dhanapala P, Doran T, Tang MLK & Suphioglu C (2016): Molecular 
and immunological analysis of hen’s egg yolk allergens with a focus on YGP42 (Gal 
d 6), Molecular Immunology: 71: 152-160. 
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2.1 Introduction 
 
Hen’s egg has been a very popular diet in most regions of the world since ancient 
times [120]. Nevertheless, immunological hypersensitivity to hen’s egg is present in 
a significant percentage of children [121, 122]. The major allergens are found in the 
egg white.  On the other hand, egg yolk is also reported to exhibit low level 
allergenicity in humans [78]. Food allergy can be divided into primary and secondary 
food allergies based on the sensitisation process.  Allergic hypersensitivity reactions 
independent of sensitisation to offending food source is defined as primary food 
allergies. Secondary food allergy is defined as allergic hypersensitivity reactions 
arising as a result of initial sensitisation to offending food source. A study has 
demonstrated that approximately 9.4% and 5.5% of the population are affected by 
primary and secondary food allergies, respectively [123].  In adults, secondary food 
allergy often follows primary food allergy caused by inhalant or contact allergens. 
Secondary food allergy is mainly attributed to cross-reactive IgE antibodies that 
recognize homologous sequences among allergens. On the other hand, primary food 
allergies are mainly seen in children caused by the offending food allergens [123, 
124].  
Clinical studies have shown that sensitisation to egg white allergens precede onset of 
clinical reactivity to hen’s egg yolk. Development of egg allergy starts with 
sensitisation to Gal d 1 and Gal d 2. However, during the course of the disease, 
patients tend to produce IgE antibodies against other egg white allergens (Gal d 3 
and Gal d 4) and finally against egg yolk allergens. Furthermore, IgE reactivity to 
Gal d 5 has been identified as a marker for egg yolk sensitisation. Nevertheless, not 
all egg yolk allergic patients react with Gal d 5 and therefore, Gal d 6 or other 
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potential egg yolk allergens, such as apolipoproteins, may play a role in development 
of allergy to egg yolk [98, 124].  
Patients suffering from allergy to hen’s egg face significant challenges in terms of 
quality of life. Due to the lack of cure for egg allergy, avoidance of eggs and egg 
derived food products represents the sole strategy to manage the condition. As a 
consequence, there is a current trend towards consuming eggs from different bird 
species such as quail, duck, turkey (Meleagris gallopavo), sea-gull and emu 
(Dromaius novaehollandiae), as an alternative to hen’s egg. Nevertheless, clinical 
and serological cross-reactivity between hen’s egg allergens and proteins from other 
bird eggs such as turkey, duck, goose and sea-gull have been reported [125]. 
Additionally, allergy to quail, duck and goose eggs, independent from allergy to 
hen’s egg, have been reported as well [120, 126].  
Current data regarding hypersensitivity to bird eggs suggest that diagnosis of egg 
allergy should include discrimination of egg white and the yolk proteomes at 
molecular level. For proper patient management, in detail diagnosis, based on 
molecular techniques, may equip clinicians to provide better dietary advice. As a 
result, patients can avoid unnecessary dietary restrictions leading to improvements in 
quality of life. An important requirement for successful molecular based diagnosis is 
the availability of well-defined standardized allergen preparations. A popular 
approach for developing allergen preparations for diagnosis is the use of recombinant 
DNA technology to produce recombinant allergens that mimic the IgE-reactivity of 
their natural counterparts [116].  
The overall objective of this chapter was to subject egg yolk proteins of hen, emu 
and quail using immunological, proteomic and molecular methods in order to shed 
light on egg yolk allergy. The first aim of this chapter involved investigating the 
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sensitisation profiles of egg white allergic patients and compared in vitro IgE 
reactivity of egg yolk proteins from hen, emu and quail eggs. Furthermore, we 
discriminately analysed free range and caged chicken eggs in order to investigate if 
different environmental conditions of laying hens would influence the allergenicity 
of the egg yolk proteins. In this chapter, we used a cohort of 25 patients diagnosed 
with allergy to hen’s egg white using in vitro immunological methods.    
The second objective of this chapter involved producing an immunologically active 
recombinant hen’s egg yolk allergen Gal d 6 (rGal d 6).  In this chapter, we present 
the successful expression of rGal d 6 as a soluble fraction in E. coli. rGal d 6 was 
then subjected to in vitro immunological analysis using patients’ serum sensitised to 
natural Gal d 6 (nGal d 6) to compare its’ allergenicity with crude hen’s egg yolk 
extract.  
2.2 Materials & methods 
2.2.1 Immunological analysis of hen, quail and emu egg yolk extracts 
 
2.2.1.1 Human patients’ sera 
 
Sera from 25 patients allergic to hen’s egg white and non-allergic individuals as 
healthy controls were obtained from the Royal Children’s Hospital (Melbourne, VIC, 
Australia). The egg white specific IgE levels of patients are shown in Table 2.1. 
Experimentation involving patients’ sera was conducted in compliance with the 
National Statement on Ethical Conduct in Human Research (2007) with approval 
from Deakin University Faculty of Science, Engineering and Built Environment 
Human Ethics Advisory Group (HEAG), with a project approval number of STEC-
34-2013-DHANAPALA. 
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Table 2.1: The levels of allergen specific IgE antibodies against egg white 
determined by ImmunoCAP (Phadia) 
Patient 
number 
IgE level (IU/mL) against 
hen’s egg white 
1 93.50 
2 28.80 
3 13.60 
4  9.26 
5 13.20 
6 8.63 
7 6.89 
8 18.50 
9 16.50 
10 4.13 
11 3.62 
12 1.02 
13 1.21 
14 1.32 
15 1.72 
16 2.08 
17 2.21 
18 2.58 
19 1.78 
20 1.19 
21 1.25 
22 1.05 
23 0.32 
24 0.18 
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Patient 
number 
IgE level (IU/mL) against 
hen’s egg white 
25 0.47 
 
2.2.1.2 Preparation of crude egg yolk extracts (CEY) from hen, quail and emu 
eggs 
 
Chicken (White Leghorns) and emu eggs were provided by the Australian Animal 
Health Laboratory (AAHL, Geelong, VIC, Australia). Caged chicken eggs, free-
range chicken eggs and quail eggs were bought from a local market. Shelling and 
separation of the egg yolk from the albumen was performed manually. In order to 
minimize egg white contamination, intact yolks were rinsed thoroughly with 
deionized water (dH2O) and rolled on a filter paper to remove remaining residual egg 
white as much as possible. The vitelline membrane was pierced using a pair of 
tweezers and the yolk constituents were extracted with a pipette. The solubilisation 
of egg yolk samples was based on the method published by Guilmineau et al., [127]. 
One volume of egg yolk was mixed with 12 volumes of 0.1 M glycine/NaOH buffer 
(pH 9; 0.56 NaCl) and kept overnight at 4°C to equilibrate.  
2.2.1.3 SDS-PAGE analysis of CEYs of hen, quail and emu eggs 
 
Novex 4-20% Tris-Glycine gels (Thermo Fisher Scientific®, Waltham, MA, USA) 
were used for all sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) under reducing and denaturing conditions. Approximately 25 μg of protein 
was applied per lane. The CEY samples were prepared by dissolving in Novex Tris-
Glycine SDS sample buffer (2×) (Thermo Fisher Scientific®, Waltham, MA, USA), 
NuPAGE sample reducing agent (10×) (Thermo Fisher Scientific®, Waltham, MA, 
USA) and dH2O. The egg yolk samples were mixed by pipetting and heated at 85°C 
for 2 minutes prior electrophoresis. SeeBlue pre-stained protein standard (Thermo 
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Fisher Scientific®, Waltham, MA, USA) was used as the molecular weight marker. 
Electrophoretic separation was performed using an X-Cell SureLock Mini-Cell 
system (Thermo Fisher Scientific®, Waltham, MA, USA) applying a constant voltage 
of 125 V for 90 minutes. The protein bands were then stained for visualization using 
SimplyBlue SafeStain (Thermo Fisher Scientific®, Waltham, MA, USA). 
2.2.1.4 Western immunoassay of CEYs 
 
2.2.1.4.1 Western immunoassay of hen’s CEY with individual patients’ sera 
 
For the immunoassay with individual patients’ sera, only CEY prepared from hen’s 
eggs provided by AAHL was used. Following SDS-PAGE, proteins were electro-
transferred on to nitrocellulose membranes using X-Cell II Blot Module system 
(Thermo Fisher Scientific®, Waltham, MA, USA). The egg yolk immobilised 
nitrocellulose membranes were developed using WesternBreeze® Chromogenic 
Western Blot Immunodetection Kit according to manufacturer’s instructions 
(Thermo Fisher Scientific®, Waltham, MA, USA).  Following transfer, the 
nitrocellulose membrane was stained with Ponceau S solution (Sigma-Aldrich, MO, 
USA) for visualization of proteins. Lanes containing the CEY profiles were cut into 
individual strips. Then all nitrocellulose membrane strips were destained with 0.1 M 
NaOH and immediately blocked using the blocking solution (hammersten casein 
solution) provided in the kit. Then, egg yolk immobilised strips were individually 
incubated overnight at 4°C with patients’ sera (patient no. 1 to 25) (diluted 1:10 in 
blocking solution) and 5 non-allergic subjects’ sera (diluted 1:10 in blocking 
solution) as negative controls. Then, unbound antibodies were removed by washing 
the serum-incubated nitrocellulose strips four times in the antibody wash solution 
provided in the kit for 5 minutes. Following washing, all serum-incubated 
nitrocellulose strips were incubated with monoclonal anti-human IgE mouse 
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antibodies labelled with alkaline phosphatase (diluted 1:1000 in blocking solution)  
(Sigma-Aldrich, MO, USA) for 2 hours at room temperature. CEY immobilised 
strips without any serum incubations, (“no serum” negative controls) were incubated 
for 2 hours at room temperature with anti-human IgE mouse antibodies labelled with 
alkaline phosphatase (diluted 1:1000 in blocking solution). Then all the nitrocellulose 
strips were washed with antibody wash solution. The signal was developed by adding 
5-bromo-4-chloro-3’indolyphosphate p toluidine/nitro-blue tetrazolium chloride 
(BCIP/NBT) chromogenic substrate. This immunoassay was repeated one more time 
to ensure the reproducibility. The blot IgE reactivity for each IgE-reactive protein 
was then analysed by eye.   
2.2.1.4.2 Western immunoassay of hen, quail and emu CEYs with pooled 
patients’ sera 
 
A second Western immunoassay was conducted using a pool of sera (diluted 1:10 in 
blocking solution) composed from patients 1, 3, 10, 14, 15, 16 and 25, against all 
CEYs. SDS-PAGE of CEY samples was conducted according to method mentioned 
in section 2.2.1.3. Then, separated CEYs were electro-transferred on to nitrocellulose 
membranes and developed according to the method mentioned in Section 2.2.1.4.1. 
Another Western immunoassay was carried out using a pool of non-allergic 
individuals’ sera (diluted 1:10 in blocking solution) as a negative control. This 
immunoassay was repeated one more time to ensure the reproducibility. 
2.2.1.5 Proteomic analysis of IgE reactive proteins from CEYs 
 
The IgE reactive protein bands were excised from SDS-PAGE gels and subjected to 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). The proteins were 
in-gel digested with trypsin and incubated overnight at 37°C. Then, analysis of 
digested peptide mixtures was carried out at Bio21 Institute (Melbourne, VIC, 
42 
 
 
 
Australia) on a LTQ Orbitrap Elite (Thermo Fisher Scientific®, Waltham, MA, USA) 
coupled to an Ultimate 3000 RSLC nanosystem (Dionex, Sunnyvale, CA). Analysis 
of data was done using a Proteome Discoverer (Thermo Fisher Scientific® version 
1.4) with a MASCOT search engine against the BIRDS database. 
Carbamidomethylation of cysteine was set as the fixed modification while oxidized 
methionine was set as the variable modification. The precursor mass tolerance was 
set at 10 ppm and fragment mass tolerance was set at 0.6 Da. One missed cleavage 
was allowed.  
2.2.2 Cloning and expression of Gal d 6 in E. coli expression system 
 
2.2.2.1 Strains, vectors and growth conditions 
 
NEB Express Iq Competent E. coli cells (New England Biolabs (NEB), Ipswich, MA, 
USA) were used as the cloning and expression host.  E. coli cells were grown in 
lysogeny broth (LB) supplemented with 50 µg/mL ampicillin at 37°C. pTrcHis A 
expression vector (Thermo Fisher Scientific®, Waltham, MA, USA) contains the 
ampicillin resistance gene (β-lactamase), which allows growth on media containing 
ampicillin. The selection of E. coli cells transformed with pTrcHis A vectors were 
performed by growing on LB agar medium supplemented with 50 µg/mL ampicillin 
at 37°C. 
2.2.2.2 Extraction of Poly A+ mRNA from chicken liver 
 
Animal experimentation/sampling was conducted under protocol AEC1496, 
approved by the Australian Animal Health Laboratory, Commonwealth Scientific 
and Industrial Research Organisation (AAHL-CSIRO) Animal Ethics Committee and 
in accordance with the Australian code of practice for the care and use of animals 
for scientific purposes. 
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Total messenger ribonucleic acid (mRNA) from chicken liver was extracted using 
Oligotex Direct mRNA kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s instructions. All the centrifugation steps were carried out at 13, 000 
rpm. A freshly harvested liver from an egg laying hen was stabilized in RNA 
stabilization reagent RNAlater, which was provided by AAHL (Geelong, VIC, 
Australia). The liver tissue was immediately frozen in liquid nitrogen upon removal 
from RNAlater and ground until a fine powder was formed using a sterile mortar and 
pestle. 186 mg of tissue powder was measured in a sterile liquid nitrogen cooled 15 
mL tube and mixed with 2 mL of buffer OL1 containing 0.42 M β-mercaptoethanol 
(β-ME). 700 µl of the resulting lysate was transferred into a QIAshredder spin 
column, contained in a 2 ml collection tube and centrifuged for 2 minutes.  1.2 mL of 
buffer ODB was added to the lysate and mixed by pipetting prior centrifugation for 3 
minutes. The supernatant was transferred into a sterile microcentrifuge tube and 165 
µL of Oligotex suspension was added to the sample and mixed by vortexing. The 
mixture was incubated at room temperature for 10 minutes and centrifuged for 5 
minutes to pellet the Oligotex: mRNA complex. The supernatant was discarded. 
Oligotex: mRNA pellet was then resuspended in 200 µL of buffer OL1 containing 
0.42 M β-ME and mixed by vortexing. Then, 400 µL of buffer ODB was added to 
the sample and incubated at 70°C for 3 minutes and placed at room temperature for 
10 minutes. Oligotex: mRNA complex was then pelleted by centrifugation for 5 
minutes. The supernatant was discarded and the pellet was resuspended in 400 µl of 
buffer OW1 by vortexing. The lysate was then transferred into a small spin column 
placed in a sterile microcentrifuge tube and centrifuged for 1 minute. The flow-
through was discarded. The spin column was centrifuged again for 1 minute and the 
flow-through was discarded. Then, 600 µL of buffer OW2 was added on to the spin 
column and centrifuged for 1 minute in a new sterile microcentrifuge tube. The flow-
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through was discarded. The spin column was centrifuged again for 1 minute and the 
flow-through was discarded. The spin column was then transferred into a new 
RNase-free microcentrifuge tube and 200 µL of hot (70°C) buffer OEB was loaded 
on to the column. The resin was resuspended in buffer OEB by pipetting and 
centrifuged for 1 minute to elute mRNA. The concentration of the collected mRNA 
sample was measured using a Thermo Fisher Scientific® NanoDrop™ 1000 
spectrophotometer.   
2.2.2.3 Reverse transcription polymerase chain reaction (RT-PCR) 
amplification of Gal d 6 
 
The RT-PCR amplification of Gal d 6 was performed using OneStep RT-PCR kit 
(QIAGEN, Hilden, Germany) according to manufacturer’s instructions. 
Oligonucleotide primers used for amplification of Gal d 6 gene were based on the 
sequence published for VTG-1 precursor in Genbank (Genbank accession number: 
D89547). The sequence that code for Gal d 6 of the VTG-1 gene was amplified with 
oligonucleotide forward primer 5’-CGCGGATCCCCTGAAATAGCTTCACAAAT 
AGCAC-3’ and oligonucleotide reverse primer 5’-CGCGAATTCTTAACTACAGT 
CACCAGTGCAG-3’. BamHI and EcoRI restriction sites were incorporated into 5’ 
ends of the forward and reverse primers, respectively for cloning (restriction sites 
underlined in the primer sequences). Furthermore, a 5’ CGC extension sequence was 
added to each primer in order to increase the cleavage efficiency of the restriction 
enzymes. The RT-PCR master mix was prepared by mixing 10 µL of 5× QIAGEN 
One-Step RT-PCR buffer, 2 µL of 10 mM dNTP mix, 10 µL of 5× Q-solution, 1 µL 
of 1 µM forward primer, 1 µL of 1 µM reverse primer, QIAGEN One-Step RT-PCR 
enzyme mix and 170.82 ng of mRNA in a 50 µL total reaction volume in a sterile 
PCR tube. The thermal cycler conditions used for RT step were 30 minutes at 50°C 
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for RT and 15 minutes at 95°C for activation of HotStart DNA polymerase. The 
parameters used for the 3 step PCR cycling step were 35 cycles of 1 minute 
denaturation at 94°C, 1 minute annealing at 53°C, 2 minute extension at 72°C and a 
final 10 minute extension at 72°C.  
2.2.2.4 Analysis and gel purification of PCR amplified Gal d 6 gene 
 
The PCR product was electrophoretically analysed on 1% (W/V) agarose gel stained 
with GelRed™ nucleic acid stain (Biotium, Hayward, CA, USA). The electrophoresis 
was performed at 100 V for 45 minutes. Following electrophoresis, the PCR product 
was purified using MinElute Gel Extraction kit (QIAGEN, Hilden, Germany) 
according to manufacturer’s instructions. The gel section containing the PCR 
fragment was excised using a sterile scalpel and weighed. 3 volumes of buffer QG 
was added to 1 volume of gel (100 mg gel ~ 100 µL). The tube was incubated at 
50°C for 10 minutes to dissolve the gel slice. Then, 1 gel volume of isopropanol was 
added to the sample and mixed. The sample was applied to a MinElute column 
placed in a 2 mL collection tube and centrifuged for 1 minute. The flow-through was 
discarded. 500 µL of buffer QG was added to the tube and centrifuged for 1 minute. 
The flow-through was discarded. Then, 750 µL of Buffer PE was added to the tube 
and allowed to stand for 5 minutes prior centrifugation for 1 minute to wash. The 
flow-through was discarded and the tube was centrifuged again for 1 minute to 
remove residual wash buffer. The column was placed in a clean microcentrifuge 
tube. Then, 50 µL of buffer EB was added to the centre of the MinElute column and 
allowed to stand for 1 minute. The DNA was then eluted by centrifuging for 1 
minute. The concentration of gel purified PCR sample was measured using a 
NanoDrop™ spectrophotometer and stored at -20°C until needed. 
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2.2.2.5 Synthesis of pTrcHis A-Gal d 5 construct 
 
The restriction enzyme digestion of PCR amplified Gal d 6 and pTrcHis A plasmid 
was conducted according to New England Biolabs (NEB) Time-Saver™ protocol. 1 
μg of DNA was digested with 1 μL of BamHI, 1 μL EcoRI and 5 μL of 10× 
NEBuffer 3.1 in a 50 μL total reaction volume. As a negative control, 1 μg of 
pTrcHis A was mixed with 5 μL of 10× NEBuffer 3.1 in a 50 μL total reaction 
volume without restrictions enzymes. All samples were then incubated at 37°C for 1 
hour. Then, all three samples were electrophoretically analysed on 1% (W/V) 
agarose gel stained with GelRed™ nucleic acid stain. The DNA samples were gel 
purified using QIAquick Gel Extraction kit as mentioned in Section 2.2.2.3. The 
concentrations of gel purified DNA samples were measured using a NanoDrop™ 
spectrophotometer and stored at -20°C until needed. 
The ligation reaction was performed under standard conditions [23]. Equal amounts 
(~30 ng) of digested Gal d 6 gene and linearized pTrcHis A were ligated with 1 μL 
of T4 DNA ligase (New England Biolabs, Ipswich, MA, USA) and 10× T4 DNA 
ligase reaction buffer (New England Biolabs, Ipswich, MA, USA) in a 10 μL total 
reaction volume. As a negative control, approximately 30 ng of undigested pTrcHis 
A plasmid vector was mixed with T4 DNA ligase and 10× T4 DNA ligase buffer in a 
10 μL total reaction volume. Both samples were then incubated overnight at 4°C.  
2.2.2.6 Chemical transformation of E. coli 
 
The ligation reaction was chemically transformed into competent E. coli according to 
NEB high efficiency transformation protocol. A tube of chemically competent E. coli 
cells was thawed on ice for 10 minutes. 5 µL of ligation reaction was added to the 
cell mixture and mixed by flicking the tube 5 times. The tube was placed on ice for 
30 minutes. Then, heat shock was performed at 42°C for 20 seconds. The tube was 
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again placed on ice for 5 minutes. Then, 950 µL of room temperature super optimal 
broth with catabolite repression (SOC) media was added to the tube and incubated at 
37°C with shaking at 250 rpm for 1 hour. 100 µL and 200 µL of transformation 
mixture were plated on LB agar and incubated overnight at 37°C.   
2.2.2.7 Growth of transformant colonies and plasmid isolation 
 
Five individual colonies from the overnight transformation plates were picked using 
sterile pipette tips and inoculated into fresh LB and allowed to grow overnight at 
37°C with shaking at 250 rpm. Then, plasmid isolation from overnight bacterial 
cultures was performed using QIAprep Spin Miniprep kit (QIAGEN, Hilden, 
Germany), according to the manufacturer’s instructions. All centrifugation steps 
were performed at 13, 300 rpm at room temperature. 1.5 mL of overnight bacterial 
culture was centrifuged for 3 minutes and the supernatant was discarded. Then 250 
µL of buffer P2 was added to the suspension and mixed by inverting the tube. 350 
µL of buffer N3 was added to the cell suspension and mixed by inverting the tube.  
The tube was then centrifuged for 10 minutes. Then, 800 µL of the supernatant was 
added to the QIAprep 2.0 spin column and centrifuged for 1 minute. The flow-
through was discarded. The spin column was washed by adding 750 µL of buffer PE 
and centrifuging for 1 minute. The flow-through was discarded and the spin column 
was centrifuged for 1 minute to remove residual wash buffer. The spin column was 
then placed in a new microcentrifuge tube and 50 µL of buffer EB was applied to the 
centre of the column and allowed to stand for 1 minute, prior centrifuging for 1 
minute to elute DNA.  The concentrations of isolated plasmid DNA samples were 
measured using a NanoDrop™ spectrophotometer and stored at -20°C.  
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2.2.2.8 Restriction enzyme digest screening for colonies harbouring the pTrcHis 
A-Gal d 5 construct 
 
The restriction enzyme digestions of isolated plasmids were performed according to 
the NEB Time-Saver™ protocol (Section 2.2.2.5) using restriction enzymes BamHI 
and EcoRI. All digested samples were electrophoretically analysed on 1% (W/V) 
agarose gel stained with GelRed™ nucleic acid stain. For all the positive clones, 
glycerol stocks were made by mixing 0.5 mL overnight bacterial culture with 0.5 mL 
of sterile 80% (v/v) glycerol and stored at -80°C until needed. The plasmids 
harbouring the insert were then sequenced using pTrcHis A forward primer 5’- 
GAGGTATATATTAATGTATCG-3’ and pTrcHis A reverse primer 5’- 
GATTTAATCTGTATCAGG-3’ (Micromon-Monash University Clayton, VIC, 
Australia). The DNA sequences were then compared against the nucleotide sequence 
database of National Centre for Biotechnology Information (NCBI) web site using 
the nucleotide Basic Local Alignment Search Tool (BLAST). 
2.2.2.9 Time course of expression and analysis of recombinant protein 
expression levels 
 
The selected transformant clone was streaked for single colonies on LB agar media 
from the glycerol stock and incubated overnight at 37°C. Following incubation, a 
single colony was picked using a sterile pipette tip and inoculated into 10 mL of LB 
media and allowed to grow overnight at 37°C with shaking at 250 rpm. The 
overnight culture was then re-inoculated into fresh LB media and allowed to grow at 
37°C with shaking at 250 rpm until optical density reached 0.4 - 0.6 at 600 nm. Then, 
expression was induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) to 
give a final concentration of 1 mM. The culture was allowed to grow for 5 hours and 
cell pellets were collected every hour by centrifugation.  
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All cell pellets were resuspended in 400 µL of CellLytic™ B bacterial cell lysis 
reagent (Sigma-Aldrich, MO, USA) and briefly vortexed. The resultant cell lysate 
was mixed using a tube mixer for 10 minutes. The cell lysate was then centrifuged at 
13, 000 rpm for 5 minutes to separate soluble and insoluble fractions. The insoluble 
fractions were further resuspended in 100 μL of Novex® Tris-Glycine SDS-Sample 
Buffer (2×). The expression levels were examined on SDS-PAGE gels according to 
the protocol mentioned in Section 2.2.1.3. Un-induced culture fractions were run as 
controls. The authenticity of the recombinant protein was confirmed by Western 
immunoblotting. Separated proteins were electro-transferred on to a nitrocellulose 
membrane and developed according to the protocol mentioned in Section 2.2.1.4.1 
with the following changes. Monoclonal Anti-Xpress™ antibody produced in mouse 
(Thermo Fisher Scientific®, MA, USA) (diluted 1:1000 in blocking solution) was 
used as the primary antibody while alkaline phosphatase-conjugated anti mouse IgG 
antibody (Thermo Fisher Scientific®, MA, USA) was used as the secondary 
antibody.  
2.2.2.10 Purification of rGal d 6 
 
rGal d 6 fused to a 6×His affinity tag was purified using Ni2+-Nitrilotriacetic acid 
(Ni-NTA) resin using Ni-NTA spin kit (Qiagen, Hilden, Germany) under native 
conditions according to manufacturer’s instructions. In brief, a pellet derived from a 
5 mL cell culture volume was resuspended in 630 µL of lysis buffer (50mM 
NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0). After centrifugation, the 
cleared lysate containing 6×His tagged rGal d 6 protein was loaded on to the Ni-
NTA spin column pre-equilibrated with lysis buffer. The resin was then washed 
thrice with 600 µL wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 
pH 8.0). The recombinant protein was eluted using 200 µL of elution buffer (50mM 
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NaH2PO4, 300 mM NaCl, 500 mM imidazole, pH 8.0). The collected fractions were 
then analysed on SDS-PAGE and Western immunoblotting according to the protocol 
mentioned in Section 2.2.2.9. 
2.2.3 Immunological analysis of rGal d 6 
 
2.2.3.1 Inhibition enzyme-linked immunosorbent assay (ELISA) 
 
In brief, 10 µg of crude egg yolk in 50 µL of coating buffer (60 mM NaHCO3, 30 
mM Na2CO3, pH 9.3) was used to coat each well of an ELISA microtiter plate. The 
proteins were allowed to coat the wells for 2 hours at 37°C. Each sample was done in 
triplicates. After triple washing the wells with 0.05% phosphate buffered saline with 
Tween 20 (PBST), each well was blocked with 50 µL of 1% (w/v) bovine serum 
albumin (BSA) in 1× PBS for 2 hours at 37°C. The serum pool from patients 3, 5, 10, 
16 and 25 were used since they had the highest reactivity against Gal d 6 and due to 
the limited availability of sera. The wells were triple washed with 0.05% PBST. 
Then, all wells were incubated with 50 µL control serum pool (diluted 1:10 in 0.05% 
BSA in 1× PBS) and 50 µL serum pools which were pre-incubated with different 
amounts (10 µg and 50 µg) of rGal d 6 for 1 hour at room temperature. Following 
triple washing with 0.05% PBST, all wells were incubated with 50 µL of monoclonal 
anti-human IgE mouse antibodies labelled with alkaline phosphatase (diluted 1:2000 
in 0.05% BSA in 1× PBS) for 1 hour at 37°C. After triple washing the wells with 
0.05% PBST, 50 µL of alkaline phosphatase yellow (pNPP) liquid substrate (Sigma-
Aldrich, MO, USA) was added to each well and incubated at 37°C. After the colour 
development, the reaction was terminated by adding 13 µL of 3 M NaOH, and 
absorbance was read at 405 nm. Percentage of inhibition was calculated using the 
following formula. 
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% Inhibition = 100 – (absorbance value with inhibitor/absorbance value without 
inhibitor × 100) 
A second ELISA was also done using CEY to inhibit IgE binding to coated rGal d 6 
according to the same method described above.  Wells of the microtiter plate was 
coated with 10 µg of rGal d 6 in 50 µL of coating buffer. The test serum pool was 
pre-incubated with 10 µg or 50 µg of CEY. The absorbance was measured at 405 nm 
and the percentage of inhibition was calculated.  
2.3 Results 
2.3.1 Immunological and mass spectrometry analysis of CEY fractions from 
hen, emu and quail eggs 
 
The complexity of CEY profiles of different bird species is evident as seen on SDS-
PAGE (Figure 2.1). The resulting protein profiles of various CEYs show a large 
number of protein bands. Although there are some overlapping bands, most proteins 
could be clearly distinguished. Approximately 13, 7 and 11 different proteins ranging 
from 10-250 kDa could be distinguished in the hen (Figure 2.1, A), emu (Figure 2.1, 
B) and quail (Figure 2.1, C) egg yolks, respectively.  No differences were observed 
for the protein profiles generated from caged chicken eggs, free-range chicken eggs 
and hen’s eggs obtained from AAHL. However, a high molecular weight protein just 
under 250 kDa marker can be observed in the hen’s egg yolk from free range eggs. 
This high molecular weight protein was absent in both the caged eggs and eggs 
obtained from AAHL. Considerable number of proteins from all three avian species 
had similar migration levels on the SDS-PAGE indicating potential homology among 
proteins. Nevertheless, all three egg yolk samples from different bird species were 
clearly distinguishable from each other based on their protein profiles on SDS-
PAGE.  
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Figure 2.1: SDS-PAGE analysis of CEYs under reducing and denaturing 
conditions. (A) SDS-PAGE of hen’s CEY. Lane 1: CEY from chicken eggs obtained 
from AAHL, Lane 2: CEY from caged chicken eggs, Lane 3: CEY from free-range 
chicken eggs. (B) SDS-PAGE of CEY from emu eggs. (C) SDS-PAGE of CEY from 
quail eggs. MW: molecular weight marker in kDa (SeeBlue pre-stained protein 
standard). Arrows indicate Gal d 5 and Gal d 6 at 69 kDa and 42 kDa, respectively. 
Proteins were stained with SimplyBlue SafeStain. 
 
Western immunoassay performed with individual patients’ sera (Figure 2.2) against 
hen’s CEY extract revealed multiple IgE reactive proteins. The repeated 
immunoassay also reproduced the same result. 56% (14 out of 25) of the egg white 
allergy patients tested in this study had IgE reactivity to multiple egg yolk proteins 
with varying degrees of intensities. A second Western immunoblot was conducted 
with a pool of sera composed of patients seropositive for hen’s egg yolk against 
CEYs prepared from all bird eggs (Figure 2.3). The repeated immunoassay also 
reproduced the same result.   Immunoblots conducted with pooled sera against hen, 
emu and quail CEYs showed multiple IgE reactive proteins. IgE reactive proteins 
from various CEYs were assigned with an identification code. The serum pool 
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detected seven different proteins (P1 to P7) (Figure 2.3, A) from hen’s CEY, which 
were also detected in the Western blot performed with individual patients’ sera 
(Figure 2.2).  When analysing the immunoblots of hen’s CEY, it was clear that not 
all hen’s egg yolk proteins had genuine IgE reactivity (Figure 2.2 and Figure 2.3, A). 
Hen’s egg yolk proteins P6 and P7 had reactivity in negative control no serum and 
non-allergic serum lanes indicating non-specific binding with the secondary 
antibody.  Furthermore, all patient serum lanes also had reactivity with P6 and P7. 
This result indicates that reactivity of proteins P6 and P7 in patients are due to non-
specific binding with the detection antibody and not due to genuine sensitisation. In 
this study, proteins P6 and P7 were not considered as proteins with potential 
allergenic capacity. As a result, patients 6, 12, 13, 20 and 21 that have only reacted 
with proteins P6 and P7 were considered non-sensitised towards CEY. Therefore, the 
percentage of patients with genuine IgE-reactivity to hen’s CEY is 36% (9 out of 25) 
after the exclusion of patients with false positives. The percentage of patients reacted 
to each protein is shown in Figure 2.4. Table 2.2 shows the IgE binding data of hen’s 
egg yolk sensitised patients.  
Emu CEY showed six IgE reactive proteins (X1 to X6) (Figure 2.3, B). Quail CEY 
showed five IgE reactive proteins (Y1 to Y5) (Figure 2.3, C).   The band intensities 
of IgE reactive proteins from hen’s CEYs were very similar. However, in CEY from 
caged chicken eggs, the protein P5 had slightly higher IgE-reactivity when compared 
to CEYs from AAHL and free-range eggs.  
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Figure 2.2: Western immunoassay conducted using individual patients’ sera 
against hen’s CEY. Lanes 1-25: CEY immobilised nitrocellulose strip 1 to 25 
incubated with patient serum 1 to 25, respectively, Lanes 26-29: CEY immobilised 
nitrocellulose strips incubated with sera of non-allergic subjects, N: Negative control 
strips incubated with secondary antibody only, MW: molecular weight marker in 
kDa (SeeBlue pre-stained protein standard). 
 
  
Figure 2.3: Western immunoblots conducted using pooled patients’ sera against 
all CEYs. (A) Immunoblot of hen’s CEYs. Lane 1: CEY from chicken eggs obtained 
from AAHL, Lane 2: CEY from caged chicken eggs, Lane 3: CEY from free-range 
chicken eggs. (B) Immunoblot of CEY from emu eggs. (C) Immunoblot of CEY 
from quail eggs. MW: molecular weight marker in kDa (SeeBlue pre-stained protein 
standard). Arrows indicate IgE reactive egg yolk proteins.  
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Table 2.2: Qualitative IgE binding data from Western immunoassay based on 
Figure 2.2. The type of egg yolk proteins each patient had reacted with and the 
degree of intensity with their corresponding clinical data. + mild reactivity, ++ 
moderate reactivity, +++ very strong reactivity. 
Patient 
number 
IgE level (IU/mL) Blot IgE sensitivity 
Egg white Rye Peanut Protein band IgE 
reactivity 
1 93.50 0 81.1 P2 +++ 
P5 (Gal d 6) +++ 
3 13.60 0 0 P1 +++ 
P2 +++ 
P3 +++ 
P4 (Gal d 5) +++ 
P5 (Gal d 6) +++ 
P6 +++ 
P7 +++ 
5 13.20 0 >100 P5 (Gal d 6) + 
P6 + 
P7 + 
6 8.63 0 0 P6 + 
P7 + 
9 16.5 0 0 P5 (Gal d 6) + 
P6 + 
P7 + 
10 4.13 0 2.15 P1 ++ 
P4 (Gal d 5) ++ 
P5 (Gal d 6) ++ 
P6 ++ 
P7 + 
12 1.02 0 0.07 P6 + 
P7 + 
13 1.21 0 3.44 P6 + 
P7 + 
14 1.32 0 0 P4 (Gal d 5) + 
P6 + 
P7 + 
15 1.72 0 0 P1 ++ 
P3 ++ 
P5 (Gal d 6) ++ 
P6 ++ 
P7 ++ 
16 2.08 0 2.47 P4 (Gal d 5) ++ 
P6 + 
P7 + 
20 1.19 0 1.42 P6 + 
P7 + 
21 1.25 0 0.08 P6 + 
P7 + 
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Patient 
number 
IgE level (IU/mL) Blot IgE sensitivity 
Egg white Rye Peanut Protein band IgE 
reactivity 
25 0.47 88.7 3.64 P5 (Gal d 6) + 
P6 + 
P7 + 
 
 
Figure 2.4: Percentage of patients with IgE reactivity to proteins (P1 to P7) of 
hen’s egg yolk, as analysed from the Western immunoblot in Figure 2.2 and 
Table 2.2. 
 
In order to determine the identities of the IgE reactive proteins of various CEYs, they 
were subjected to proteomic analysis using LC-MS/MS.  The identity of each protein 
band was determined from critically analysing both the mass spectrometry data and 
molecular weights of each protein based on SDS-PAGE. The identities revealed for 
all the IgE reactive proteins were previously known hen’s egg yolk proteins. The 
identities of proteins analysed from the LC-MS/MS and their approximate molecular 
weights on SDS-PAGE are listed in the Table 2.3. The mass spectrometry result 
confirmed that all the IgE reactive proteins of hen’s CEYs are fragments derived 
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from well-known precursor proteins of the hen; VTG-1, VTG-2 and Apo B. The 
proteomic analysis of hen’s egg yolk proteins identified P4 as Gal d 5 and P5 as Gal 
d 6 (Table 2.3). According to the Western immunoassay conducted with individual 
patients’ sera 16% of the patients tested have recognized Gal d 5 (P4) while 28% of 
subjects have recognized Gal d 6 (P5) (Table 2.2). The degree of IgE reactivity in 
both allergens ranged from very strong to mild in sensitised patients. The identities 
of IgE reactive proteins from emu and quail CEYs are listed in Table 2.3. Here also 
majority of the proteins were found to be fragments of precursor proteins as in the 
IgE reactive hen’s egg yolk proteins. However, the mascot BIRD database is not 
complete with all the bird species. Therefore, it was clear that the majority of emu 
and quail proteins had matches to proteins with close homologies from other bird 
species such as chicken, duck and turkey.  Some of the IgE-reactive proteins in the 
emu and quail egg yolks came up as egg white proteins such as ovalbumin and 
ovotransferrin indicating minor contamination with the egg white. However, mass 
spectrometry analysis did not reveal any contamination with human proteins.  
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Table 2.3: Protein identities revealed from mass spectrometry analysis, their 
approximate molecular weights on SDS-PAGE, score and percentage sequence 
coverage for each protein 
Protein 
band 
Molecul
ar 
weight 
Identity Species Score Sequence 
coverage 
(%) 
P1 120 Vitellogenin II 
 
Chicken 13575 52 
P2 90 Apolipoprotein B 
 
Chicken 8412 30 
P3  72 Apolipoprotein B 
 
Chicken 523037 30 
P4 (Gal d 5) 65 Chicken serum 
albumin 
 
Chicken 3490 54 
P5 (Gal d 6) 42 Vitellogenin I 
 
Chicken 5438 35 
P6 35 Vitellogenin I 
 
Chicken 5500 28 
P7 30 Vitellogenin II 
 
Chicken 5294 37 
X1 120 Apolipoprotein B 
 
Chicken 524 14 
X2 72 Ovotransferrin  
 
Emu 943 46 
X3 65 Ovalbumin 
 
Emu 455 21 
X4 52 Apolipoprotein B 
 
Chicken 723 15 
X5 42 Fibrinogen beta 
chain 
 
Zebra 
finch 
520 16 
X6 35 Vitellogenin II 
variant 1 
 
Emu 548 14 
Y1 90 Transferrin receptor 
protein I-like 
Turkey 574 13 
Y2 68 Serum albumin Domesti
c duck 
2971 29 
Y3 42 Ovalbumin Common 
quail 
1111 43 
Y4 34 Apolipoprotein A-I Japanese 
quail 
795 70 
Y5 31 Apolipoprotein A-I Japanese 
quail 
2298 86 
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2.3.2 Expression of rGal d 6 in E. coli 
 
Analysis of RT-PCR product on 1% (W/V) agarose gel showed a predominant band 
approximately in between 500 bp and 1000 bp markers (expected size: 876 bp) 
(Figure 2.5). E. coli cells transformed with pTrcHis A-Gal d 6 construct had growth 
when incubated on LB agar under ampicillin resistance. When BamHI and EcoRI 
digested plasmids of transformant clones were electrophoresed on 1% (W/V) agarose 
gel, all clones showed the insert approximately at 1000 bp marker (expected size: 
876 bp) (Figure 2.6). Sequencing analysis of plasmids harbouring the insert 
confirmed the in-frame ligation of the Gal d 6 into the pTrcHis A vector within the 
multiple cloning site (MCS). The NCBI BLAST search of the derived sequence from 
pTrcHis A-Gal d 6 construct produced Gallus gallus vitellogenin 1 (VTG1) 
(sequence ID: refΙNM_0010044008.2) as the top match with a 99% similarity 
corresponding to the mature peptide YGP42 (Gal d 6) of the C-terminal part of the 
VTG-1 gene (Figure 2.7).  
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Figure 2.5: RT-PCR of Gal d 6 gene. The RT-PCR product was electrophoresed 
on a 1% (W/V) agarose gel. Lane 1: RT-PCR product of Gal d 6 gene. Lane 2: 
negative control RT-PCR without template mRNA. MW, molecular weight marker 
GeneRuler 1kb Plus DNA ladder in bp. Arrow indicates the RT-PCR amplified Gal d 
6 gene. 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Restriction enzyme digest screening for E. coli colonies harbouring 
pTrcHis A-Gal d 6 construct. The digested plasmids were electrophoresed on a 
1% (W/V) agarose gel. Lanes 1-5: BamHI and EcoRI digested plasmids of five 
individual E. coli colonies grown on transformation plate with antibiotic. MW: 
molecular weight marker GeneRuler 1kb Plus DNA ladder in bp. Arrow indicates the 
Gal d 6 gene.  
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Figure 2.7: Sequence alignment comparison of DNA sequence derived for 
pTrcHis A-Gal d 6 construct using NCBI Nucleotide BLAST tool. The DNA 
sequence represents the mature peptide YGP42 (Gal d 6) of the C-terminal part of 
the VTG-1 gene.  
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The Western immunoblot of time-course of expression experiment showed a 
predominant protein band approximately at 42 kDa region when probed with Anti-
Xpress antibody.  E. coli cells harbouring the construct have expressed majority of 
the rGal d 6 as an insoluble fraction. However, a reasonable amount of soluble rGal d 
6 was also expressed by the E. coli cells, with an optimum time of 5-hour post IPTG 
induction (Figure 2.8).   
The production of a recombinant protein fused to a short polypeptide such as 6×His 
tag permits the purification of the fusion peptide using a metal chelating resin (Figure 
2.9). The SDS-PAGE analysis (Figure 2.9, A) of the purified soluble rGal d 6 using 
the Ni-NTA resin revealed a predominant band approximately at 42 kDa region. 
However, several E. coli derived proteins were also present in the purified fraction. 
The Western immunoblot of purified protein fraction probed with Anti-Xpress 
antibody showed a clear band approximately at 42 kDa region corresponding to the 
protein band in SDS-PAGE (Figure 2.9, B).  
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Figure 2.8: Time-course of expression of soluble and insoluble E. coli cell 
culture fractions harbouring rGal d 6. Lane 1: un-induced culture fractions. Lanes 
2-5: IPTG induced culture fractions at time points 2nd, 3rd, 4th and 5th hours, 
respectively, analysed by (A) SDS-PAGE and (B) Western immunoassay. Arrows 
indicate rGal d 6 in the soluble fraction at 42 kDa. MW: molecular weight marker in 
kDa (SeeBlue pre-stained protein standard). 
 
 
 
Figure 2.9: Purification of 6×His tagged rGal d 6. Lane 1: cleared lysate, Lane 2: 
flow- through, Lane 3-5: 1st, 2nd and 3rd wash, respectively. Lane 6: elution, analysed 
by (A) SDS-PAGE and (B) Western immunoassay.  MW: molecular weight marker 
in kDa (SeeBlue pre-stained protein standard). Arrows indicate purified rGal d 6 at 
42 kDa.  
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2.3.3 Inhibition ELISA experiments 
 
The results of inhibition ELISA experiments are shown in Figure 2.10.  The results 
shown in Figure 2.10 demonstrate that rGal d 6 is able to inhibit IgE binding to CEY 
by up to 30%. The amount of rGal d 6 required to achieve maximum IgE binding 
inhibition of 30% was 50 μg. On the other hand, CEY was able to inhibit IgE binding 
to rGal d 6 by up to 31% as shown in Figure 2.10. Further, inhibitions with 
increasing amounts of proteins were not achieved in both cases. The amount of CEY 
required to achieve maximum IgE binding inhibition of 31% was 50 μg. However, 
inhibitions with increasing amounts of proteins reached a plateau at 50 μg in both 
cases. This experiment was only conducted once due to the limited availability of 
sera.  
 
Figure 2.10: Inhibition ELISA experiments. When rGal d 6 was used as an 
inhibitor, CEY was immobilised on to the wells of the microtiter plate. When CEY 
was used as an inhibitor, rGal d 6 was immobilised on to the wells of the microtiter 
plate. The IgE antibody binding of selected seven patients reactive towards CEY 
proteins was detected calorimetrically at OD 405 nm.  
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2.4 Discussion 
 
Hen’s egg is one of the most well-known sources of allergens. Egg white allergens 
have much stronger allergenic potential than the yolk proteins. Hen’s egg yolk 
allergy is still a developing area within the domain of food allergy.  Allergy to egg 
white and egg yolk has been often investigated separately. However, concomitant 
sensitisation to egg white and yolk proteins due to cross reactive proteins has been 
reported previously [98]. Nevertheless, the association between egg white and egg 
yolk allergies have been overlooked by many researchers. Egg white and egg yolk 
allergens have a similar origin and therefore, occurrence of cross sensitisation or co-
sensitisation in egg allergic patients would be a high possibility.  
CEY extracts were made according to the method reported by Guilmineau et al., 
[127]. The protein profiles of CEYs were investigated on SDS-PAGE without 
delipidation. Most studies have used delipidated egg yolk fractions in order to reduce 
the smearing effect caused by the high lipid content. Chemicals used during 
delipidation process can significantly alter the nature of proteins and thereby 
affecting the result of immunoassays. Therefore, we used the whole egg yolk extract 
without subjecting to delipidation throughout the study. The SDS-PAGE profile of 
the un-delipidated CEYs obtained offered good resolution of protein bands, 
indicating that most of the egg yolk proteins have been solubilized in the 0.1 M 
glycine/NaOH buffer (pH 9; 0.56 NaCl). An important advantage of the approach 
used here is that egg yolk proteins are presented in the same format as would be 
encountered by an individual during the sensitisation process. The egg yolk allergens 
Gal d 5 and Gal d 6 are both glycoproteins, which were identified using fractioned 
yolk extracts [81, 82]. In theory, any protein can act as an IgE reactive allergen. 
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Therefore, it is imperative to bring the whole egg yolk under investigation to reveal 
allergenicity of other yolk proteins. 
The protein profiles generated from caged chicken eggs, free-range chicken eggs and 
hen’s eggs obtained from AAHL were similar. However, a high molecular weight 
protein just under 250 kDa marker was observed in the hen’s egg yolk from free 
range eggs. This could be a marker of free-range condition. However, further 
proteomic analyses are required to investigate if the presence of high molecular 
weight protein in free-range eggs is due to the environmental factors.  In this study, 
we employed Western immunoblotting as a rapid method of identifying IgE reactive 
proteins in various CEYs. The sera we used in this study came from a cohort of 
patients diagnosed with allergy to hen’s egg white. However, no clinical data were 
available regarding sensitisation or allergic reactivity to hen’s egg yolk in those 
patients. Therefore, these patients may or may not have clinical reactivity to hen’s 
egg yolk.  First major aim of this chapter was to investigate the sensitisation profiles 
of egg white allergic patients and compare in vitro IgE reactivates of egg yolks from 
hen, emu and quail. Sensitisation to a certain allergen does not necessarily imply 
clinical allergy [3, 7]. However, it is well known that majority of patients with 
sensitisation develops clinical symptoms upon ingestion of the offending food. 
Therefore, the major epitopes relevant to sensitisation are of great interest. 
Western immunoassay results showed that multiple egg yolk proteins from hen, emu 
and quail have reacted with IgE antibodies of many patients. Sensitisation to egg 
yolk proteins could be a result of direct exposure to yolk proteins during 
consumption or due to the existence of similar IgE binding epitopes present in egg 
white and yolk proteins. In such cases, both types of allergens are responsible for 
overall pathogenesis and pathophysiology of egg allergy. Therefore, it is imperative 
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that clinical diagnosis of egg allergy include both the egg white and egg yolk and 
determine appropriate management and treatment strategies based on a patient’s total 
sensitisation profile. . However, proteins P6 and P7 were considered as false 
positives due to the influence of the secondary antibodies. A possible reason behind 
this could be the presence of hen’s egg proteins in the diet fed to mouse. As a 
consequence the mouse immune system may have generated IgG antibodies against 
egg yolk proteins P6 and P7. Production of IgG antibodies against non-pathogenic 
proteins is considered as a normal process of a healthy immune system [22]. 
However, it is not possible to elucidate why the mouse immune system only 
produced IgG antibodies against only those two egg yolk proteins.  
Furthermore, sensitised patients against hen’s CEY were also able to recognize a 
number of proteins from the yolk proteomes of emu and quail.  Here also, cross 
sensitisation to egg yolk proteins from different bird species could be a result of 
direct exposure to respective bird eggs or due to the existence of similar IgE binding 
epitopes among different egg proteins. If sensitisation is due to cross-reactive IgE 
antibodies, allergic reactions to emu and quail egg proteins can occur during the first 
exposure even without the initial sensitisation phase. Therefore, for such patients, 
emu and quail eggs may not be suitable to use as an alternative to hen’s eggs.  
Sensitisation to certain allergens is not a definitive marker of allergy. This is because 
not all sensitised individuals develop clinical symptoms of allergic hypersensitivity 
when exposed to relevant allergens.  Therefore, this result does not confirm allergy to 
egg yolk in patients identified with sensitisation to egg yolk proteins. Nevertheless, 
presence of reactive antibodies is considered a risk factor for allergy. Furthermore, it 
has been shown that sensitisation to allergens can be used to predict the onset of 
clinical allergy. For example, presence of hen’s egg white specific IgE antibodies 
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even without clinical symptoms can be used to predict the development of allergy 
before 7-10 years of age [3]. 
IgE reactive egg yolk proteins from all CEYs were subjected to proteomic analysis in 
order to reveal their identities. According to the mass spectrometry results, all IgE 
reactive hen’s egg yolk proteins belongs to major precursor protein families VTG-1, 
VTG-2 and apolipoprotein B (Apo B). VTG-1 precursor is already implicated in 
allergy. The allergen Gal d 6 is the C-terminal part of VTG-1 precursor [81]. Already 
known hen’s egg yolk allergens Gal d 5 and Gal d 6 were able to identify through 
proteomic analysis. Gal d 5 is a protein with a molecular weight of 69 kDa. 
However, on the SDS-PAGE analysis it was seen approximately at 65 kDa region. 
This may be due to the limited solubility resulted by the presence of high lipid 
content or due to the alteration of three dimensional structure caused by method used 
for CEY preparation.  
Furthermore, Walsh et al., reported apovitellenin I and VI to be significantly 
allergenic in some patients with egg allergy. Therefore, this result is consistent with 
our result since apovitellenin I is a fragment derived from Apo B [98]. Both VTG-1 
and VTG-2 are collectively known as vitellogenins. During egg formation, 
vitellogenins are transported into developing oocyte through a process known as 
receptor mediator endocytosis. Once they are transported into the egg yolk, mature 
proteins are produced as a result of enzymatic cleavage. On the other hand, Apo B is 
also produced in liver and transported into growing oocytes the same way as 
vitellogenins, resulting in the formation of mature Apo B fragments through 
enzymatic activity [96, 128, 129]. The MASCOT bird database is not complete with 
proteins from all bird species. Therefore, most proteins from emu and quail had 
matches to proteins with closest homologies from other bird species such as hen.  
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Inability to identify the exact mature proteins derived from vitellogenins or Apo B 
precursors is a limitation of this study. Egg yolk is a more complex system than the 
albumen, with a significant proportion of lipids. The presence of high amounts of 
lipids has made identification of allergens from the egg yolk very challenging and 
may have thus contributed to fewer studies reported in the literature. Nevertheless, 
this study had narrowed down the search for allergens out of hundreds of different 
proteins for just three classes of precursor proteins. In order to identify IgE reactive 
proteins, each mature protein derived from precursors should be purified and 
subjected to immunological testing using sera from patients allergic to hen’s egg. 
Furthermore, we performed the immunological analysis of egg yolk using sera from 
patients allergic to hen’s egg white. This also can be considered as another limitation 
of this study since clinical reactivity to yolk proteins may not exist in those patients, 
even though sensitisation is present. Therefore, in order to establish the clinical 
relevance of those three egg yolk precursor proteins, it is imperative to subject those 
proteins to both in vivo and in vitro studies using patients with clinical reactivity to 
hen’s egg yolk.  
Comparison of immunoblot results with the patients’ clinical data showed that the 
majority of patients that reacted strongly with the egg yolk had high IgE levels 
against hen’s egg white. However, this was not always the case since some patients 
with low IgE also had strong reactivity against egg yolk proteins, suggesting 
presence of clinically unique allergens in the egg yolk. In this study, more patients 
had reacted with Gal d 6 (28%) than Gal d 5 (16%). It was previously suggested that 
Gal d 6 is a minor allergen implicated in egg allergy. However, our results indicate 
that Gal d 6 may be more allergenic and affects more patients than originally 
thought.  
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The cDNA coding for the mature egg yolk allergen Gal d 6 was selectively amplified 
from the VTG-1 precursor using liver tissue from an egg-laying hen. The sequencing 
result obtained for Gal d 6 gene showed several insertion mutations, especially at the 
end of the sequence. However, this does not affect the validity of the construct.  
These errors are mainly attributed to the introduction of artefactual mutations, rather 
than due to true mutations resulted during the PCR amplification. The Gal d 6 was 
cloned into pTrcHis A plasmid vector where the trc promoter leads the translation of 
the fusion peptide with the 6×His tag on the N-terminal side. The soluble and 
insoluble fractions of IPTG induced and un-induced E. coli fractions were subjected 
to Western immunoassay and probed with anti-Xpress antibody specific to the fusion 
peptide. The developed immunoblot revealed a clear band at 42 kDa, which is the 
expected size of natural Gal d 6.  
This result is in excellent agreement with studies conducted by Mann & Mann., and 
Yamamura et al., where they reported the size of natural Gal d 6 as 42 kDa [96, 130]. 
Furthermore, our proteomic analysis of CEY proteins also indicated that the protein 
P5 approximately at 42 kDa region to be YGP42 or Gal d 6. However, the theoretical 
molecular weight of Gal d 6 is 31.45 kDa as calculated by ExPASy ProtParam tool. 
On the other hand, the study by Amo et al., which confirmed YGP42 as an allergen, 
reported a molecular weight of 35 kDa from SDS-PAGE [81]. The discrepancies 
observed regarding the molecular weight on SDS-PAGE could be attributed to the 
different sample preparation methods used. 
The solubility of recombinant proteins produced by bacteria is a major concern in the 
production process. Although bacterial expression systems provide a convenient way 
for recombinant protein expression, many foreign proteins expressed in bacterial 
hosts undergo partial or irregular folding resulting in insoluble and refractile 
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aggregates known as inclusion bodies (IB) [131].  Therefore, to retain the biomedical 
value, it is essential to produce the recombinant protein as a soluble fraction in its 
native form. However, it is not possible to predict the solubility of a foreign protein 
before the actual expression [131, 132]. In this study, majority of the rGal d 6 has 
been produced as an insoluble protein as seen by the Western immunoassay result. 
However, there were reasonable amount of soluble rGal d 6 produced by the E. coli 
cells that could be used for purification and other downstream applications. 
Therefore, enhancement of bacterial cells to increase production of rGal d 6 as a 
soluble fraction was not necessary.  
The production of a recombinant protein fused to a short polypeptide such as 6×His 
tag permits the purification of the fusion peptide using a metal chelating resin. The 
SDS-PAGE analysis of the purified soluble rGal d 6 using the Ni-NTA resin revealed 
a predominant band at around 42 kDa. However, the final purified rGal d 6 
preparation was present with several potential contamination E. coli proteins. The 
authenticity of the rGal d 6 was determined by probing the purified protein with 
Anti-Xpress antibody. Furthermore, most water soluble proteins are highly 
susceptible to proteolytic degradation [133]. However, in this study no such 
degradation was observed.  
Obtaining a recombinant protein as a soluble fraction in sufficient amounts is highly 
desirable. Although bacteria have the capacity to produce protein with the correct 
amino acid sequence based on the gene, they lack the machinery for post-
translational modification. Recombinant allergens produced in bacteria are 
structurally different than their wild type counterparts [134]. Therefore, analysing the 
immunological potency of recombinant allergen in comparison to natural allergen is 
a crucial step in recombinant allergy research [116]. In this study, we analysed the 
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immunological relevance of rGal d 6 through inhibition ELISA technique and 
showed that it has cross reactivity with CEY. rGal d 6 showed clear IgE reactivity by 
inhibiting IgE binding to CEY. Similarly, CEY was able to inhibit IgE binding to 
rGal d 6. It is usually expected that the percentage of inhibition could reach nearly 
100% due to the abundant existence of Gal d 6 in the CEY extract. However, the 
inhibition of rGal d 6 due to CEY was only 31%. This may be because of the three 
dimensional structures of proteins often altered when immobilised on ELISA plates. 
The alteration of structure of proteins can also change the IgE binding epitopes and 
therefore, reduce inhibition. These results indicate that rGal d 6 is immunologically 
reactive and allergenic. Therefore, it is clear that IgE binding epitopes are present in 
rGal d 6. However, these results are not sufficient to establish the immunological 
equivalence in comparison to natural Gal d 6 (nGal d 6). In order to overcome this 
limitation, rGal d 6 must be compared with purified nGal d 6 through RAST using a 
panel of sera from patients diagnosed with allergy to hen’s egg yolk. However, 
purification of nGal d 6 proves to be a challenge and thus purified rGal d 6 provides 
a more logical option.       
In conclusion, results of this chapter suggest that some patients with allergy to hen’s 
egg white are sensitised against egg yolk proteins. Furthermore, our results indicated 
that sensitisation is not limited to hen’s egg yolk. It was shown that a number of yolk 
proteins from emu and quail were also able to react with egg white allergy patients’ 
serum. Therefore, in those patients’ development of allergy can be attributed to 
allergens derived from both the albumen and yolk. Furthermore, these results suggest 
that there are potentially undiscovered allergens within the egg yolks of hen, emu 
and quail. Mass spectrometry results revealed that IgE reactive yolk proteins derived 
from VTG-1, VTG-2 and Apo B precursor families. In addition, we report the 
successful production of rGal d 6 as a soluble fraction in E. coli. The inhibition 
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ELISA immunoassays showed clear IgE binding to rGal d 6 and indicated a similar 
level of allergenicity to natural CEY. However, it is important to analyse the exact 
level of allergenicity of rGal d 6 in comparison to purified nGal d 6 in future studies. 
Knowledge on exact allergenicity of rGal d 6 would be highly valuable to researchers 
where it would facilitate decision-making when subjecting it to further molecular 
studies such as epitope analysis, production of hypoallergenic mutants and 
determining structural and functional basis of allergenicity. Indeed, our results 
highlight the significance of Gal d 6 (YGP42) as an important allergen of the egg 
yolk, and paves the way for the preparation of recombinant allergens for potential 
use in future diagnostics and therapeutics of egg yolk allergy. 
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3.1 Introduction 
 
Gal d 5 is a partially heat-labile allergen from the egg yolk of domestic chicken. Gal 
d 5 is synthesised in the liver of laying hens, and is present in both the blood 
circulation and the egg yolk. It is considered as the most common avian allergenic 
serum albumin and is the causative allergen implicated in bird-egg syndrome [82, 
135]. Gal d 5, like most other serum albumins, can act as both a food and an inhalant 
allergen resulting in respiratory and food allergy symptoms, respectively. In bird-egg 
syndrome, sensitisation to Gal d 5 usually starts with the exposure to airborne 
chicken serum through the respiratory tract. Development of clinical allergy then 
takes place when the immune system encounters Gal d 5 derived from the egg yolk 
or chicken serum [82, 92]. 
Studies on IgE sensitisation to Gal d 5 is very limited when compared to egg white 
allergens, and other allergenic serum albumins from different species [92]. A cross-
sectional survey on IgE reactivity to various allergens reported that 0.14% of subjects 
had IgE sensitisation to Gal d 5 [136]. However, another study reported the 
percentage of IgE sensitisation to Gal d 5 to be high as 20% [137]. Furthermore, to 
the best of our knowledge there are no reports of production of a recombinant Gal d 
5 (rGal d 5). The use of recombinant allergens over natural allergen extracts in 
allergy diagnosis, treatment, and research offer many advantages due to their 
superior pharmaceutical quality as discussed in Chapter 1. Current applications and 
future potential developments of recombinant allergen use in clinical and research 
settings are extensively discussed in the scientific literature [115, 116, 118, 133, 138, 
139].     
The first aim of this chapter was to produce a recombinant version of Gal d 5 as a 
soluble fraction. We first used NEB Express Iq Competent E. coli to produce rGal d 
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5. In this study, the E. coli strain was not successful at producing rGal d 5 as a 
soluble fraction despite successful expression of rGal d 6 in Chapter 2. Our pilot 
expression study showed that 100% of the rGal d 5 was produced as IBs indicating 
the unpredictability and challenging nature of recombinant protein production.  
However, in the event of IB formation, manipulation of microbiological growth 
conditions may result in induction of soluble protein production. These include 
changing culture media composition, growth temperature, production rate and the 
availability of heat-shock chaperones. However, implicating such changes do not 
guarantee the minimization of IB formation. Therefore, we employed a different 
recombinant protein production platform as an alternative approach to express rGal d 
5 as a soluble fraction in a eukaryotic expression system [131, 132]. 
In this chapter, we present the successful cloning and expression of rGal d 5 as a 
soluble fraction using Kluyveromyces lactis (K. lactis) yeast strain. Then, in this 
study, we immunologically compared rGal d 5 and natural Gal d 5 (nGal d 5) using 
serum from patients allergic to hen’s egg white. The IgE-mediated allergic reaction is 
the most common form of food allergy. Therefore, we comparatively analysed 
specific IgE binding capacity of rGal d 5 with nGal d 5 using ELISA and Western 
dot blot analysis. 
3.2 Materials and methods 
3.2.1 Human patients’ sera 
 
Sera from 21 patients allergic to hen’s egg white were obtained from the Royal 
Children’s Hospital (Melbourne, VIC, Australia). The egg white specific IgE levels 
of patients are shown in Table 2.1. Experimentation involving patients’ sera was 
conducted in compliance with the National Statement on Ethical Conduct in Human 
Research (2007) with approval from Deakin University Faculty of Science, 
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Engineering and Built Environment Human Ethics Advisory Group (HEAG), with a 
project approval number of STEC-34-2013-DHANAPALA. 
Table 3.1: The levels of allergen specific IgE antibodies against egg white 
determined by ImmunoCAP (Phadia) 
Patient 
number 
IgE level (IU/mL) against 
hen’s egg white 
1 93.50 
2 28.80 
3 13.60 
4  9.26 
7 6.89 
8 18.50 
9 16.50 
10 4.13 
11 3.62 
13 1.21 
14 1.32 
15 1.72 
16 2.08 
17 2.21 
18 2.58 
19 1.78 
21 1.25 
22 1.05 
23 0.32 
24 0.18 
25 0.47 
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3.2.1 Cloning and expression of Gal d 5 in E. coli expression system 
 
3.2.1.1 RT-PCR amplification of Gal d 5 
 
RT-PCR amplification of Gal d 5 was performed using OneStep RT-PCR kit 
according to the manufacturer’s instructions. The oligonucleotide primers required 
for amplification of mature Gal d 5 gene were based on the nucleotide sequence 
published on NCBI (NCBI reference number: NM_205261.2). The oligonucleotide 
forward primer 5’-CGCGGATCCTTTGCTCGTGATGCAGAGC-3’ and reverse 
primer 5’-CGCGAATTCTTAAGCACCAATTCCTAATGTGGC-3’ were 
synthesised at Micromon-Monash University (Clayton, VIC, Australia). BamHI and 
EcoRI restriction enzyme sites were incorporated into 5’ ends of forward and reverse 
primers, respectively to facilitate cloning of Gal d 5 gene (restriction sites are 
underlined in the primer sequences). Furthermore, a 5’ CGC extension was added to 
each primer in order to increase the cleavage efficiency of the restriction enzymes. 
Total mRNA extracted from the chicken liver in Section 2.2.2.2 was used as the 
template for RT-PCR. The RT-PCR master mix was prepared by mixing 10 µL of 5× 
QIAGEN One-Step RT-PCR buffer, 2 µL of 10 mM dNTP mix, 10 µL of 5× Q-
solution, 1 µL of 1 µM forward primer, 1 µL of 1 µM reverse primer, QIAGEN One-
Step RT-PCR enzyme mix and 170.82 ng of mRNA in a 50 µL total reaction volume 
in a sterile PCR tube. The thermal cycler conditions used for RT step were 30 
minutes at 50°C for RT and 15 minutes at 95°C for activation of HotStart DNA 
polymerase. The parameters used for the 3 step PCR cycling step were 35 cycles of 1 
minute denaturation at 94°C, 1 minute annealing at 53°C, 2 minute extension at 72°C 
and a final 10 minute extension at 72°C. The RT-PCR product was then analysed on 
1% (W/V) agarose gel and purified according to the protocol mentioned in Section 
2.2.2.4.  
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3.2.1.2 Synthesis of pTrcHis A-Gal d 5 construct and expression of rGal d 5 in 
E. coli 
  
Restriction enzyme digestion and cloning of Gal d 5 gene into pTrcHis A plasmid 
vector was performed according to the protocol mentioned in Section 2.2.2.5. The 
ligation reaction was transformed into chemically competent NEB Express Iq 
Competent E. coli according to the protocol mentioned in Section 2.2.2.6. Five 
transformant clones were picked using sterile pipette tips and inoculated into fresh 
LB media containing 50 μg/mL ampicillin and allowed to grow overnight at 37°C 
with shaking at 250 rpm. Then, plasmid isolation of all five overnight bacterial 
cultures was performed according to the protocol outlined in Section 2.2.2.7. 
Restriction enzyme digest screening for clones harbouring pTrcHis A-Gal d 5 
construct and sequencing of the constructs were done according to the protocol 
mentioned in Section 2.2.2.8. Time course of expression analysis of rGal d 5 was 
carried out according to the method mentioned in Section 2.2.2.9. E. coli culture 
fractions were collected at 2nd, 3rd and 5th hourly time points.  
3.2.2 Cloning and expression of Gal d 5 in K. lactis eukaryotic protein 
expression system 
3.2.2.1 Natural allergen extract 
 
Lyophilized chicken serum albumin (nGal d 5) powder (chicken serum albumin, 
CSA62-0001) available at the highest purification level (≥ 96% purity) was 
purchased from Equitech-Bio, Inc. (Kerrville, TX, USA) and prepared at a 
concentration of 10 mg/mL in 1× PBS. 
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3.2.2.2 Strains, vectors and growth conditions 
 
E. coli strain NEB® 5-alpha F’ Iq (New England Biolabs Inc., MA, USA) was used as 
the cloning host and was grown in LB medium supplemented with 50 µg/mL 
ampicillin at 37°C. K. lactis strain GG799 (New England Biolabs Inc., MA, USA) 
was used as the host strain for the secretion of rGal d 5. K. lactis were grown in 
either YPGal medium (1% (W/V)  yeast extract, 2% (W/V)  peptone, 2% (W/V)  
galactose) or YPGlu medium (1% (W/V) yeast extract, 2% (W/V) peptone, 2% 
(W/V) glucose) at 30°C. The K. lactis integrative expression vector pKLAC2 (New 
England Biolabs Inc., MA, USA) contains the Aspergillus nidulans acetamidase gene 
(amdS), which allows growth on nitrogen-free minimal medium containing 
acetamide. The selection of K. lactis cells transformed with pKLAC2 vectors were 
grown on yeast carbon base (YCB) agar medium supplemented with 5 mM 
acetamide at 30°C.   
3.2.2.3 PCR amplification of Gal d 5 gene with a C-terminal hemagglutinin (HA) 
epitope tag 
 
Gal d 5 gene was amplified by PCR technique using the QIAGEN Fast Cycling PCR 
kit (Qiagen, Hilden, Germany). pTrcHis A-Gal d 5 expression vector was used as the 
template DNA (constructed in Section 3.2.1.2). Primers used for amplification of Gal 
d 5 gene were based on the sequence published on NCBI (NCBI accession number: 
NM_205261.2).  
The sequence coding for the mature Gal d 5 was amplified with the forward primer 
5’-CGCCTCGAGAAAAGATTTGCTCGTGATGCAGAGCACAAGAG-3’ and 
reverse primer 5’-CGCGCGGCCGCTTATGCATAATCTGGAACATCATATGG 
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ATAAGCACCAATTCCTAATGTGGCTCTGC-3’. XhoI and NotI restriction 
enzyme sites were incorporated into 5’ sides of forward and reverse primers, 
respectively (restriction sites underlined in the primer sequences). Forward primer 
contains a Kex protease cleavage site immediately downstream of the XhoI 
restriction site (nucleotides in italics). The reverse primer contains sequences for C-
terminal hemagglutinin (HA) epitope (nucleotides in bold) and a TTA stop codon 
immediately downstream the NotI restriction site. Both primers contain CGC 
extensions at the 5’ ends. The PCR reaction mix was prepared by mixing 10 µL of 
QIAGEN PCR Fast Cycling Master Mix, 4 µL of 5×Q-Solution, 2.5 µL of forward 
primer to a final concentration of 0.5 µM, 1.82 µL of reverse primer to a final 
concentration of 0.5 µM and 1.82 µL of template DNA (<300 ng) in a 20 µL total 
reaction volume.  The thermal cycler conditions were 5 minutes at 95°C for 
activation of HotStart DNA polymerase, 35 cycles of 5 seconds denaturation at 96°C, 
5 seconds annealing at 60°C, 5.34 minutes of extension at 68°C and a final extension 
for 1 minute at 72°C. The PCR product was then analysed on E-Gel® CloneWell™ 
agarose gel with 0.8% SYBR Safe™ DNA Gel stain (Thermo Fisher Scientific®, MA, 
USA), powered through E-Gel® iBase Power System (Thermo Fisher Scientific®, 
MA, USA). The PCR product was then extracted from the bottom collection wells of 
the precast gel by pipetting. The concentration of the gel-purified PCR product was 
then measured by NanoDrop™ spectrophotometer and stored at -20°C until needed.   
3.2.2.4 Construction of pKLAC2-Gal d 5 expression vector 
 
The mature Gal d 5 gene was cloned into the XhoI and NotI sites, in frame with the 
α-mating factor (α-MF) secretion leader sequence of the pKLAC2 vector, to yield 
pKLAC2-Gal d 5 construct. The mature Gal d 5 gene and the pKLAC2 vector were 
digested with restriction enzymes XhoI and NotI according to NEB Time-Saver™ 
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protocol (protocol mentioned in Section 2.2.2.5). Ligation of the digested products 
was conducted under standard conditions with a 1:6 vector to insert ratio keeping the 
total DNA under 10 ng. The amounts of vector and insert DNA were calculated using 
the following formula.  
  
 
 
4 ng of digested pKLAC2 vector and 4.80 ng of linearized Gal d 5 gene were ligated 
using 1 μL of T4 DNA ligase and 10× T4 DNA ligase reaction buffer in a 10 μL total 
reaction volume. The ligation reaction was incubated overnight at 4°C. The ligation 
reaction was chemically transformed into NEB 5-alpha F’ Iq Competent E. coli 
according to NEB high efficiency transformation protocol (protocol mentioned in 
Section 2.2.2.6). Transformed cells were grown overnight on LB agar medium at 
37°C. Screening for E. coli colonies harbouring pKLAC2-Gal d 5 construct was 
performed by restriction enzyme digestion of isolated plasmids with XhoI and NotI 
(Protocol outlined in Section 2.2.2.8). The plasmids harbouring the insert were then 
sequenced using #S1274 LAC4mt promoter sequencing forward primer 5’- 
GCGGATAACAAGCTCAAC-3’ (Micromon-Monash University, Clayton, VIC, 
Australia). The DNA sequences obtained from sequencing were then subjected to 
nucleotide BLAST search using the NCBI online tool. 
3.2.2.5 Production of linearized pKLAC2 expression cassette 
 
pKLAC2-Gal d 5 construct was digested with SacII restriction enzyme in order to 
produce the linear expression cassette. 1 µg of pKLAC2-Gal d 5 construct was 
digested with 1 µL of SacΙΙ and 5 µL of NEBuffer 3.1 in a 50 µL total reaction 
ng Insert = ng Vector × bp Insert 
   bp Insert 
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volume. The sample was then incubated at 37°C for 1 hour. The digested DNA was 
then desalted using QIAquick® PCR purification kit (QIAGEN, Hilden, Germany) 
according to manufacturer’s instructions. All centrifugation steps were carried out at 
13, 000 rpm at room temperature. 5 volumes of Buffer PB were mixed with 1 volume 
of linearized DNA. Then, 10 µL of 3 M sodium acetate (C2H3NaO2) (pH 5.0) was 
added to the sample to adjust the pH. To bind DNA, two SacII digested pKLAC2-
Gal d 5 reactions (100 µL of total volume) were run through a single QIAquick 
column placed in a 2 mL collection tube by centrifugation for 1 minute. The flow-
through was discarded. Then, 750 µL of Buffer PE was added to the QIAquick 
column and centrifuged for 1 minute to wash. The flow-through was discarded. The 
QIAquick column was centrifuged for an additional 1 minute and the flow-through 
was discarded. The QIAquick column was placed in a clean 1.5 mL microcentrifuge 
tube. To elute DNA, 50 µL of Buffer EB was added to the centre of the QIAquick 
membrane and allowed to stand for 1 minute, prior centrifugation for 1 minute. The 
concentration of purified DNA was measured using a NanoDrop™ 
spectrophotometer.   
3.2.2.6 Transformation of K. lactis  
 
Linearized expression cassette was introduced into K. lactis GG799 competent cells 
by chemical transformation according to the manufacturer’s instructions. A tube of 
K. lactis competent cells was thawed on ice. Then, 620 µL of NEB Yeast 
Transformation Reagent was added to the cells and mixed by inverting the tube until 
the solution was homogeneous. 1 µg of linearized pKLAC2 expression cassette was 
added to the cell mixture in a volume less than 15 µL and mixed by inverting the 
tube several times. The mixture was incubated at 30°C for 30 minutes. Then, the 
cells were heat shocked by incubating at 37°C for 1 hour in a water bath. The cells 
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were pelleted by centrifugation at 7000 rpm for 2 minutes. The supernatant was 
discarded. The cell pellet was resuspended in 1 mL sterile YPGlu medium and 
centrifuged at 7000 rpm for 2 minutes. The supernatant was discarded. The cell pellet 
was resuspended again in YPGlu media in a sterile 1.5 mL tube and incubated at 
30°C for 3.5 hours with shaking at 250 rpm. The cell mixture was then transferred 
into a new microcentrifuge tube. The cells were pelleted by centrifugation at 7000 
rpm for 2 minutes and the supernatant was discarded. The cell pellet was 
resuspended in 1 mL of sterile 1× PBS. Then, 50 µL and 100 µL aliquots were plated 
on YCB agar medium containing 5 mM acetamide and incubated at 30°C for 3.5 
days until colonies formed.  
3.2.2.7 Identification of multi-copy integrants 
  
K. lactis transformants with multi-copy integrants were identified through whole cell 
PCR analysis. Individual K. lactis colonies were patched onto fresh YCB agar 
medium plates containing 5 mM acetamide and incubated at 30°C for 1-2 days. Cells 
from an area approximately 1 mm2 were harvested by scraping with a sterile pipette 
tip and resuspended in 25 µL 1 M sorbitol (Sigma-Aldrich, MO, USA) containing 10 
mg/mL lyticase (Sigma-Aldrich, MO, USA). The cells were mixed by vortexing and 
incubated at 30°C for 1 hour. Lyticase-treated cells were lysed in a thermocycler by 
incubating at 98°C for 10 minutes. Then, PCR reaction was made by adding 10 µL of 
10× integration primer 2 (5’-ATCATCCTTGTCAGCGAAAGC-3’), 10 µL of 10× 
integration primer 3(5’-ACCTGAAGATAGAGCTTCTAA-3’), 10 µL of 2 mM 
dNTPs, 10 µL of 10× ThermoPol Buffer, 1 µL of Taq DNA Polymerase and 34 µL 
of deionised water to lyticase-treated cells in a final reaction volume of 100 µL. The 
thermal cycler conditions were: 30 cycles at 30 seconds at 94°C, 30 seconds at 50°C 
and 3 minutes at 72°C and a final incubation at 72°C for 10 minutes. The whole cell 
85 
 
 
 
PCR products were analysed on E-Gel® CloneWell™ agarose gel with 0.8% SYBR® 
Safe DNA gel stain. 
3.2.2.8 Time course of expression and detection of secreted rGal d 5 
 
Transformed K. lactis strain containing multi-copy integrants were screened for its’ 
ability to secrete rGal d 5 in YPGal medium. A small aliquot of frozen K. lactis cells 
was revived on YCB agar medium containing 5 mM acetamide by incubating at 
30°C for 1.5 days. For expression, a single K. lactis colony was grown in 5 mL of 
YPGal medium at 30°C with shaking at 250 rpm for 7 days.  Culture supernatants 
were harvested by centrifugation daily starting from 2nd day to 7th day during the 
time course of expression. Collected culture supernatants were then analysed by 
SDS-PAGE (protocol mentioned in Section 2.2.1.3) and Western blotting (protocol 
mentioned in Section 2.2.1.4.1). Here, monoclonal anti-HA antibody produced in 
mouse (diluted 1:1000 in blocking solution) (Sigma-Aldrich, MO, USA) was used as 
the primary antibody, while alkaline phosphatase-conjugated anti-mouse IgG 
antibody was used as the secondary antibody. 
3.2.2.9 Purification of rGal d 5 
 
Purification of rGal d 5 was performed using Pierce Magnetic HA-Tag IP/Co-IP kit 
(Thermo Fisher Scientific®, MA, USA) according to the manufacturer’s instructions. 
25 µL of Pierce anti-HA Magnetic Beads were mixed with 175 µL of IP Lysis/Wash 
Buffer by gently vortexing in a microcentrifuge tube. The tube was placed into a 
magnetic stand to collect the beads. The supernatant was discarded. 1 mL of IP 
Lysis/Wash Buffer was added to the microcentrifuge tube and gently vortexed for 1 
minute. The magnetic beads were collected using a magnetic stand. The supernatant 
was discarded. 300 µL of culture supernatant sample containing HA-tagged rGal d 5 
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from 6th day was added to the pre-washed magnetic beads and incubated at room 
temperature for 30 minutes with mixing. Then magnetic beads were collected with a 
magnetic stand and the unbound sample was removed and saved for analysis. 300 µL 
of IP Lysis/Wash Buffer was added to the tube and mixed gently. The beads were 
collected with a magnetic stand and the supernatant was discarded.  This washing 
step was repeated twice. Then, 300 µL of DI water was added to the tube and gently 
mixed. The beads were collected with a magnetic stand and the supernatant was 
discarded. 100 µL of Elution Buffer was added to the magnetic beads and incubated 
at room temperature with mixing for 10 minutes. Then, magnetic beads were 
separated on a magnetic stand and the supernatant containing the recombinant 
protein was collected for analysis. All the fractions were then analysed on SDS-
PAGE and Western blotting as mentioned in the Section 3.2.2.8.  
3.2.2.10 Identification of patients sensitized to nGal d 5 
 
Western dot blot analysis was conducted using the Bio-Dot Microfiltration apparatus 
(Bio-Rad, Hercules, CA, USA) with the buffers provided in WesternBreeze 
Chromogenic immunodetection system. 3 µg of nGal d 5 in a total volume of 100 µL 
of 1× PBS, was spotted on to a nitrocellulose membrane. Following blocking using 
the bocking buffer, nGal d 5 spots were incubated with 21 individual patients’ sera 
(diluted 1:10 in blocking buffer) allergic to hen’s egg white and 2 non-allergic 
subjects’ sera (diluted 1:10) overnight with gentle agitation at room temperature. 
After washing, all serum pre-incubated spots were incubated with monoclonal anti-
human IgE antibody produced in goat and labelled with alkaline phosphatase (diluted 
1:2000 in blocking buffer). The signal was developed by incubating the 
nitrocellulose membrane with BCIP/NBT chromogenic substrate. 
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3.2.2.11 Dot-blot analysis of rGal d 5 
 
3 µg of rGal d 5 was spotted on to nitrocellulose membrane using the Bio-Dot 
Microfiltration apparatus according to the protocol mentioned in Section 3.2.2.10 
above. rGal d 5-spotted membrane was probed with pooled sera (diluted 1:5 in 
blocking buffer) composed of patients sensitised to nGal d 5 (patients 3, 10, 15, 16, 
17, 19, 24 and 25). As a negative control, two rGal d 5 spots were probed with sera 
from 2 non-allergic individuals. After washing, all serum pre-incubated spots were 
incubated with monoclonal anti-human IgE antibody produced in goat labelled with 
alkaline phosphatase (diluted 1:2000 in blocking buffer). The signal was developed 
by incubating the nitrocellulose membrane with BCIP/NBT chromogenic substrate.  
3.2.2.12 Indirect ELISA for quantification of specific IgE against rGal d 5 and 
nGal d 5 
 
In brief, 1 µg of nGal d 5 and rGal d 5 in 100 µL of coating buffer (100 mM 
bicarbonate/carbonate coating buffer, pH 9.6) were allowed to coat wells of an 
ELISA microtiter plate. The proteins were allowed to coat the microtiter wells 
overnight at 4°C. After triple washing with 0.05% PBST, all protein coated wells 
were blocked with 1% (W/V) non-fat dry milk in 1× PBS for 2 hours at room 
temperature. The plates were triple washed with 0.05% PBST. nGal d 5 and rGal d 5 
coated wells were then incubated with patient sera (diluted 1:10 in 1% (W/V) non-fat 
dry milk in 1× PBS) 3, 10, 15, 16, 17, 19, 24, 25 and one non-allergic sera (diluted 
1:10 in 1% (W/V) non-fat dry milk in 1× PBS) overnight at 4°C. Each sample was 
done in triplicates. After triple washing the wells with 0.05% PBST, all wells were 
incubated with monoclonal anti-human IgE antibody produced in goat and labelled 
with alkaline phosphatase (diluted 1:1000 in 1% non-fat dry milk in 1× PBS) for 2 
hours at room temperature. Following triple washing with 0.05% PBST, 200 µL of 
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alkaline phosphatase Yellow (pNPP) liquid substrate was added to the wells and 
incubated at 37°C. The colour development was terminated by adding 3 M NaOH 
(50 µL per well) and the plate was read at 405 nm using a plate reader.  
3.3 Results  
 
3.3.1 Expression of rGal d 5 in E. coli 
 
Analysis of RT-PCR product on 1% (W/V) agarose gel showed a predominant band 
between 1500 bp and 2000 bp markers (expected size: 1827 bp) (Figure 3.1). E. coli 
cells transformed with pTrcHisA-Gal d 5 construct had growth when grown on LB 
agar under ampicillin resistance. When BamHI and EcoRI digested plasmids of 
selected transformant clones were electrophoresed on 1% (W/V) agarose gel, 4 out of 
5 clones showed the insert approximately at 2000 bp marker (expected size: 1827 bp) 
(Figure 3.2). Sequencing analysis of plasmids harbouring the insert confirmed the in-
frame ligation of the Gal d 5 gene within the MCS of pTrcHis A vector. The NCBI 
BLAST search of the derived sequence produced Gallus gallus albumin (sequence 
ID: refΙNM 205261.2) as the top match with a 96% sequence similarity (Figure 3.3).  
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Figure 3.1: RT-PCR of Gal d 5 gene. The PCR product was electrophoresed on 
a 1% (W/V) agarose gel. Lane 1: RT-PCR product of chicken Gal d 5gene. Lane 2: 
negative control RT-PCR without template mRNA. MW: molecular weight marker 
GeneRuler 1kb Plus DNA ladder in bp. The arrow indicates the RT-PCR amplified 
Gal d 5 gene.  
 
 
 
 
 
 
Figure 3.2: Restriction enzyme digest screening for the colonies harbouring the 
pTrcHis A-Gal d 5 construct. The digested plasmids were electrophoresed on a 
1% (W/V) agarose gel. Lanes 1-5: BamHI and EcoRI digested plasmids of 5 
individual bacterial colonies grown on transformation plate with antibiotic. MW: 
molecular weight marker GeneRuler 1kb Plus DNA ladder in bp. The arrow indicates 
the Gal d 5 gene.  
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Figure 3.3: Sequence alignment comparison of DNA sequence derived for 
pTrcHis A-Gal d 5 construct using NCBI Nucleotide BLAST tool. 
 
SDS-PAGE Analysis of transformed E. coli culture fractions of the pilot expression 
study showed multiple protein bands in both the soluble and insoluble fractions 
(Figure 3.4, A). The Western blot analysis of E. coli culture fractions showed a 
predominant band in between 64 kDa and 98 kDa markers on the insoluble culture 
fractions (expected size: 69 kDa) (Figure 3.4, B). The highest band intensity was 
observed on 5-hour post IPTG induction. No bands were detected in between 64 kDa 
and 98 kDa markers on the soluble fraction of the Western blot. However, several 
low molecular weight breakdown products of rGal d 5 can be seen in both the soluble 
and insoluble fractions.  
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Figure 3.4: Time-course of expression of soluble and insoluble E. coli cell 
culture fractions harbouring rGal d 5. Lane 1: un-induced culture fractions. Lanes 
2-4: IPTG-induced culture fractions at time points 2nd, 3rd and 5th hours, respectively, 
and analysed by (A) SDS-PAGE and (B) Western immunoassay. MW: molecular 
weight marker in kDa (SeeBlue Pre-Stained protein standard). The arrows indicate 
the rGal d 5 in the insoluble fraction. 
 
3.3.2 Expression of Gal d 5 in K. lactis 
 
The full-length cDNA coding for the mature Gal d 5 gene was amplified in a single 
step using QIAGEN Fast Cycling PCR kit. A single predominant band was visible 
just below 2000 bp marker (expected size: 1827 bp) when electrophoresed on E-Gel® 
CloneWell™ agarose gel (Figure 3.5). E. coli cells transformed with newly 
synthesised pKLAC2-Gal d 5 construct had growth when grown on LB agar under 
ampicillin resistance. When XhoI and NotI digested plasmids of selected 
transformant clones were electrophoresed on 1% agarose gel, 6 out of 7 clones 
showed the insert approximately at 2000 bp marker (expected size: 1827 bp) (Figure 
3.6). Sequencing analysis pKLAC2-Gal d 5 constructs confirmed the ligation of Gal 
d 5 gene in-frame with the α-MF secretion signal of the pKLAC2 vector. The NCBI 
BLAST search of the derived sequence produced Gallus gallus albumin (sequence 
ID: refΙNM 205261.2) as the top match with a 98% sequence similarity (Figure 3.7). 
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Figure 3.5: PCR amplification of Gal d 5 gene. The PCR product was 
electrophoresed on E-Gel® CloneWell™ agarose gel with 0.8% SYBR Safe™ 
DNA Gel stain. Lane 1: PCR amplified Gal d 5 gene. MW: molecular weight marker 
in bp (E-Gel® 96 High Range DNA marker). The arrow indicates the PCR amplified 
Gal d 5 gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Restriction enzyme digest screening for the colonies harbouring the 
pKLAC2-Gal d 5 construct. The digested plasmids were electrophoresed on a 
1% (W/V) agarose gel. Lanes 1-7: XhoI and NotI digested plasmids of 7 individual 
bacterial colonies grown on transformation plate under ampicillin resistance. MW: 
molecular weight marker in bp (E-Gel® 96 High Range DNA marker). The arrow 
indicates the Gal d 5 gene.  
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Figure 3.7: Sequence alignment comparison of DNA sequence derived for 
pKLAC2-Gal d 5 construct using NCBI Nucleotide BLAST tool. 
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pKLAC2-Gal d 5 construct isolated from the selected clone was digested with SacΙΙ 
to generate the linearized expression cassette in order to facilitate integrative 
transformation of K. lactis. Electrophoresis of SacII digested pKLAC2-Gal d 5 
construct on 1% (w/v) agarose gel confirmed successful digestion of the construct 
(Figure 3.8). There are 2 SacII restriction enzyme sites in the pKLAC2 vector. The 
SacII digested construct showed a fragment of >6.2 kb which contains PLAC4-PBI, the 
cloned Gal d 5 gene and the amdS selection gene, and another fragment with an 
approximate size of 2.8 kb containing the remainder of the pKLAC2 vector. 
Following introduction of linearized expression cassette into K. lactis cells, 
transformants were selected by growth on YCB agar minimal media containing 5 
mM acetamide. A randomly selected K. lactis transformant was then subjected to 
whole cell PCR to confirm the multiple integration of expression cassettes. Analysis 
of whole cell PCR product showed an amplification product approximately at 2.3 kb 
when electrophoresed on 1% (w/v) agarose gel (Figure 3.9).   
 
 
Figure 3.8: SacII digest of the pKLAC2-Gal d 5 construct. The digested plasmid 
was electrophoresed on a 1% (w/v) agarose gel. Lane 1: SacII digest of the 
pKLAC2-Gal d 5 construct. Arrow a, indicates the expression cassette containing the 
Gal d 5 gene. Arrow b, indicates the remainder of the pKLAC2 vector. MW: 
molecular weight marker in bp (E-Gel® 96 High Range DNA marker).  
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Figure 3.9: Whole cell PCR analysis for screening of strains containing multi-
copy integrants. The PCR product was electrophoresed on a 0.8 % precast 
agarose gel with SYBR Safe™ DNA gel stain. Lane 1: PCR product. MW: 
molecular weight marker in bp (E-Gel® 96 High Range DNA marker). Arrow 
indicates the PCR amplicon at 2.3 kb.  
 
 
A time course of expression was performed to confirm the secretion of rGal d 5 and 
to determine the optimum recombinant protein expression conditions of K. lactis 
cells harbouring rGal d 5. The culture supernatant samples were analysed by SDS-
PAGE (Figure 3.10, A) and Western blot (Figure 3.10, B). SDS-PAGE analysis of 
culture supernatants showed a single predominant band in between 64 kDa and 98 
kDa markers in all the culture fractions (expected size: 1827 bp). The Western blot 
showed a predominant band approximately in between 64 kDa and 98 kDa markers 
corresponding to the protein on SDS-PAGE confirming the authenticity of rGal d 5. 
SDS-PAGE analysis of nGal d 5 also showed a predominant band in between 64 kDa 
and 98 kDa markers and was comparable to the SDS-PAGE of rGal d 5 (Figure 3.10, 
C). The SDS-PAGE analysis of the time course of expression showed the highest 
recombinant protein production on the 6th day. 
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Figure 3.10: Time-course of expression of K. lactis culture supernatants 
containing secreted rGal d 5 and SDS-PAGE of nGal d 5. Lanes 1-6: culture 
supernatants from day 2 to 7, respectively analysed by (A) SDS-PAGE and (B) 
Western immunoassay. (C) SDS-PAGE of nGal d 5. MW: molecular weight marker 
in kDa (SeeBlue Pre-Stained protein standard). Arrows indicates rGal d 5 
approximately at 69 kDa region.  
 
Expression of a recombinant protein fused to an epitope tag such as HA epitope 
provides the means to purify the fusion peptide using immunoprecipitation. The 
SDS-PAGE analysis of immunoprecipitation purified rGal d 5 showed a predominant 
band approximately at 69 kDa with no visible contaminant K. lactis proteins (Figure 
3.11, A). The Western immunoblot of immunoprecipitation-purified rGal d 5 probed 
with monoclonal anti-HA antibody produced in mouse showed a predominant band 
approximately at 69 kDa corresponding to the protein band on SDS-PAGE (Figure 
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3.11, B). Furthermore, no proteolytic degradation of rGal d 5 was observed in all 
SDS-PAGE and Western immunoblot analysis of K. lactis culture supernatants.  
 
 
 
 
 
 
Figure 3.11: Analysis of immunoprecipitation purified rGal d 5. (A) SDS-PAGE 
and (B) Western immunoassay of purified rGal d 5 fractions. Lane 1: unbound 
sample. Lane 2: elution containing rGal d 5. MW: molecular weight marker in kDa 
(SeeBlue Pre-Stained protein standard). Arrows indicate rGal d 5. 
 
3.3.3 Immunological analysis of nGal d 5 and rGal d 5 
Sera from 21 patients’ allergic to hen’s egg white were tested with dot-blot analysis 
to examine the frequency and degree of IgE sensitisation against nGal d 5. The dot-
blot analysis was performed only once due to the limited availability of patients’ 
sera. The dot-blot analysis (Figure 3.12) showed that 38% (8 out of 21) of egg white 
allergy patients to have IgE reactivity to nGal d 5. Out of the all sensitised patients, 
patient 3 exhibited significantly high IgE reactivity against nGal d 5 when compared 
to others. Other sensitised patients exhibited mild IgE reactivity to Gal d 5. The 
ability to recognize rGal d 5 by the immune systems of nGal d 5 sensitised patients 
was demonstrated by Western dot blot (Figure 3.13). rGal d 5 showed clear IgE 
reactivity when probed with pooled patients’ sera. rGal d 5 showed negligible level 
of IgE reactivity when probed with non-allergic sera.  
An indirect ELISA assay was performed to compare the degree of IgE reactivity of 
nGal d 5 and rGal d 5 (Figure 3.14). The result shows that patient 3 to have the 
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highest IgE reactivity against both nGal d 5 and rGal d 5. The remaining patients 
showed mild reactivity to nGal d  
5 and rGal d 5. Furthermore, in every patient the amount of IgE reactivity directed at 
nGal d 5 and rGal d 5 were very similar.  
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Testing of patients allergic to hen’s egg white described in Table 1 
for IgE reactivity with dot-blotted nGal d 5. The grid above shows the identity of 
the serum used corresponding to each spot. nGal d 5 sensitised patients are 
highlighted in the grid. Dots denoted by N are non-allergic serum.   
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Testing of patients sensitised to nGal d 5 for IgE reactivity with 
dot-blotted rGal d 5. Dots denoted by N are sera from non-allergic subjects.   
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Figure 3.14: Comparison of the binding activity of human specific IgE against 
recombinant and natural Gal d 5. Blue boxes represent IgE reactivity against nGal 
d 5 and red boxes represent IgE reactivity against rGal d 5. N denotes the non-
allergic serum and numbers denotes different patients’ sera. Data are average of 
triplicate measurements SE ±. 
 
3.4 Discussion 
 
The main objective of Chapter 3 was to produce an IgE-reactive recombinant version 
of hen’s egg yolk allergen Gal d 5 and analyse its’ IgE binding capacity in 
comparison to nGal d 5. The first challenge of this study was to successfully clone 
and express sufficient amounts of rGal d 5 as a soluble fraction. Variety of 
recombinant production platforms are being designed in order to meet these 
demands. However, there is no universal protein expression system or a predictive 
tool, which can guarantee the desired outcome. This is mainly attributed to the 
biochemistry of each protein and its effects on the host expression system [140]. 
Due to the success with expressing rGal d 6 in E. coli, it was decided to clone and 
express rGal d 5 in the same strain. Analysis of RT-PCR result indicated that cDNA 
coding for the mature egg yolk allergen Gal d 5 was selectively amplified from total 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
3 10 15 16 17 19 24 25 N
A
bs
or
ba
nc
e 
(4
05
 n
m
) 
Human patients serum 
nGal d 5
rGal d 5
100 
 
 
 
mRNA extracted from liver tissue. Analysis of SDS-PAGE and Western blot results 
of IPTG induced culture fractions of E. coli harbouring pTrcHis A-Gal d 5 confirmed 
the successful expression of rGal d 5. These data suggest that the PCR amplified Gal 
d 5 gene has been successfully integrated to the MCS of the pTrcHis A vector. 
Therefore, translation of rGal d 5 fusion peptide with a N-terminal 6×his tag has been 
successfully lead by the Ptrc resulting in high levels of recombinant protein yield. 
However, complete lack of soluble rGal d 5 indicates that rGal d 5 has undergone 
irregular folding resulting in insoluble and refractile IBs.  
Even though, E. coli host expression systems are well known for their versatility in 
recombinant protein production, they also contain few drawbacks. For example 
production of recombinant proteins, which contains large amounts of disulphide 
bonds (DBs) has always been challenging. DBs are very common in proteins such as 
mammalian proteins, hormones and secreted proteins [141]. Gal d 5 is a secreted 
protein with 17 DBs stabilizing it [142]. DBs are crucial for correct protein folding, 
stability and functionality. In general, the cytoplasm of E. coli cells does not offer a 
favourable environment for DB formation due to the presence of numerous DB 
reductases, such as thioredoxins and glutaredoxins. These DB reductases quickly 
reduce DBs formed between two cysteine groups back to its thiolate state. Failure to 
form DBs in the recombinant proteins results in it being formed as inactive IBs. 
Therefore, it is highly possible that the large number of DBs present in Gal d 5 
haven’t been formed in the E. coli cytoplasm and have undergone IB formation [141, 
143]. On the other hand it is clear why Gal d 6 protein production by E. coli as a 
soluble fraction had relative success when compared to Gal d 5 protein production. It 
is evident that lack of DBs in Gal d 6 [144] may have contributed to undergo 
successful expression of it as a soluble fraction.  
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In order to retain the biomedical value of a biomolecule, it is essential that the 
recombinant protein is produced in a soluble fraction, resembling as much as 
possible to its native form. Therefore, in the event of IB formation, a number of 
strategies have been recommended to promote the production of recombinant 
proteins as a soluble fraction in the literature. If IB formation is due to lack of DB 
formation, in vitro refolding can be used to obtain a functional protein. However, it is 
well known that refolding in IBs is often unpredictable and challenging. 
Furthermore, in vitro refolding is highly time consuming and require a large amounts 
of reagents [143]. Majority of the mentioned implications are aimed at changing 
growth conditions of the host strain to induce soluble protein expression. 
Nevertheless, introducing changes in growth conditions do not always guarantee 
successful expression of soluble recombinant protein [131, 132]. Therefore, overall 
generation of the soluble protein is the preferred choice [143].  
As an alternative approach, we decided to use a different host organism to express 
rGal d 5 as a soluble fraction. In this chapter, we used the eukaryote yeast strain K. 
lactis to produce rGal d 5 as a secreted protein. Our results confirmed that rGal d 5 
produced by K. lactis is IgE-reactive and has very similar IgE binding levels to nGal 
d 5. Furthermore, in vitro immunoassay results indicate that patients with allergy to 
hen’s egg white can have reactive IgE antibodies against Gal d 5, indicating potential 
allergy to hen’s egg yolk.  
Analysis of PCR results indicated that cDNA coding for the mature egg yolk allergen 
Gal d 5 was selectively amplified from the pTrcHis A-Gal d 5 construct. The 
randomly selected K. lactis transformant strain was confirmed as a multi-copy 
integrant using the whole cell PCR technique.  In this strategy, only strains 
containing multiple copies of pKLAC2 expression cassette will produce an amplicon 
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with a size of 2.3 kb. Strains harbouring multiple copy inserts may have higher 
recombinant protein expression levels than single copy integrants.  However, this 
technique is unable to indicate the number of integrated expression vector fragments 
in the cells [145]. K. lactis transformant selection is based on acetamide selection 
instead of traditional antibiotic selection. It has been reported that acetamide 
selection enriches transformants with multi-copy integrants over transformants with 
single copy integrants. As a result, majority of the strains contain multiple copies of 
the expression fragment [145, 146]. Therefore, we were able to obtain a strain with 
multi-copy integrants with relative ease. 
Analysis of galactose-induced K. lactis culture supernatants with SDS-PAGE and 
Western immunoassay confirmed the presence of rGal d 5 at the expected size. These 
data suggests that the pKLAC2 containing Gal d 5 gene has been successfully 
integrated into the K. lactis genome at the LAC4 locus, which drives protein 
expression. Furthermore, this result indicates that cloning of Gal d 5 gene into 
pKLAC2 expression vector had been done in-frame with the α-MF secretion leader 
sequence. The α-MF domain directs the fusion protein to be efficiently transported 
through yeast secretory pathway. Furthermore, there were not any visible K. lactis 
derived proteins in the culture supernatants. Therefore, lack of detectable amounts of 
native host proteins serves as the first step of purification. Lack of native of K. lactis 
proteins in the spent culture media indicates that those proteins haven’t been secreted 
efficiently through the yeast secretory pathway. Multiple integration of Gal d 5 gene 
may have resulted in overexpression of the recombinant protein. Therefore, a high 
amount of recombinant Gal d 5 can enter the K. lactis secretory pathway preventing 
or reducing the secretion of native proteins.    
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The expression of fusion protein with a HA-epitope tag provides the means to 
selectively purify proteins through immunoprecipitation in addition to serving as an 
identification tag. The rGal d 5 was purified to homogeneity by immunoprecipitation 
using anti-HA magnetic beads. There were no visible K. lactis derived proteins on 
SDS-PAGE indicating a high level of purity. The Western immunoassay of purified 
rGal d 5 indicated that the majority of the anti-HA magnetic beads were able to 
capture the target rGal d 5 protein without any cross reactivity with native K. lactis 
host proteins. A major concern in recombinant protein production is protein 
degradation due to proteolysis [133]. Our results confirmed that there was no 
proteolytic degradation of rGal d 5.   
The dot-blot immunoassay showed that 38% (8 out of 21patients) of egg white 
patients to have IgE sensitisation directed against nGal d 5. However, only one 
patient (patient number 3) out of the 8 IgE-reactive patients had significant reactivity 
against nGal d 5 when compared to non-allergic controls. The amount of specific IgE 
antibodies directed against a certain allergen can vary from person to person 
influenced by a combination of genetic and environmental factors. However, exact 
determinants responsible for producing such high amounts of specific IgE against 
nGal d 5 in our experiment cannot be deduced without further investigations. 
Furthermore, the remaining seven patients which have sensitisation against nGal d 5 
had very minor reactivity. This could be attributed to the fact that Gal d 5 is a minor 
allergen. A limitation in this study is the use of sera from patients diagnosed with egg 
white allergy rather than from patients diagnosed with egg yolk allergy. At the 
present time, allergy to hen’s egg yolk is not commonly tested in hospitals which 
forced us to use sera from egg white allergy patients. The patients sensitized towards 
nGal d 5 may or may not develop symptoms of allergy from Gal d 5. Nevertheless, 
presence of such antibodies is considered a risk factor for allergy and to have a 
104 
 
 
 
predictive value. For example, it has been shown that presence of hen’s egg white 
specific IgE antibodies even without clinical symptoms can be used to predict the 
development of allergy before 7-10 years of age [3].  
IgE binding capacity between recombinant and their corresponding natural allergens 
may be different. Therefore, in this study we comparatively analysed the degree of 
IgE binding of rGal d 5 and nGal d 5. The ELISA experiment showed that both 
recombinant and natural Gal d 5 to exhibit very similar levels of IgE binding. 
Furthermore, the dot-blot analysis of rGal d 5 confirmed that it is IgE reactive. These 
results together suggest that rGal d 5 produced by K. lactis is recognizable by the 
human immune system and bears similar epitopes to that of nGal d 5.    
In conclusion, Chapter 3 presents the successful production of IgE-reactive rGal d 5 
using K. lactis yeast strain. We have shown that rGal d 5 has similar allergenicity to 
nGal d 5 by comparing IgE binding activity of both using sera from egg white allergy 
patients. Furthermore, we were able to isolate rGal d 5 with a high level purity with 
relative ease. Therefore, rGal d 5 produced in this chapter is a potential candidate to 
be used in in vitro allergy diagnosis in the future. However, it is also important to 
further subject rGal d 5 into immunological investigations using sera from patients 
allergic to hen’s egg yolk. Immunological analysis of rGal d 5 in comparison to nGal 
d 5 using patients with allergy to hen’s egg yolk may provide some in depth 
validation to the results presented in this chapter.  Furthermore, availability of IgE 
reactive recombinant allergens opens the way to develop recombinant based 
hypoallergenic variants with the aim to reduce IgE-mediated side effects during 
immunotherapy. The efficacy of immunotherapy combined with recombinant based 
hypoallergenic allergens has demonstrated promising results. For example, 
subcutaneous immunotherapy trials conducted using recombinant hypoallergenic 
105 
 
 
 
variants of grass and birch pollen allergens showed that recombinant vaccines have 
vaccination characteristics and is clinically effective [116]. Therefore, availability of 
an IgE reactive recombinant hen’s egg yolk allergen Gal d 5 provide the means for 
development of hypoallergenic derivatives using techniques such as site-directed 
mutagenesis (SDM) [147]. Consequently, availability of hypoallergenic rGal d 5 
variants in the future may open new treatment strategies to cure egg allergy.  
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Chapter 4: Production of hypoallergenic variant 
of recombinant hen’s egg yolk allergen chicken 
serum albumin (Gal d 5) 
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4.1 Introduction 
 
 
The use of genetically engineered recombinant based hypoallergenic variants in SIT 
has proved its therapeutic supremacy over crude allergen extracts during SIT [116]. 
Furthermore, the reduced risk of side effects in patients undergoing SIT with 
hypoallergens has been well commended [116, 119]. For example, recombinant 
based hypoallergenic variants of peanut and birch pollen allergens has been shown to 
perform SIT without the risk of severe allergic reactions in patients [119, 148].  In 
Chapter 3, we produced an immunologically active recombinant version of Gal d 5 
with similar IgE reactivity to its wild type counterpart, which may be useful as 
standardised reagents in diagnostics in the future. In addition, rGal d 5 produced in 
the previous chapter can be used as a platform to develop hypoallergenic variants 
with reduced IgE binding capacity for potential use in SIT for patients suffering from 
hen’s egg yolk allergy.  
The availability of information regarding IgE binding allergenic epitopes can 
immensely benefit the production of hypoallergens. IgE binding epitopes could be 
either sequential or conformational. Reducing or complete elimination of IgE binding 
can be achieved by introducing a number of mutations targeting the allergenic 
epitopes using techniques such as SDM. Furthermore, in addition to serving as a tool 
for introducing mutations to a DNA sequence, SDM can also be used to successfully 
map epitopes of allergens, especially conformational epitopes [147, 148].  
A common approach to develop hypoallergenic mutants is by changing the overall 
conformation of the allergen by disrupting disulfide bonds (DB) by using the SDM 
technique. DBs can be deleted by substituting corresponding cysteine residues that 
form DBs with a different amino acid by introducing appropriate mutations to the 
DNA sequence. Systematic disruption of DBs allows researchers to evaluate the 
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relationship between the allergen confirmation and the degree of IgE-mediated 
immune response. Gal d 5 is stabilized by 17 DBs [142]. In this chapter, our primary 
aim was to develop a mutant variant of Gal d 5 with reduced IgE binding capacity, 
which could be used as a SIT hypoallergen in the future. However, due to the lack of 
data regarding IgE binding antigenic epitopes of Gal d 5, an alternative approach was 
required to develop a mutant with reduced IgE binding reactivity.  
In this chapter, we first developed a mutant variant of Gal d 5 by simultaneously 
disrupting two randomly selected DBs, by substituting cysteine (Cys) with alanine 
(Ala). We hypothesised that removal of DBs would result in a mutant variant of Gal 
d 5 with reduced or no IgE-binding reactivity at all. In order to test the hypothesis, 
we comparatively analysed the IgE binding capacity of recombinant based mutant 
Gal d 5 and native Gal d 5 using patients’ sera.  The mutant variant of Gal d 5 was 
developed by deleting two DBs at Cys196-Cys205 and Cys388-Cys397 by replacing 
cysteine residues at positions 205 and 397 with alanine, using SDM. The mutant Gal 
d 5 (Gal d 5196/205-388/397) DNA sequence was generated using the pThcHis A-Gal d 5 
construct as the template from Chapter 3. The Gal d 5196/205-388/397 DNA was 
selectively amplified and subcloned into pKLAC2 expression vector to synthesise 
pKLAC2- Gal d 5196/205-388/397 construct for expression in K. lactis yeast strain. 
However, recombinant Gal d 5196/205-388/397 (rGal d 5196/205-388/397) was not expressed 
by K. lactis despite successful cloning.  
Therefore, we decided to express Gal d 5196/205-388/397 cDNA in an E. coli expression 
system. The mutant plasmid pThcHis A-Gal d 5196/205-388/397 produced by SDM was 
used to transform E. coli cells for expression of rGal d 5196/205-388/397.  Here, 
expression of rGal d 5196/205-388/397 as a soluble fraction by E. coli was successful. The 
contribution of the combined effect of disrupting Cys196-Cys205 and Cys388-
Cys397 of Gal d 5 to human IgE binding was comparatively analysed with native 
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Gal d 5 expressed by E. coli and K. lactis in the previous chapters. The immunoassay 
results showed that IgE binding capacity of rGal d 5196/205-388/397 has been completely 
abolished due to disruption of DBs. Therefore, rGal d 5196/205-388/397 may contain a 
therapeutic value as a hypoallergen.  However, lack of IgE reactivity of a mutant 
variant based on Western immunoassay does not necessarily confirm it as a 
hypoallergen. Even with reduced IgE binding capacity, the allergenicity of some 
mutant variants of allergens are known to be unaffected [148]. Therefore, the true 
allergenicity of the mutant Gal d 5 produced in this chapter must be assessed using 
techniques such as mediator release assays and T cell proliferation assays in order to 
confirm its immune reactivity.  
4.2 Materials and methods  
 
4.2.1 Site-directed mutagenesis of Gal d 5 
 
 
Gal d 5196/205-388/397 variant, with two Cys-Ala substitutions leading to the disruption 
of the corresponding DB, were generated by using the QuickChange Lightning Multi 
Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA). The 
construct pTrcHis A-Gal d 5 synthesised in Section 3.2.1.4 was used as the template 
for mutant strand synthesis. Mutagenic primers were designed using the web-based 
QuickChange Primer Design Program available online at 
www.agilent.comgenomics/qcpd. Two TGC codons corresponding for cysteine 
residues at 205 and 397 (UniProt identifier #P19121) were changed to GCC codons 
for alanine using primers Cys205 and Cys397 and their corresponding reverse 
primers (Table 4.1).  
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Table 4.1: Mutagenic primers used for disruption of disulfide bridges in Gal d 5 
(CSA). Substitutions of Cys by Ala residues are indicated by the codon GCC 
bolded and underlined. 
 
Site-directed mutagenesis reaction was prepared by mixing 2.5 µL of 10× 
QuickChange Lighting Multi reaction buffer, 16.08 µL of double-distilled water, 
0.75 µL of QuikSolution, 100 ng of template DNA, 100 ng of each mutagenic 
primer, 1 µL of dNTP and 1 µL of QuikChange Lighting Multi enzyme blend in a 25 
µL total reaction volume in a sterile PCR tube. The site-directed mutagenesis 
reaction was then subjected to PCR according to the cycling parameters outlined in 
Table 4.2. Following temperature cycling, the reaction was placed on ice for 2 
minutes to cool below 37°C. Then 1 µL of Dpn I restriction enzyme was added to the 
amplification reaction and incubated at 37°C for 5 minutes to digest the parental non-
mutated double stranded DNA (ds-DNA). 
Table 4.2: Thermal cycling conditions for mutant strand synthesis 
Segment Cycles Temperature Time 
1 1 95°C   2 minutes 
2 30 95°C 20 seconds 
55°C 30 seconds 
65°C 30 seconds/kb of plasmid length 
3 1 65°C   5 minutes 
 
4.2.2 Transformation of XL10-Gold ultracompetent cells 
 
Following digestion of parental ds-DNA, mutated single stranded DNA (ssDNA) 
was transformed into XL10-Gold ultracompetent cells (Agilent Technologies, Santa 
Primer 
name 
Position 
of 
disulfide 
bond 
Targeted 
cysteine 
residue 
Mutagenic primers (5’-3’) 
Cys205 196-205 
 
205 GAGTGATGTCGGTGCTGCCCTGGACACCAAGG 
Cys397 388-397 
 
397 AACTGATAACCCTGCTGAGGCCTACGCAAATG
CTCAAGAG 
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Clara, CA, USA). First, a tube of XL10-Gold ultracompetent cells was thawed on 
ice. Then, 45 µL of ultracompetent cells were mixed with 2 µL of β-ME provided 
with the kit in a pre-chilled Eppendorf tube and mixed by swirling. The tube was 
incubated on ice for 10 minutes, swirling gently every 2 minutes. Then 1.5 µL of the 
Dpn I treated DNA was transferred into the aliquot of ultracompetent cells and gently 
mixed by swirling. The transformation reaction was incubated on ice for 30 minutes. 
Following incubation, the tube was heat-pulsed at 42°C for 30 seconds in a heat-
block and incubated on ice for 2 minutes. Then, 0.5 mL of preheated (42°C) NZY+ 
broth was added to the tube and incubated at 37°C for 1 hour with shaking at 250 
rpm. The transformation reaction was then spread on LB agar plates containing 50 
µg/mL ampicillin and incubated overnight at 37°C.   
4.2.3 Identifying colonies harbouring pTrcHis A-Gal d 5196/205-388/397 construct 
 
E. coli colonies grown on LB agar plates were propagated in fresh LB containing 50 
µg/mL ampicillin and plasmids were isolated according to the method outlined in 
Section 2.2.2.6. Then, colonies containing pTrcHis A-Gal d 5196/205-388/397 were 
verified by plasmid DNA sequencing using pTrcHis forward primer (5’-
GAGGTATATATTAATGTATCG-3’) and pTrcHis reverse primer (5’-
GATTTAATCTGTATCAGG-3’). The sequencing was carried out at Micromon, 
Monash University. 
4.2.4 Cloning and expression of rGal d 5196/205-388/397 in K. lactis  
 
4.2.4.1 Cloning of Gal d 5196/205-388/397 in K. lactis  
 
The Gal d 5196/205-388/397 gene was amplified using PCR technique with XhoI and NotI 
restriction sites incorporated on 5’ and 3’ ends, respectively with a C-terminal HA 
epitope tag to facilitate cloning into the pKLAC2 expression vector. The pTrcHis A-
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Gal d 5196/205-388/397 construct was used as the template. The PCR was done using 
QIAGEN Fast Cycling PCR kit according to the method outlined in Section 3.2.2.3. 
The PCR amplified Gal d 5196/205-388/397gene was cloned into the XhoI and NotI sites 
in frame with the α-MF secretion leader sequence of the pKLAC2 vector to yield 
pKLAC2-Gal d 5196/205-388/397 construct according to the method outlined in Section 
3.2.2.4. The   pKLAC2-Gal d 5196/205-388/397 was then digested using SacII restriction 
enzyme to produce the linearized expression cassette and desalted according to the 
method outlined in Section 3.2.2.5. Then, linearized expression cassette containing 
Gal d 5196/205-388/397 was chemically transformed into competent K. lactis cells 
according to the method outlined in Section 3.2.2.6. The transformed K. lactis cells 
were selected by growing on YCB agar medium containing 5 mM acetamide and 
incubated at 30°C for 3.5 days until colonies formed. Then, K. lactis strains 
harbouring tandem copies of expression cassette were scored by whole cell PCR 
technique according to the method outlined in Section 3.2.2.7.  
4.2.4.2 Detection of secreted rGal d 5196/205-388/397 by transformed K. lactis 
 
Transformed K. lactis strains containing multi-copy integrants were screened for its 
ability to secrete rGal d 5196/205-388/397 in YPGal medium. A small aliquot of frozen K. 
lactis cells was revived on YCB agar medium containing 5 mM acetamide by 
incubating at 30°C for 2 days. For expression, individual K. lactis colonies were 
grown in 5 mL of YPGal medium at 30°C with shaking at 250 rpm for 2 days.  Then, 
culture supernatants were harvested by centrifugation and analysed by SDS-PAGE 
and Western blot technique for the presence of secreted rGal d 5196/205-388/397 
according to the method outlined in Section 3.2.2.8.   
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4.2.4.3 Cloning and expression of rGal d 5196/205-388/397 in E. coli  
 
pTrcHis A- Gal d 5196/205-388/397 construct synthesised previously was chemically 
transformed into NEB 5-alpha F’ Iq Competent E. coli cells according to NEB high 
efficiency transformation protocol mentioned in Section 2.2.2.6. E. coli colonies 
harbouring the pTrcHis A-Gal d 5196/205-388/397 construct were grown on LB agar 
under ampicillin resistance. Then E. coli transformants were subjected to a time 
course of expression study to determine the optimum recombinant protein expression 
conditions. The time course of expression analysis was conducted through SDS-
PAGE and Western immunoblot technique according to the method outlined in 
Section 2.2.2.9. Here, only soluble fractions of E. coli culture fractions were 
analysed by SDS-PAGE and Western blot for the presence of rGal d 5196/205-388/397. 
For the Western blot monoclonal Anti-Xpress™ antibody produced in mouse was 
used as the detection antibody.  
4.2.5 Immunological analysis of rGal d 5 and mutant rGal d 5196/205-388/397  
 
A Western immunoassay was conducted to comparatively analyse the level of egg 
white allergic patients’ IgE binding to rGal d 5 produced by K. lactis in Chapter 3, 
rGal d 5 produced by E. coli as an insoluble fraction in Chapter 3 and mutant rGal d 
5196/205-388/397 produced by E. coli in Chapter 4. Crude E. coli extracts containing rGal 
d 5, mutant rGal d 5196/205-388/397 and purified K. lactis derived rGal d 5 were 
electroblotted to a nitrocellulose membrane according to the method outlined in 
Section 2.2.1.4.1. The identities of each rGal d 5 proteins were again verified through 
Western blot technique using the relevant primary antibodies prior immunoassay 
using the method outlined in Section 2.2.1.4.1. The protein immobilised 
nitrocellulose membrane was stained with Ponceau S solution for visualization of 
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proteins. The regions containing rGal d 5 proteins were separated by cutting with a 
scissor. The rGal d 5 immobilised nitrocellulose membranes were destained with 0.1 
M NaOH and blocked with blocking solution. Protein immobilised membranes were 
individually incubated overnight with pooled sera (diluted 1:10 in blocking solution) 
from patients sensitized to nGal d 5 (patients 3, 10, 15, 16, 17, 19, 24 and 25) at 4°C. 
As a negative control, all rGal d 5 immobilised membranes were incubated with non-
allergic patients’ sera (diluted 1:10 in blocking solution) as well. Then, all serum pre-
incubated nitrocellulose membranes were incubated with monoclonal anti-human 
IgE antibody produced in goat labelled with alkaline phosphatase (diluted 1:1000 in 
blocking solution) for 1 hour at room temperature. The signal was developed by 
adding BCIP/NBT chromogenic substrate. 
4.3 Results  
 
4.3.1 Recombinant production of Gal d 5196/205-388/397 in K. lactis 
 
Transformed XL10-Gold ultracompetent cells with pTrcHis A-Gal d 5196/205-388/397 
construct following SDM had growth under ampicillin resistance. Transformant 
colonies were screened for plasmids bearing the mutation Cys to Ala at positions 205 
and 397 by plasmid DNA sequence analysis. The Nucleotide BLAST search of the 
derived plasmid DNA sequences produced Gallus gallus albumin (sequence ID: 
refΙNM 205261.2) as the top match. Furthermore, sequence alignment comparison of 
the mutant and non-mutant Gal d 5 DNA confirmed the successful mutations of 
native sequence TGC into GCC at Cys 205 (Figure 4.1) and Cys397 (Figure 4.2).  
The full-length Gal d 5196/205-388/397 gene amplified with restriction sites XhoI and 
NotI and a C-terminal HA tag showed a single predominant band at approximately 
2000 bp marker (expected size: 1827 bp) when electrophoresed on agarose gel 
(Figure 4.3, A). NEB Express Iq Competent E. coli cells transformed with newly 
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synthesised pKLAC2-Gal d 5196/205-388/397 construct had growth when grown on LB 
agar under ampicillin resistance. However, only one colony was able to grow on 
transformation plates. When XhoI and NotI digested plasmid of the transformant 
clone were electrophoresed on agarose gel, an insert at approximately 2000 bp 
marker confirming the successful construction of pKLAC2-Gal d 5196/205-388/397 
(expected size: 1827 bp) (Figure 4.3, B). Sequencing analysis of plasmids harbouring 
the Gal d 5196/205-388/397 insert confirmed the ligation of Gal d 5196/205-388/397 in-frame 
with the α-MF secretion signal of the pKLAC2 vector. The NCBI BLAST search of 
the derived sequence produced Gallus gallus albumin (sequence ID: refΙNM 
205261.2) as the top match with a 97% sequence similarity. Furthermore, sequence 
alignment comparison of the mutant and non-mutant Gal d 5 DNA confirmed the 
presence of mutations introduced to pTrcHis A- Gal d 5196/205-388/397 (Figure 4.4 and 
Figure 4.5).  
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Figure 4.1: Nucleotide BLAST search result of the pTrcHis A-Gal d 5196/205-388/397 
DNA sequence (plus strand) obtained from pTrcHis forward primer. The 
sequence in the box shows the nucleotide substitution that resulted by SDM on the 
plus strand. Nucleotides T and G of the codon TGC (Cys 205) substituted by 
nucleotides G and C resulting in codon GCC (Ala 205).  
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Figure 4.2: Nucleotide BLAST search result of the pTrcHis A-Gal d 5196/205-388/397 
DNA sequence (minus strand) obtained from pTrcHis reverse primer. The 
sequence in the box shows the mutations resulted by SDM on the minus strand. 
Nucleotides C and A of the anti-codon GCA (codon TGC: Cys 397) substituted by 
nucleotides G and C resulting in anti-codon GGC (codon GCC: Ala 397).  
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Figure 4.3: (A) PCR of Gal d 5196/205-388/397. The PCR product was 
electrophoresed on E-Gel® CloneWell™ agarose gel with 0.8% SYBR Safe™ 
DNA Gel stain. Lane 1: PCR amplified Gal d 5196/205-388/397. The arrow indicates the 
PCR amplified Gal d 5196/205-388/397 (B) Restriction enzyme digest screening of the 
colony harbouring the pKLAC2- Gal d 5196/205-388/397 construct. Lane 1: XhoI and 
NotI digested pKLAC2- Gal d 5196/205-388/397 construct of the transformant clone. The 
arrow indicates the Gal d 5196/205-388/397. MW: molecular weight marker (Quick-Load 
Purple 2-Log DNA ladder).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MW MW MW 1 1 
(A) (B) 
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Figure 4.4: Nucleotide BLAST search result of the pKLAC2- Gal d 5196/205-388/397 
DNA sequence (plus strand) obtained from pTrcHis forward primer. The 
sequence in the box shows the nucleotide substitution that resulted by SDM on the 
plus strand. Nucleotides T and G of the codon TGC (Cys 205) substituted by 
nucleotides G and C resulting in codon GCC (Ala 205).  
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Figure 4.5: Nucleotide BLAST search result of the pKLAC2-Gal d 5196/205-388/397 
DNA sequence (minus strand) obtained from pTrcHis reverse primer. The 
sequence in the box shows the mutations that resulted by SDM on the minus strand. 
Nucleotides C and A of the anti-codon GCA (codon TGC: Cys 397) substituted by 
nucleotides G and C resulting in anti-codon GGC (codon GCC: Ala 397).  
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The pKLAC2-Gal d 5196/205-388/397 construct was digested with SacII restriction 
enzyme in order to facilitate insertion of the expression cassette into the K. lactis 
genome by integrative transformation. Electrophoresis of SacII digested pKLAC2-
Gal d 5196/205-388/397 construct on 1% (w/v) agarose gel showed two bands 
approximately at 2.8 kb and the other with a size of >6.2 kb confirming the 
successful digestion of the plasmid (Figure 4.6). In this study, we only scored for K. 
lactis strains harbouring multiple copies of the expression fragment by whole cell 
PCR. Analysis of whole cell PCR products showed an amplification product 
approximately at 2.3 kb in K. lactis clones when electrophoresed on 1% (w/v) 
agarose gel (Figure 4.7). Only strains containing tandem copies of expression 
fragment amplifies a PCR product of 2.3 kb. Our results show that the 87.5% (7 out 
of 8) of the K. lactis transformant population to bear multi-copy integrants.  
All the K. lactis strains bearing multi copy integrants were screened their ability to 
secrete rGal d 5196/205-388/397 in YPGal medium. Analysis of culture supernatant 
samples on SDS-PAGE showed multiple secreted proteins by K. lactis strains 
(Figure 4.8). The Western blot analysis of the corresponding SDS-PAGE produced a 
negative result (result not shown). Western blot analysis confirmed that all the K. 
lactis strains tested did not secrete the rGal d 5196/205-388/397 into the culture media.  
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Figure 4.6: SacII digest of the pKLAC2-Gal d 5196/205-388/397 construct. The 
digested plasmid was electrophoresed on E-Gel® CloneWell™ agarose gel with 0.8% 
SYBR Safe™ DNA Gel stain. Lane 1: SacII digest of the pKLAC2- Gal d 5196/205-
388/397 construct. Lane MW: molecular weight marker in kb (Quick-Load Purple 2-
Log DNA ladder). Arrow a indicates the expression cassette containing the Gal d 5 
gene. Arrow b indicates the remainder of the pKLAC2 vector.  
 
 
 
 
 
 
Figure 4.7: Whole cell PCR analysis for screening of K. lactis strains containing 
multi-copy integrants. The PCR product was electrophoresed on E-Gel® 
CloneWell™ agarose gel with 0.8% SYBR Safe™ DNA Gel stain. Lane 1-7: K. lactis 
test strains harbouring multi-copy integrants. Arrow indicates the amplicon at 2.3 kb. 
Lane 8: K. lactis test strain without multi-copy integrants. MW: molecular weight 
marker (Quick-Load Purple 2-Log DNA ladder).  
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Figure 4.8: SDS-PAGE analysis of spent culture media from K. lactis strains 
harbouring rGal d 5196/205-388/397. Lane 1-7: spent culture medium of K. lactis test 
strains harbouring multi-copy integrants. MW: molecular weight marker in kDa 
(SeeBlue Pre-Stained protein standard). 
 
4.3.2 Recombinant production of rGal d 5196/205-388/397 in E. coli 
 
E. coli cells transformed with pTrcHisA-Gal d 5196/205-388/397 construct had growth 
when grown on LB agar under ampicillin resistance. Pilot expression study 
confirmed the expression of rGal d 5196/205-388/397 as a soluble fraction. The SDS-
PAGE analysis of soluble E. coli culture fractions showed multiple proteins (Figure 
4.9, A). The corresponding Western blot analysis of soluble E. coli culture fractions 
showed a predominant band in between 64 kDa and 98 kDa markers (expected size: 
69 kDa) (Figure 4.9, B). The optimum recombinant protein production was seen at 4-
hour post IPTG induction.  
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Figure 4.9: Time-course of expression of soluble E. coli cell culture fractions 
harbouring rGal d 5196/205-388/397. Lane 1: un-induced culture fractions. Lanes 2-4: 
IPTG induced culture fractions at time points 3rd, 4th and 5th hours, respectively 
analysed by (A) SDS-PAGE and (B) Western immunoassay probed with monoclonal 
Anti-Xpress™ antibody produced in mouse. MW: molecular weight marker in kDa 
(SeeBlue Pre-Stained protein standard). Arrows indicate rGal d 5196/205-388/397. 
 
4.3.3 Immunological analysis of non-mutant and mutant rGal d 5  
 
The identities of each rGal d 5 were confirmed prior immunoassay through Western 
blot technique. The recombinant proteins on Ponceau S stained membrane and 
antibody-probed membranes were comparable (Figure 4.10). Immunological 
reactivity of rGal d 5 produced by K. lactis, insoluble rGal d 5 produced by E. coli 
and mutant rGal d 5196/205-388/397 produced by E. coli were comparatively analysed in 
terms of IgE binding capacity through Western immunoassay (Figure 4.11). Western 
immunoassay performed with pooled patients’ sera showed that rGal d 5 expressed 
by K. lactis to have the highest IgE reactivity. The insoluble rGal d 5 also had 
detectable IgE reactivity however, at a very low level. Western immunoblot of rGal d 
5196/205-388/397 showed no IgE reactivity at all. The control Western immunoblots 
conducted with non-allergic individuals’ sera did not show IgE reactivity against any 
rGal d 5.  
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Figure 4.10: Western blot analysis of non-mutant rGal d 5 expressed by K. lactis 
and E. coli and mutant rGal d 5196/205-388/397 produced by E. coli. (A) Ponsceau S 
stained blot: Lane 1: purified rGal d 5 expressed by K. lactis. Lane 2: non-mutant 
rGal d 5 produced by E. coli as an insoluble fraction (crude cell culture extract). Lane 
3: mutant rGal d 5196/205-388/397 produced by E. coli as a soluble fraction (crude cell 
culture extract). (B) Western blot of rGal d 5 expressed by K. lactis probed with 
monoclonal anti-HA antibody produced in mouse, Lane 1: immunoprecipitation 
purified rGal d 5. (C) Western blot of rGal d 5 expressed by E. coli. Lane 1: non-
mutant rGal d 5 expressed by E. coli as an insoluble fraction (crude cell culture 
extract). Lane 2: mutant rGal d 5196/205-388/397 produced by E. coli as a soluble fraction 
(crude cell culture extract) probed with monoclonal Anti-Xpress™ antibody produced 
in mouse. MW: molecular weight marker in kDa (PageRuler Plus Prestained Protein 
Ladder).  
 
 
 
 
 
 
 
 
 
Figure 4.11: Western immunoblots conducted using nGal d 5 sensitised 
patients’ sera against non-mutant rGal d 5 expressed by K. lactis and E. coli and 
mutant rGal d 5196/205-388/397 produced by E. coli. Lane 1: non-mutant rGal d 5 
expressed by K. Lactis. Lane 2: non-mutant rGal d 5 expressed as an insoluble 
fraction by E. coli. Lane 3: mutant rGal d 5196/205-388/397 produced by E. coli as a 
soluble fraction. (A) Western immunoblot incubated with nGal d 5 sensitized 
patients’ sera. (B) Negative control Western immunoblot incubated with non-allergic 
sera. MW: molecular weight marker in kDa (PageRuler Plus Prestained Protein 
Ladder). 
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4.4 Discussion 
 
 
In Chapter 3, we successfully cloned the cDNA for Gal d 5 and demonstrated that the 
recombinant protein retained the human IgE binding reactivity. Furthermore, our 
results in Chapter 3 confirmed that rGal d 5 retained the antigenic structure of the 
native allergen, by quantitative IgE binding assays using sera from sensitised 
patients. Therefore, these results indicate that the rGal d 5 is a suitable model system 
for producing hypoallergenic variants and for investigating the antigenic 
determinants of Gal d 5. The main objective of Chapter 4 was to produce a mutant 
variant of Gal d 5 with reduced IgE binding capacity for development of a 
hypoallergen, for potential future use in SIT.  
The first challenge of this study was to successfully introduce mutations to the cDNA 
sequence of Gal d 5, in order to reduce the IgE binding reactivity.  However, linear 
or conformational IgE-binding epitopes of Gal d 5 are not yet described. Therefore, 
we simultaneously disrupted two randomly selected DBs via SDM. In certain 
allergens the disruption of intramolecular DBs has been shown to induce protein 
unfolding and decrease of allergenicity [148]. Using our mutagenesis strategy, one 
cysteine from each pair of 2 selected DBs was replaced with alanine, preventing the 
disulfide bond from forming at that position. When Cys196-Cys205 and Cys388-
Cys397 lacking Gal d 5 cDNA was cloned into the K. lactis, no secreted recombinant 
protein was detected in the spent culture media. However, our results confirmed that 
transformed K. lactis colonies grown under acetamide selection had multiple copies 
of expression fragments containing rGal d 5196/205-388/397.  
There could be several reasons why a recombinant protein is poorly expressed or not 
expressing at all. Toxicity of the protein to the host cell, insolubility or mRNA 
secondary structure preventing interactions with the cellular machinery and lack of 
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DB formation are some reasons causing difficulties with recombinant protein 
expression [143, 149]. The mutant Gal d 5 cDNA was cloned in frame with α-MF 
secretion leader sequence in order to facilitate secretion of the recombinant protein. 
If protein expression was achieved, the α-MF domain directs the fusion protein to be 
efficiently transported through the K. lactis secretory pathway into the growth 
medium. Complete lack of secreted recombinant protein indicates that expression of 
the fusion peptide was not directed by the K. lactis protein production machinery. 
The most likely reason for this is that the mutated mRNA Gal d 5 secondary 
structures may be blocking interactions with the cellular machinery and thereby 
preventing translation of the recombinant protein. Furthermore, the mutant Gal d 5 
proteins may have undergone incorrect folding due to DB disruption, and thereby not 
being able to secrete into the growth media. If this is the case, the improperly folded 
mutant Gal d 5 may exist in yeast cell pellets. The main goal of the project is to 
produce a biologically active mutant Gal d 5 protein lacking IgE-reactivity. If mutant 
Gal d 5 has been produced as IBs it is more likely to be non-functional and offer very 
little or no biomedical value for experiments conducted in this PhD project and 
future applications suggested [131, 132]. As a result, we did not attempt to extract 
mutant Gal d 5 proteins from yeast cell pellets.  
In order to achieve rGal d 5196/205-388/397 expression, pTrcHis A-Gal d 5196/205-388/397 
construct generated from SDM was transformed into NEB 5-alpha F’ Iq Competent 
E. coli strain. Here, the rGal d 5196/205-388/397 was expressed as fusion peptide with a 
C-terminal 6×His tag. The Western blot of the IPTG induced soluble culture 
fractions confirmed that the rGal d 5196/205-388/397 was expressed under the direction of 
Ptrc as a soluble fraction. To retain the biomedical value, it is essential to produce 
the recombinant protein as a soluble fraction in its native form [131, 132]. Therefore, 
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we did not analyse the insoluble culture fraction and therefore, our result does not 
indicate the expression levels of insoluble rGal d 5196/205-388/397. 
Previously E. coli failed to express wild type Gal d 5 as a soluble fraction. However, 
E. coli cells were able to express mutant Gal d 5 as a soluble fraction. This again 
proves the unpredictable nature of protein production host platforms [140]. A 
possible explanation for this double nature of the E. coli host expression system may 
attributed to the presence or absence of DBs. E. coli cells were only successful at 
expressing mutant Gal d 5 which lacked two DBs as a soluble fraction. It is well 
known that the cytoplasm of E. coli cells have a reducing effect on DBs, and thereby 
preventing the formation of DBs resulting in IBs [143]. The lack of DBs in mutant 
Gal d 5 may have contributed to undergo proper folding in the E. coli cytoplasm.  
The Western immunoassay results confirmed that simultaneous deletion of Cys196-
Cys205 and Cys388-Cys397 DBs resulted in complete elimination of IgE reactivity. 
As per the non-mutant recombinant Gal d 5, we analysed K. lactis and E. coli 
expressed proteins as well. As expected, native rGal d 5 expressed by K. lactis as a 
soluble fraction had very strong IgE reactivity when compared to E. coli derived 
insoluble rGal d 5 and mutant rGal d 5196/205-388/397. This is mainly due to the fact that 
K. lactis expressed native rGal d 5 had maintained the antigenic structure which 
contributes towards IgE binding better than the latter two.  Unlike E. coli, eukaryotic 
systems like K. lactis may result in posttranslational modifications leading to better 
conservation of the native structure of Gal d 5.  Furthermore, expression of rGal d 5 
as a soluble fraction by K. lactis guarantees the proper folding of the protein again 
resulting higher structural similarity to the native protein.   
Furthermore, this result validates the dot-blot immunoassay conducted with rGal d 5 
in Chapter 3 where rGal d 5 was shown to be IgE reactive. Insoluble rGal d 5 
expressed by E. coli had very low but detectable IgE reactivity. This confirmed that 
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the native rGal d 5 expressed as an IB has not completely lost its IgE reactivity. 
However, when compared with non-mutant rGal d 5 expressed by K. lactis, it was 
clear that significant level of IgE reactivity of E. coli derived rGal d 5 was lost due to 
improper folding.  
 
The elimination of IgE binding reactivity can be directly attributed to the disruption 
of the two DBs. The disruption of two DBs may have altered the confirmation of 
native Gal d 5 and lead to protein unfolding. Therefore, it is clear that the Cys196-
Cys205 and Cys388-Cys397 DBs together have a significant contribution to 
maintaining the IgE binding structure of Gal d 5. However, this result does not reject 
the existence and contribution of linear IgE binding epitopes to the IgE binding 
reactivity. Sequential IgE binding epitopes may also require a certain structural 
context for proper interactions with IgE antibodies. As a result, disruption of DBs 
may have reduced or completely impaired access to sequential IgE binding epitopes 
due to the modified confirmation [148]. However, another contributing factor leading 
to lack of IgE-reactivity of mutant Gal d 5 could be the availability of less mutant 
protein immobilized on the nitrocellulose membrane, compared to the natural Gal d 
5. Reduced amount of mutant Gal d 5 may have resulted in less IgE-reactivity being 
detected. According to the visual analysis of the Western blot there were reasonable 
amount of mutant Gal d 5 available for IgE-reactivity. As a consequence, complete 
lack of IgE-reactivity of shown by this experiment can still be considered reliable. 
However, complete lack of IgE-reactivity may attribute to the combined effect of the 
mutation along with reduced amount of mutant Gal d 5 on the nitrocellulose 
membrane.  
 
Although rGal d 5196/205-388/397 produced in this chapter confirms complete lack of IgE 
reactivity, our results are not sufficient to verify it as a hypoallergen. Previous studies 
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have shown discrepancies between IgE-binding reactivity and allergenic potency. 
Even with reduced IgE binding reactivity following DB elimination, some 
recombinant mutants retained the allergenicity [148]. These results confirmed that 
the disruption of DBs have no effect on the allergenic potency. Therefore, it is 
important to further extend investigation of rGal d 5196/205-388/397 in order to evaluate 
its allergenicity in comparison to its native counterparts. Analysis of allergenicity can 
be conveniently performed by subjecting rGal d 5196/205-388/397 into mediator release 
assays using cells expressing human FcεRI for IgE. Determination of levels of 
mediator release induced by mutant rGal d 5 proteins can provide a better 
understanding of the effect of deleting DBs on the allergenic nature. In addition, it is 
important to show that such hypoallergens maintain their ability to proliferate T cells 
so that they can modulate the non-allergenic (Th1 and Tr1) immune pathway. 
 
In conclusion, our results provide some understanding of the contribution of Cys196-
Cys205 and Cys388-Cys397 to the IgE binding reactivity. The initial step of 
producing a hypoallergen is successfully performed in this chapter. Therefore, the 
mutant Gal d 5 designed in this chapter is a potential candidate for specific 
immunotherapy applications. It would now be of great interest to further extend this 
work to confirm the hypoallergenic nature of the rGal d 5196/205-388/397. 
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Chapter 5: General discussion 
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Allergy to hen’s egg is one of the most common forms of food allergies affecting 
humans. Research conducted regarding food allergies generally investigates the 
whole food source in order to understand the relationship between disease and the 
causative allergens. Surprisingly, in allergy to hen’s egg, only the egg white 
proteome has been subjected to investigation, leaving egg yolk proteome untouched 
by vast majority of studies. The egg yolk was mainly excluded in research because 
initially it was not found to cause severe allergic reactions like allergens from the egg 
white. Therefore, knowledge regarding allergy to egg yolk did not have much 
progression like egg white allergy. As a result, misunderstandings regarding hen’s 
egg yolk allergy may have occurred especially with clinicians and other health care 
workers. It is widely believed that allergy to egg yolk does not exist or at least 
allergy to egg white is required in order to experience hypersensitivity reactions 
against egg yolk proteins. The main scope of this PhD thesis was to subject hen’s egg 
yolk proteome into immunological studies in relation to food allergy. In this PhD 
project, various proteomic and molecular methods were employed in order to shed 
light on to IgE-mediated hypersensitivity to hen’s egg yolk proteins.  Furthermore, 
the use of recombinant DNA technology has been very popular in the field of allergy. 
Recombinant allergens have been successfully used in both diagnosis and treatment 
of allergies. In addition, recombinant DNA technology has been a powerful tool to 
investigate allergy at molecular level revealing many facts [116, 118]. As per our 
knowledge, there are no known published reports regarding recombinant production 
of Gal d 5 and Gal d 6, the two major allergens of hen’s egg yolk. Therefore, a 
significant amount of knowledge can be uncovered with the application of 
recombinant DNA technology to egg yolk allergens.  
In Chapter 2, we first investigated if patients allergic to hen’s egg white would have 
sensitisations to egg yolk proteins from hen, emu and quail. Western immunoassay 
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result confirmed that many patients tested had genuine sensitisation against multiple 
egg yolk proteins from all the bird eggs. Interestingly, this finding is contrary to the 
popular belief that reactivity to egg white is not associated with sensitisation to egg 
yolk. Currently, there is no available literature regarding immunological studies on 
any type of bird eggs other than hen’s egg. This result suggests that patients with 
hen’s egg white allergy can have sensitisations to bird eggs from different species as 
well. In such patients, sensitisation to those egg yolks may occur as a result of direct 
exposure or due to common epitopes present among proteins due to high degree of 
homology. As a result, those patients may develop IgE-mediated hypersensitivity 
reactions in the event of exposure to those eggs. Therefore, such patients will not be 
able to consider emu and quail eggs as an alternative to chicken eggs.  
Sensitisation to allergens does not necessarily imply clinical hypersensitivity and 
therefore, our result is unable to confirm clinical allergy in those patients. However, 
sensitisation is found to be a risk factor for allergy and can be used to predict the 
development of allergy as in allergy to egg white [3]. The actual state of clinical 
reactivity to egg yolk in those patients is not known since egg yolk is not used for in 
vitro or in vivo diagnosis of allergy. Findings of this result confirm that concomitant 
sensitisation to egg white and egg yolk is not uncommon and emphasise hen’s egg 
yolk as an important source of allergens. Therefore, our result suggests that including 
both the egg white and the egg yolk during diagnosis of egg allergy is very 
important. As a result, knowledge obtained by using both the egg white and the yolk 
at diagnosis stage may help avoid unnecessary dietary restrictions and immensely 
benefit managing egg allergy better.  
A limitation of this study was the inability to identify the IgE-reactive egg yolk 
proteins conclusively due to the use of crude egg yolk preparations. In order to 
identify proteins precisely the use of purified proteins is essential. However, through 
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proteomic analysis we were able to identify that most IgE-reactive proteins belong to 
major precursor proteins of the hen’s egg yolk namely; VTG-1, VTG-2 and Apo B. 
YGP42 (Gal d 6), which is the C-terminal part of VTG-1, is already confirmed as an 
allergen. Apovitellenin I and apovitellenin VI that are derived from Apo B are 
reported to exhibit significant allergenicity in some patients [81, 96, 98, 150, 151]. 
However, those proteins are not yet confirmed as food allergens. A large number of 
mature protein fragments derived from those precursors exist in the egg yolk, which 
may have significant allergenic potential. Therefore, it would be of great interest to 
subject each mature protein in its purified form to immunological analysis in order to 
reveal their allergenicity.  
 
The second major aim of this PhD project was to produce IgE-reactive recombinant 
proteins of both Gal d 5 and Gal d 6. This PhD thesis for the first time presents the 
successful production of recombinant versions of Gal d 5 and Gal d 6. In Chapter 2, 
we first successfully cloned and expressed Gal d 6 in E. coli as a soluble fraction. 
Producing recombinant proteins as a soluble fraction in its native form is a common 
challenge faced by researchers very often. Majority of the rGal d 6 has been 
produced as IBs. However, there were reasonable amount of soluble rGal d 6 
produced by the E. coli cells that could be used for purification and other 
downstream applications. Therefore, enhancement of bacterial cells to increase 
production of rGal d 6 as a soluble fraction was not necessary. 
A crucial stage in recombinant allergy research is the analysis the IgE-reactivity 
profile of recombinant proteins in comparison to natural counterparts in a given 
population. Here, we showed that rGal d 6 is IgE-reactive by inhibition ELISA 
experiments. rGal d 6 and CEY of hen was able to inhibit binding of IgE to each 
other in similar amounts (approximately 30%). However, it is not possible to 
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determine the exact IgE binding level of rGal d 6 with this experiment. In order to 
determine the precise IgE-reactivity it is essential to compare the IgE-reactivity in 
comparison to purified natural Gal d 6.  However, our work confirms that rGal d 6 
produced by E. coli is IgE-reactive and therefore, can be considered for in vitro and 
in vivo diagnosis of egg yolk allergy after further validation of its immune reactivity. 
Furthermore, rGal d 6 produced here can be used as a platform to develop 
hypoallergenic variants with reduced IgE binding capacity for potential use in SIT 
for patients suffering from hen’s egg yolk allergy.  
In Chapter 3, we successfully produced an IgE-reactive version of Gal d 5 as a 
soluble fraction. However, our first attempt to produce rGal d 5 as a soluble fraction 
using NEB Express Iq Competent E. Coli failed. Although, rGal d 5 was expressed in 
sufficient amounts, 100% of the recombinant protein was expressed as insoluble IBs. 
Formation of IBs indicates irregular folding of the recombinant protein losing its 
native conformation. As a result, rGal d 5 produced by E. coli may have lost its 
immunological potency due to irregular folding, making it less useful for other 
downstream applications. Gal d 5 is a secreted protein with 17 DBs stabilizing it 
[142]. DBs are crucial for correct protein folding, stability and functionality. In 
general, the cytoplasm of E. coli cells does not contain a favourable environment for 
DB formation due to the presence of numerous DB reductases such as thioredoxins 
and glutaredoxins. These DB reductases quickly reduce DBs formed between two 
cysteine groups back to its thiolate state. Failure to form DBs in the recombinant 
proteins, results in it being formed as inactive IBs. Therefore, it is highly possible 
that the large number of DBs present in Gal d 5 haven’t been formed in the E. coli 
cytoplasm and have undergone IB formation [141, 143]. 
As an alternative approach, we decided to use a different host strain to express rGal d 
5 as a soluble fraction. In Chapter 3, we used the yeast strain K. lactis to produce 
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rGal d 5 as a secreted protein. Here, we successfully expressed rGal d 5 as a secreted 
protein and isolated with high-level purity and confirmed it as IgE-reactive. 
Furthermore, ELISA experiment conducted with patients’ sera confirmed that both 
the nGal d 5 and rGal d 5 have very similar IgE-reactivity. These results suggest that 
rGal d 5 produced by K. lactis is recognizable by the human immune system and 
bears similar epitopes to that of nGal d 5. As a result, rGal d 5 presented in this PhD 
project may be an excellent reagent for the use of in vitro and in vivo diagnosis of 
allergy to egg yolk. Further confirmation of the results presented in Chapter 3 can be 
accomplished by subjecting rGal d 5 to immunoassays with sera from patients 
diagnosed with allergy to hen’s egg yolk.  
rGal d 5 produced in Chapter 3 is a suitable model system for producing 
hypoallergenic variants and for investigating the antigenic determinants of Gal d 5. A 
large number of recombinant based hypoallergenic variants have been designed by 
many researchers globally [116, 118, 147, 148]. However, to the best of our 
knowledge, there are no known published reports on the production of a 
hypoallergenic variant of Gal d 5. Therefore, in Chapter 4, the main objective was to 
produce a recombinant-based mutant variant of Gal d 5 for the potential development 
of a hypoallergen. Here, our mutagenesis strategy involved producing a mutant 
variant of Gal d 5 by disruption of two DBs simultaneously. Usually, selection of 
DBs for disruption is based on the IgE binding epitopes of the native allergen in 
order to impair IgE-binding capacity. However, such information regarding Gal d 5 
is not yet available. Therefore, we disrupted two randomly selected DBs in order to 
induce change in the overall conformation. At this point, advantages of this approach 
are two-fold. Potential reduction of IgE-reactivity due to DB disruption also indicates 
the contribution of the targeted DBs to the maintenance of the antigenic structure of 
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Gal d 5. Previous studies have successfully used disruption of DBs to map 
conformational epitopes of allergens [147].  
In Chapter 4, our initial intention was to express mutant Gal d 5 as a secreted protein 
using K. lactis. Unexpectedly, K. lactis cells failed to express and secrete the mutant 
Gal d 5 despite successful cloning. Successful expression of a given protein is 
dependent on the nature of the protein and the host system used and there is no 
universal protein expression system or a predictive tool, which can guarantee the 
desired outcome. Therefore, this result indicates that the change caused by the 
mutation had resulted in blocking expression or secretion of the protein since the 
non-mutant Gal d 5 DNA sequence was successfully expressed and secreted by K. 
lactis.  Isolating the exact reasons behind failure to express the mutant Gal d 5 in K. 
lactis without further experimentation is difficult as there may be multiple factors 
involved. The most likely reason for this may be that the mutated mRNA Gal d 5 
secondary structures blocking interactions with the cellular machinery and thereby 
preventing translation of the recombinant protein.  Furthermore, the mutant Gal d 5 
proteins may have undergone incorrect folding due to DB disruption, and thereby not 
being able to secrete into the growth media. If this is the case the improperly folded 
mutant Gal d 5 may exist in yeast cell pellets. The main goal of the project was to 
produce a biologically active mutant Gal d 5 protein lacking IgE-reactivity. If mutant 
Gal d 5 has been produced as IBs, it is more likely to be non-functional and offer 
very little or no biomedical value for experiments conducted in this PhD project, and 
future applications suggested in this thesis [131, 132]. 
As an alternative approach, we decided to express the mutant variant of Gal d 5 in 
NEB 5-alpha F' Iq Competent E. coli strain as a soluble fraction. Here, the cloning 
and expression of the mutant Gal d 5 as a soluble fraction was successfully achieved 
by the E. coli protein production machinery. Previously E. coli failed to express wild 
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type Gal d 5 as a soluble fraction. However, E. coli cells were able to express mutant 
Gal d 5 as a soluble fraction. This again proves the unpredictable nature of protein 
production host platforms [140]. A possible explanation for this double nature of the 
E. coli host expression system may attributed to the presence or absence of DBs. E. 
coli cells were only successful at expressing mutant Gal d 5 which lacked two DBs 
as a soluble fraction. It is well known that the cytoplasm of E. coli cells have a 
reducing effect on DBs, and thereby preventing the formation of DBs resulting in IBs 
[143]. The lack of DBs in mutant Gal d 5 may have contributed to undergo proper 
folding in the E. coli cytoplasm.  
The Western immunoblot conducted to assess the IgE-binding capacity confirmed 
that the disruption of DBs have completely abolished the IgE-reactivity of mutant 
Gal d 5 expressed in E. coli. Furthermore, this result confirms that major antigenic 
epitopes of Gla d 5 are conformational and DBs Cys196-Cys205 and Cys388-Cys397 
together are highly important in maintaining the IgE-binding structure of Gal d 5. 
The ultimate goal of producing mutant variants with reduced IgE-reactivity is to 
develop a hypoallergen for successful use in specific immunotherapy. Many research 
groups have developed mutant variants of allergens with reduced IgE-reactivity 
using the same strategy as described in this PhD project [147, 148]. However, 
reduction in IgE-binding capacity does not always imply that the mutant variant is a 
hypoallergen. This is due to the fact that not all mutants with reduced IgE-reactivity 
are reported to exhibit reduced allergenicity in reality [148]. Therefore, the mutant 
Gal d 5 produced in this PhD project must be subjected to further investigations such 
as mediator release assays and T cell reactivity assays in order to confirm whether it 
is a true hypoallergen. 
In conclusion, the work presented in this PhD thesis provides some valuable insight 
into IgE-mediated hypersensitivity to hen’s egg yolk, which is one of the least 
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investigated food allergies. Our initial investigation in Chapter 1 successfully set the 
stage for entire PhD project by showing that sensitisation to hen’s egg yolk proteins 
exists in many patients diagnosed with allergy to hen’s egg white. Most IgE reactive 
proteins were identified as fragments of VTG-1, VTG-2 and Apo B precursors. This 
shows that there could be potentially undiscovered allergens within the hen’s egg 
yolk. The rGal d 6 expressed as a soluble fraction was shown to be IgE reactive. 
However, in future work, it is important to subject rGal d 6 to IgE-binding assays in 
comparison to natural Gal d 6 in order to confirm the exact level of IgE-reactivity. 
The rGal d 5 produced as a secreted protein showed very similar IgE-binding 
reactivity to nGal d 5. Therefore, rGal d 5 can be considered as an excellent reagent 
for diagnosis of egg yolk allergy. For both of the recombinant allergens produced in 
this PhD project, further validation for their IgE-reactivity profiles can be brought by 
conducting immunoassays using sera from patients diagnosed with clinical allergy to 
hen’s egg yolk. Finally, we produced a recombinant-based mutant variant of Gal d 5 
with completely impaired IgE-reactivity. Therefore, mutant Gal d 5 may serve as an 
excellent therapeutic agent for SIT as a hypoallergen. In order to validate mutant Gal 
d 5 as a hypoallergen, it is essential to conduct further investigations such as 
mediator release assays. Not using sera from patients’ allergic to hen’s egg yolk in 
the immunoassays is a limitation in this PhD project. However, results of this PhD 
project strongly suggest that allergy to hen’s egg yolk is more common than 
previously thought and showed that allergy to egg yolk is equally important as 
allergy to hen’s egg white. As a result, patients with IgE-mediated hypersensitivity to 
hen’s egg must ideally undergo clinical examinations focusing both on the egg yolk 
and the egg white, which would lead to better understanding and management of egg 
allergy. Our work in this PhD has shown the importance of egg yolk as an important 
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source of food allergens. However, yet egg yolk allergy research can be considered 
as a developing field and therefore further investigations on the subject is warranted.  
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